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Background: Due to high incidence rates and the development of new drug6resistantor multidrug6resistant strains of TB, the development of new medicines and treatmentsfor tuberculosis is a necessity. In order to develop these drugs,Mycobacterium
tuberculosis (Mtb) needs to be studied more completely; this study performs acharacterisation of the metabolome of Mtb and comparison across the phylogeneticprofile to identify notable pathways.
Methods &Materials: To unravel their roles in the cell, data has been integrated froma variety of sources, both computationally predicted and experimental, to generatemetabolic networks for the proteome. This first step involved creating a more completecatalogue of Mtb metabolic pathways and their phylogenetic profiles. The data frommultiple resources was compiled together into a matrix of all Mtb strain H37Rvproteins, along with unique (non6orthologous) proteins from strains KZN 1435,CDC1551, H37Ra and F11. For each protein, we derived a full phylogenetic profile ofover 1,000 organisms with all orthologs in the five Mtb strains. Pathway data wasinitially filled from KEGG and UniPathway data, and then additional proteins wereannotated using Gene Ontology (GO) terms, KEGG reference pathways and homology tocharacterized proteins from closely related organisms. Following this, pathwayinformation was compared between Mtb andM. leprae, C. glutamicum, E. coli, H. sapiensand all organisms across the profile to identify notable pathways for potential drugtargets. Next these functional networks were used in an attempt to find pathway holes,which could be circumstances where Mtb utilises the host genome to accomplish itsmetabolic needs.
Results: A total of 553 Mtb proteins were added to previously existing pathways basedon EC number and GO terms, and 288 reactions were characterized with enzymaticproteins based on sequence homology from BLASTP matches with closely relatedorganisms. A number of interesting pathways were identified fulfilling thesecharacteristics including arginine and proline metabolism and glycerolipid metabolism(many orthologs shared between Mtb and M. leprae), histidine metabolism and
ii
butanoate metabolism (few orthologs shared between Mtb and E. coli), xylenedegradation and porphyrin and chlorophyll metabolism (many orthologs sharedbetween Mtb and C. glutamicum) and lastly biotin metabolism, sulfur metabolism,geraniol degradation and polycyclic aromatic hydrocarbon degradation (few orthologsbetween Mtb and H. sapiens)
Conclusion: This study contributed to increasing the number of characterised enzymesand pathways in Mtb and the results suggest that the functional annotation of Mtbneeds to be updated within the KEGG database. Many proteins were functionallyannotated and notable pathways described for further research. It is hoped that thismore complete characterization and identification of potential drug targets can aid inthe understanding of the metabolism of Mtb and lead to new drug development.
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1.1 Epidemiology Tuberculosis (TB), an airborne contagious disease caused by Mycobacterium
tuberculosis (Mtb), is an ancient disease that has probably infected humans for millionsof years (Gutierrez et al., 2005). As well as being ancient, TB infects humans worldwide,killing 1.4 million people per year and causing 8.7 million new cases in 2011 alone(World Health Organization 2012). It is also a disease of poverty with 95% of deathsoccurring in the developing world, affecting mostly young adults at the most productivetime of their lives (World Health Organization 2012a). Additionally, resistance in Mtboccurs regularly; the World Health Organization (WHO) estimates that there were half amillion new multidrug6resistant cases in 2011 (World Health Organization 2013).Lastly, co6infection with both TB and HIV is common and causes additional problemswhen diagnosing and treating TB; in fact one third of the 34 million HIV6positive peoplein the world are co6infected with latent TB and one in four HIV6related deaths is due toTB (World Health Organization 2013a). In South Africa, 65% of TB patients are also HIVpositive, making the country an epicentre of the co6epidemic (World HealthOrganization 2013c). Below are two maps which show first the incidence of TB per100,000 population, and secondly the estimated HIV prevalence among TB cases.
A.
2B.
Figure 1.1 Tuberculosis around the world. The first image (A) displays the incidence of tuberculosis while
the second (B) shows HIV prevalence amongst cases of TB reference (World Health Organization, 2012a,2012b).These maps show both the high incidence of TB and the high prevalence of HIV amongnew cases of TB in sub6Saharan Africa and South Africa in particular (World HealthOrganization 2012b). In order to reduce this high incidence and prevalence shown,further studies need to be performed on the causative agent, Mycobacterium
tuberculosis. 
1.2 History The genus Mycobacterium is believed to have originated as many as 150 million yearsago (Daniel, 2006). This genus includes many different species including fast and slow6growing mycobacteria and nontuberculous and tuberculous mycobacteria. An ancestorof Mycobacterium tuberculosiswas present as early as 3 million years ago in East Africa,suggesting that it might have affected early hominids (Gutierrez et al., 2005). Today it isbelieved that all modern members of the Mtb complex (MTBC), which includes
Mycobacterium bovis, Mycobacterium canettii and Mycobacterium africanum as well asMtb, had a common ancestor in Africa 35,000615,000 years ago. Modern strains of Mtbare thought to have evolved from a common ancestor around 20,000615,000 years ago(Daniel, 2006). The earliest evidence of the disease is in human remains from around5000 BC, which show deformities in the spinal column indicative of extrapulmonarytuberculosis (Kaufmann and van Helden, 2008). During Greek times, around 460AD,
3Hippocrates wrote that phthisis, an older name for tuberculosis, was the mostwidespread disease at the time (Daniel, 2006). Three years after Louis Pasteurdeveloped the germ theory of infectious disease in 1862, Jean6Antoine Villeminexperimentally proved that tuberculosis could be inoculated from man or cow tolaboratory animals such as rabbits and guinea pigs. Villemin also showed that sputumfrom an infected patient could infect a rabbit with tuberculosis (Sakula, 1983). Theturning point in this battle against TB came on 24 March 1882, when Robert Kochidentified and described the bacteria causing TB, Mycobacterium tuberculosis, at ameeting of the Physiological Society of Berlin (Koch et al., 1982). He described thebacteria as being “rod6shaped” and “very thin”, and with a length of usually “one6fourthto one6half as long as the diameter of a red blood cell”; he found these bacilli “ordinarilyform small groups of cells which are pressed together and arranged in bundles” andremarked upon their similarity to the bacilli of leprosy (caused by Mycobacterium
leprae) (Koch et al., 1982). By the 1930s Florence Seibert developed purified proteinderivative (PPD), used to test for the presence of tuberculosis; PPD was then used bythe World Health Organization in 1955 to demonstrate the existence of latenttuberculosis infections, first noted in 1909 by Clemens Freiherr von Pirquet, in healthyschool children in countries with a high prevalence of tuberculosis. Even with this longhistory of infection in humans, the first effective treatment for the disease was onlydeveloped in 1944 with the isolation of streptomycin; isoniazid and rifamycins, alsoeffective treatment drugs for tuberculosis, were developed in 1952 and 1957,respectively (Daniel, 2006). Since the 1950s, however, few new effective drugs havebeen produced, and work must continue to develop new chemotherapies for thetreatment of tuberculosis and especially drug6resistant tuberculosis (Kaufmann andvan Helden, 2008).
1.3 Mycobacteria The genus Mycobacterium includes more than 140 described species, all of which showat least 94.3% sequence similarity in their 16S ribosomal RNA genes. Mycobacteria areaerobic, acid6fast actinomycetes and usually take the form of straight or slightly curvedrods; they have waxy and hydrophobic cell walls that are thicker than most otherbacteria as well as being rich in mycolic acids. They can be categorized into fast andslow6growing mycobacteria; fast6growing mycobacteria are typically avirulent and
4include Mycobacterium abscessus and Mycobacterium smegmatis while slow growingcause many human and animal diseases and include Mtb and Mycobacterium leprae(Hartmans et al., 2006). Current evidence shows that slow growing mycobacteriaevolved from a single ancestral fast6growing species (Tortoli, 2012). One phylogeneticbranch within the slow6growers incorporates the smooth tubercle bacilli, namedsmooth because they form smooth colonies, and the Mycobacterium tuberculosiscomplex (MTBC) bacteria; bacteria in the MTBC are the most common causes oftuberculosis in humans although smooth strains have also been isolated from humancases. Most smooth species have been isolated from locations in East Africa and it hasbeen estimated that to accumulate the observed level of synonymous nucleotidevariation within tubercle bacilli would have taken at least 2.6 to 2.8 million years todevelop; this suggests that the evolution of tubercle bacilli may have taken place in thesame location and over the same time period as the evolution of humans, and movedout of East Africa along with the migrations of humans. In addition, while smoothspecies show a high ratio of synonymous to nonsynonymous substitution showingpurifying selection over time against amino acid changes, species of the MTBC have avery low ratio suggesting recent expansion. Thus, strains of the MTBC may haverecently evolved from an ancestral6type similar to the smooth species of tuberculosis(Gutierrez et al., 2005).
1.3.1 Mycobacterium tuberculosis Complex The MTBC includes the Mtb, M. bovis, M. microti, M. africanum, M. pinnipedii and M.
caprae species. The MTBC is a clonal group that shows no recombination, unlike smoothstrains of tubercle bacilli (Garcia6Betancur et al., 2012). They appear to have originatedfrom a number of horizontal gene transfer events and then went through anevolutionary bottleneck and finally clonal expansion about 35,000 years ago (Gutierrezet al., 2005). Species of the MTBC show an extremely low level of genetic variation, withmore than 99.95% sequence similarity at the nucleotide level (Smith et al., 2009). Somewould consider bacteria of the MTBC as separate species while other reports show thatthese species may in fact belong to only one genospecies, owing to the identicalnucleotide sequences of the 16SrRNA and rpoB genes, usually used to differentiatespecies in mycobacteria. Additionally, of the MTBC members, studies of both genomicsignatures and multiple whole6genome alignments show that these bacteria could
5belong to a single species. Of the MTBC, only KZN 1435 showed a single centralinversion (Garcia6Betancur et al., 2012). Different species within the MTBC can bedifferentiated according to their distinct host preference. For example, Mtb and M.
africanum subtype 1 are human adapted, while M. bovis is mainly found in cattle and M.
pinnipedii is found in marine mammals. However, this host preference does not alwayshold true; all species have been isolated from cases of human tuberculosis and manyspecies have been isolated from mammals not identified as the primary host (Smith etal., 2009). It is most likely that animal6adapted species of the MTBC developed from ahuman6adapted ancestral strain of Mtb. Thus, the disease would have originated inhumans and subsequently evolved to infect other species (Smith et al., 2009).The biggest differences between Mtb, M. leprae, M. avium, and M. bovis are in the cellwall products and the PE/PPE/PGRS proteins, but there are also differences in lipidmetabolism, cell wall proteins, insertion sequence elements and hypothetical proteins.
M. tuberculosis H37Rv has about 3,900 genes encoding proteins while M. leprae, with asubstantially reduced genome, has about 1,650. M. leprae also shows many genomicrearrangements in comparison to Mtb. M. tuberculosis H37Rv was shown to have twounique genes compared to the other strains of Mycobacterium, while M. tuberculosisCDC1551 has 122 and M. leprae has 149. All genomes have a functional glycolyticpathway and tricarboxylic acid (TCA) cycle. Genes involved in folic acid, pantothenate,pyridoxine, thiamine biosynthesis and purine and pyrimidine biosynthesis are alsohighly conserved. M. leprae has lost many of the genes involved in lipid metabolism, butmycolic acid biosynthesis is highly conserved; M. leprae has also lost nitrate and nitritereductase, fumarate reductase, and the urease and NADH oxidase operons, limitinggrowth under anaerobic and microaerophilic conditions. Lipid metabolism and cell wallproteins could be related to virulence as many lipids function in the cell membrane, theinterface between host and pathogen. Additionally, polyketide synthases show widedifferences among the organisms, with M. leprae having lost many of the genes. Mtb hasmany PE and PPE genes, constituting 10% of its genome, while others have lowernumbers of these genes and M. leprae has very few. Lastly, there are relatively highintra6species differences in Mtb; this could also lead to differences in pathogenesis(Marri et al., 2006).
61.3.2 Phylogeny and Related Organisms Mycobacteria belong to the phylum Actinobacteria, order Actinomycetales, suborder
Corynebacterineae, family Mycobacteriaceae (Zhi et al., 2009). Order Actinomycetalescontains a diverse group of soil6growing, marine, plant sybiont and parasitic bacteria(Alam et al., 2010).
Figure 1.2 Phylogeny of the order Actinomycetales. This shows the major groups within the order
Actinomycetales including the various families, and species of those families (Alam et al., 2010).A number of organisms can be seen on the phylogeny above, including the closelyrelated organisms Corynebacterium glutamicum (a soil actinomycete extremelyimportant in industrial production of amino acids) (Kalinowski et al., 2003), Nocardia
farcinica (an infectious aerobic actinomycete causing nocardiosis in humans) (Torres etal., 2000), Rhodococcus sp. (including Rhodococcus jostii, a soil actinomycete useful inbioremediation, and Rhodococcus erythropolis, a soil actinomycete known for its abilityto degrade alkanes) (LeBlanc et al., 2008; Sekine et al., 2006) and Streptomyces
7coelicolor (important in the biotech industry for the production of antibiotics) (Alam etal., 2010). The genera Gordonia,which contains Gordonia bronchialis, also belongs to thefamily Nocardiaceae (Zhi et al., 2009).
1.4 Tuberculosis the Disease For tuberculosis to infect a human and be diagnosed multiple stages must take place.First the disease must be transmitted; secondly an infection develops, and lastlydiagnosis must occur.
1.4.1 Transmission Tuberculosis is primarily a respiratory disease spread by inhaling droplets containingthe bacterium that have been coughed or sneezed out by a person infected withinfectious tuberculosis. Infectious tuberculosis means the individuals have ‘smear6positive’ sputum, or sputum in which bacteria can be easily seen with a microscope(National Institute for Health and Clinical Excellence, 2011).
1.4.2 Infection Once the bacterium enters the lungs, it slowly begins to grow. At this stage, the immunesystem usually responds; for 80% of infected people the immune system successfullykills the bacteria and removes them from the body. In some cases the immune system isunable to kill the bacteria but successfully creates a surrounding barrier to prevent thebacteria from growing, and the bacteria enter a dormant state (National Institute forHealth and Clinical Excellence, 2011). Once this happens, a person has latent TBinfection, which can last for months, years or even decades. Someone with latent TBinfection may never develop the disease nor show any symptoms but may still needtreatment in order to prevent the disease from becoming active at a later point in time(US National Institute of Allergy and Infectious Disease, 2009). Only about one in tenindividuals infected with TB will develop active tuberculosis in their lifetime; thisoccurs when the immune system fails to contain the bacteria or the barriers breakdown at a later point in time. Oftentimes active TB strikes those with weakenedimmune systems, such as HIV infected individuals or the very young or elderly. ActiveTB typically involves infection of the lungs and will present as lesions on the lungs,coughing, fever and/or weight loss; this is called pulmonary TB. Extrapulmonary TBoccurs when bacteria are carried by the blood to other tissues in the body, and can
8affect all other bodily tissues including bones, the spine, kidneys, lymph nodes and thebrain; symptoms include pleural effusion, meningitis, miliary disease and pericardialeffusion (Dye et al., 2006).
1.4.2.1 Macrophage Environment During infection, many bacteria exist intracellularly within early phagosomes ofmacrophages by arresting development of the phagosome (Kaufmann and Parida,2008). The environment of the macrophage early phagosome is subject to debate but itis believed that this environment is characterised by hypoxia, relatively high pH of 6.2and nutrient scarcity restricting the bacteria to the use of fatty acids as a source ofcarbon (Galagan et al., 2013; Guirado et al., 2013). Indeed, Mtb preferentiallymetabolises lipid substrates over carbohydrates ex vivo so it probably has distinctivecentral carbon metabolism that helps it adapt to the macrophage environment (Rhee etal., 2011). Additionally, Mtb has been shown to hijack the host metabolism to acquiresome essential nutrients and prevent its degradation by host mechanisms (Pieters,2008).
1.4.3 Diagnosis TB diagnosis in patients can occur through a number of diagnostic tests. The first is thetuberculin skin test (TST) in which a tiny amount of Mtb protein is injected under theskin; if there is a reaction, such as if the spot turns into a raised red mark, then theperson has been exposed to the bacterium. However, this only shows exposure to thebacteria and not whether or not the person has active TB. Chest radiography is oftenused to determine if a person has the active disease because lesions or other signswould be observed on the x6rays. Sputum smear specimens are the final most commonand inexpensive diagnosis method in which sputum samples are taken from the patientand examined under the microscope. Sputum smear microscopy becomes ineffective,however, if the number of bacteria in the sputum is low (Dye et al., 2006). All thesediagnosis methods are older methods, and because of their low sensitivities, newmethods have been developed. Modern diagnosis methods include tissue biopsies,cultures and ultrasounds, as well as molecular methods such as nucleic acidamplification (Xpert MTB/RIF system) (World Health Organization, 2013d). Cultures
9are more typically used for drug resistance testing rather than diagnosis as the slow6growing bacteria can take two to three months to grow in a culture.
1.5 Reducing the Prevalence and Incidence of Tuberculosis Tuberculosis is an entirely treatable disease when the correct drugs are administered topatients; with correct treatment there is a cure rate of 90% for patients with drug6susceptible strains and 50670% for patients with multidrug6resistant strains (WorldHealth Organization, 2011). However, treatment is complicated by factors such as thelength of time drugs need to be taken (up to two years), drug6resistance,immunosuppressive diseases such as HIV and reactivations of latent tuberculosis. Thusa number of strategies have been implemented in order to combat the spread of TBaround the world.
1.5.1 Public Health Measures Tuberculosis has a greater effect on the poor throughout the world, explained by lowerlevels of access to health care, poor living conditions, malnutrition, and HIV infection.Other risk factors include smoking, alcohol abuse, diabetes mellitus and drug abuse.Improving socioeconomic conditions helps to control the spread of TB (World HealthOrganization, 2011). In addition, governments and international groups need to ensurethat tuberculosis control programs are adequately funded, health care providers areappropriately trained and supported, infection control practices are implemented,second6line drugs are made available, communities facing certain risk factors haveprograms tailored to their particular needs, and that they engage communities incontrolling tuberculosis (Abubakar et al., 2013).
1.5.2 Drugs Most of the drugs used today to treat tuberculosis were originally developed in the1940s and 1950s. The first effective drug against tuberculosis, streptomycin (SM), wasdeveloped in 1944 (Schatz, 2005). Two years later, para6aminosalicylic acid (PAS) wasdiscovered (Lehmann, 1946). Isoniazid (INH), a highly active, inexpensiveantituberculosis drug with minimal side effects, was developed in 1952. Pyrazolinamide(PZA) came shortly after in 1952, with ethionamide (ETH)/prothionamide (PTH)following in 1956. Ethambutol (EMB) was then discovered in 1961, followed by manyother drugs including cycloserine (CS), kanamycin and amikacin, viomycin,
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capreomycin and rifamycins, developed into rifampin (RIF) the most common useddrug to treat tuberculosis since the 1970s. Quinolone drugs (FQ) were only developedin the 1980s based on research conducted in the 1960s. Of these drugs, INH, RIF, PZA,EMB and SM are considered first6line drugs, whereas kanamycin, amikacin,capreomycin, CS, ETH/PTH, thiacetazone and FQ are second6line drugs. Lastly, some ofthese drugs are specific for TB or mycobacteria such as INH, PZA, PAS, ETH, EMB andthiacetazone, while the rest are broad6spectrum antibiotics (Zhang, 2005).
Figure 1.3: This image shows all the commonly used drugs to treat tuberculosis infection, including their
method of action (Zhang, 2005). Due to complications arising from drug6resistance and the life history of Mtb, (that itcan form persistent populations of bacteria that can lie dormant for many years in hostsuntil being reactivated) TB treatment typically involves a combination of drugs givenover a long period of time. The most standard form of therapy is the Directly ObservedTreatment, Short6course (DOTS), developed by the World Health Organization (WHO)for treatment of drug6sensitive tuberculosis. DOTS involves a six month regimenincluding four first6line drugs. During the first two months, INH and RIF, the two mostpowerful drugs against TB, plus EMB and PZA are all taken, and then the last fourmonths INH and RIF are continued. DOTS typically cures around 90% of drug6
11
susceptible TB cases; however, many cases now are characterised by drug6resistance,leading to more complicated and longer treatments. Treatment of drug resistant casesinvolves both first6line and second6line drugs and can take up to two years for a patientto complete treatment (World Health Organization, 2011).
1.5.3 Vaccines Currently the only vaccine in regular use for preventing tuberculosis is the bacillusCalmette6Guérin (BCG) vaccine, which has been in use since 1921 (Colditz et al., 1994).However, this vaccine typically provides protection only against childhood forms of TB,particularly meningitis and military disease, but minimal or no protection againstpulmonary TB in adults (Trunz et al., 2006). Even with high levels of BCG vaccination,there still exists a high incidence of tuberculosis in children in endemic countries likeSouth Africa (Tameris et al., 2013). Additionally, BCG vaccine can harm HIV positiveinfants and should not be administered to these children. A number of vaccines arebeing developed which are either designed to replace BCG as a recombinant live vaccineor act as a booster for BCG, but these are likely to have limited capabilities at preventinginfection and preventing activation post6exposure (Kaufmann et al., 2010). Additionally,immunotherapeutic vaccines that can boost the immune system during treatment arecurrently being tested (Jassal and Bishai, 2009).
1.5.4 Other Treatment Options Treatment of tuberculosis could also include surgery in some cases. Surgicalintervention might be considered if the patient has significant localised pulmonarytuberculosis. This option would likely be performed in infections with high levels ofresistance to drugs (Jassal and Bishai, 2009).
1.6 Complications Encountered When Treating TB As a bacterium that has evolved alongside humans for thousands of years, TB hasproven extremely difficult to treat. Over the years, multiple discoveries have led to thebelief that tuberculosis would soon be eradicated; for example, when BCG was firstdiscovered it was thought to be the vaccine to prevent all tuberculosis. Similarly, afterthe discovery of streptomycin in the 1940s it was believed that TB treatment wouldthereafter be simple (Brennan and Thole, 2012). However, Mtb has proven highlyresistant to eradication attempts, due to certain characteristics of both the bacteria and
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management of the disease. Firstly, its ability to lie dormant for years in the host allowsit to evade most current antituberculous drugs, which mainly attack the bacteria whilegrowing, and then reactivate at a later stage when drugs are no longer present in thesystem (Zhang, 2005). Secondly, delays in diagnosis of the disease due to failing healthcare systems or poor diagnostic methods can increase transmission of the disease. Next,due to the long treatment duration, lack of drugs and sometimes serious side effects ofdrugs, patient compliance to treatment regimens is often poor, allowing furthertransmission and drug resistance to arise (Jassal and Bishai, 2009). In addition, the HIVepidemic requires new treatment plans so that drugs do not interact adversely, and sothat new forms of extensively drug6resistant strains (XDR) do not develop in theabsence of a strong host immune system. Lastly, Mtb has proven highly adaptable,evolving resistance to currently available drugs relatively easily, especially when thereis slow diagnosis, poor adherence to treatment and HIV coinfection (Zhang, 2005).
1.6.1 Persistence It is estimated that one third of the world is latently infected with Mtb; these individualsserve as a reservoir of the disease from which active infection can arise (Ma et al.,2010). It has been shown that lesions filled with tubercle bacilli include at least fourdifferent sub6populations. The first are actively growing bacteria, which are killed byINH, RIF or SM. Then there are bacteria with spurts of metabolism, killed by RIF, thosein an acidic environment with low metabolic activity, killed by PZA, and finally thosethat are dormant and not killed by any currently used drug (Zhang, 2005). Dormantbacteria are the cause of such long periods of treatment. Bacteria in this dormant phase,also called persisters, are the cause of latent infection of tuberculosis, a state fromwhich activation or reactivation of virulent TB can occur. Patients with latent infectionhave a 2623% chance of reactivation of the disease in their lifetime (Zahrt, 2003). Latentinfection can be diagnosed with a positive tuberculin skin test (TST) or positive resultfrom another diagnostic tool (such as interferon gamma release assay (IGRA)) but nosymptoms of the disease. These persisters typically exist in anaerobic conditions, and ithas been thought that bacteria in this state are either slowly growing or non6replicating.Along with experiencing hypoxia, bacteria transitioning into the dormant state changetheir carbon source from glucose to fatty acids (Young et al., 2009). By existingintracellularly within early phagosomes of macrophages, they can cause a granuloma to
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be formed around the infected macrophage (Kaufmann and Parida, 2008). Thisgranuloma effectively walls off the complex from cytokines which can activate themacrophage, allowing the bacteria to persist for long periods of time (Bentrup andRussell, 2001).A number of studies have attempted to elucidate the genes involved in the transition toand maintenance of dormancy, but this is still an on6going area of research. In reality itseems that persistence in Mtb requires the “coordinated expression of numerousvirulence determinants, including those involved in intermediary and secondarymetabolism, cell wall process, stress responses and signal transduction pathways”(Wang et al., 2011). Determining which genes are involved in this coordinatedexpression, however, remains difficult because there are few clinical models that canprovide reliable data regarding mycobacterial metabolism during persistence. Forexample, in vitro models might not reflect the same conditions (energy source, presenceof antibiotics, interactions with the host) experienced in vivo and thus gene expressionpatterns will be different (Dhar and McKinney, 2010). A recent study has refuted theidea that persisters come from subpopulations of nonreplicating bacteria that areunaffected by antibiotics. This study showed that there was no subpopulation ofpersisters prior to introduction of isoniazid, and rather that single6cell growthdepended on cell size; it also showed that rather than having a semi6constantpopulation of bacteria that survive through isoniazid treatment, the persistentsubpopulation is in fact dynamic, and the population simply appears stable due to abalance between the rates of cell division and death (Wakamoto et al., 2013). Thus,persistent bacteria perhaps do not cease to replicate but rather form a stablepopulation size by balancing cell division and death rates. Research regardingpersistent populations of bacteria both in patients who have never had disease andhave recovered from active disease continues to be performed, and will hopefully solvesome of the questions and lead to better TB treatment methods.In some cases latent infection may need to be treated with preventative therapy inorder to avoid the development of active tuberculosis. In this case, isoniazid isadministered for a period of 669 months. Preventative treatment can be particularly
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effective in high6risk populations such as those who have had recent contact withsomeone who has active TB or for those who are HIV positive (Ma et al., 2010).
1.6.2 Slow Diagnosis Within communities, the most effective strategy to reduce transmission of tuberculosisis early detection followed by quick and appropriate treatment (Abubakar et al., 2013).In particular, delays in diagnosis of active tuberculosis (latent tuberculosis is notthought to be infectious) can lead to a significant increase in transmission. The WHOestimates that a person with active tuberculosis can infect 10615 other people per yearthrough contact (World Health Organization, 2013e). With an increase in the reservoirof disease in the population, the bacteria have more opportunities to develop resistanceto current drugs, which in turn makes treating the disease more difficult, ultimatelyfurthering the spread of tuberculosis in a vicious cycle.The most commonly used diagnostic method in most high6burden countries is sputumsmear microscopy, which has low sensitivity, often missing cases in those with HIVcoinfection, extrapulmonary dissemination, those with latent infection and children(Jassal and Bishai, 2009). For example, HIV6positive TB patients have been found to besmear6negative in 24%661% of cases (Getahun et al., 2007). Newer diagnostic testssuch as nucleic acid amplification and interferon gamma release assays, while providingmore accurate and quicker results, are often not available or not used in many endemicareas due to high cost and limited capacities (Jassal and Bishai, 2009). Diagnostic teststo assess drug resistance usually include cultures, which can take 468 weeks to receiveresults. This delay increases the time allowed for transmission and the development offurther drug6resistance by delaying the time spent until the appropriate treatment isadministered (Jassal and Bishai, 2009). In fact, the WHO estimates that in 2011 only19% of MDR6TB cases were found among notified cases of TB (World HealthOrganization, 2012a). While molecular methods to test for drug resistance are available,these diagnostic tests are typically more expensive and labour6intensive (Jassal andBishai, 2009). However, the Xpert MTB/RIF molecular test has been adopted by somecountries in order to diagnose TB and rifampicin resistance and should become morewidespread over time (World Health Organization, 2012a). Better diagnostic methodsthat can diagnose both active and latent infection as well as drug resistance, increased
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adoption of diagnostic methods, and improved infection control methods can disrupttransmission chains and significantly reduce the worldwide burden of tuberculosis.
1.6.3 Patient Compliance Treatment for tuberculosis typically involves long time periods over which drugs areadministered (at least six months). Additionally, some of the drugs, and particularlythose administered for drug6resistant cases, have side effects that can discouragepatients from adhering to the appropriate therapy. Long treatment period and negativeside effects can result in irregular dosing and incomplete treatment (not completing thefull six months of chemotherapy) which ultimately result in relapse and/or thedevelopment of drug resistance (Ma et al., 2010).
1.6.4 HIV Coinfection HIV positive patients have both an increased likelihood of the disease progressing toactive tuberculosis after infection and an increased likelihood of reactivation of latentinfection (Jassal and Bishai, 2009). This is compounded by the fact that rifampicin, oneof the most used first6line drugs to treat tuberculosis, interferes with manyantiretroviral drugs (Ma et al., 2010). Thus, HIV coinfection further reduces TBtreatment effectiveness.
1.6.5 Drug-Resistance Drug susceptibility in mycobacteria is thought to be an acquired trait based on theenvironmental niche of the species. Since many of the antimycobacterial drugs areproducts of soil dwelling microbes, drug resistance is an adaptation to the environmentin nontuberculous mycobacteria. Common human pathogenic mycobacteria do notusually come into contact with these microbes within the human body, and thus haveadapted drug susceptibility, possibly increasing virulence. The most drug susceptibleand virulent of mycobacteria include the MTBC, M. kansasii, M. szulgai, M. marinum, M.
malmoense, M. xenopi and M. leprae (van Ingen et al., 2012). Even so, the emergence ofdrug resistance occurred almost immediately after the first drug, streptomycin, beganbeing used to treat tuberculosis patients (Jassal and Bishai, 2009). After additionaldrugs were discovered, treatment regimens were formulated that seemed to preventresistance from developing. However, by the 1980s new forms of multidrug6resistantstrains began to develop; this emergence typically is caused by system failures such as
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incomplete or inadequate treatment, lack of drugs leading to monotherapy, baddiagnostics and lack of regulation in accessing antibiotics. While these factors oftenresult in acquired resistance, leading to reactivation within previously treated patients,many new cases of drug6resistance arise due to transmission of drug6resistant strains,particularly in areas of high incidence (Abubakar et al., 2013). Resistance can also beamplified, whereby a currently resistant strain develops increased levels of resistancedue to inappropriate administration of drugs (Jassal and Bishai, 2009).Additionally, on6going division during the latent phase may increase the likelihood ofevolution of resistant strains. Drug resistance is not only caused by mutations but canalso be caused by reversible phenotypic tolerance of drugs. It is possible that some ofthis tolerance is caused by epigenetic effects, as sister cells had a correlated survivalrate under INH treatment (Jassal and Bishai, 2009).Standardised treatment methods may not be appropriate for drug6resistant cases. Thisis certainly the case with XDR tuberculosis, where individualised treatment methodsare necessary both in order to accurately treat the patient and to prevent furtherresistance from developing (Jassal and Bishai, 2009).
1.7 Bioinformatics The publication of the human genome in February 2001 initiated a new era in the fieldof biology. Following this publication, a number of additional genomes have beenpublished across a range of bacterial, plant and animal species. The combination ofcomputer science, mathematics and statistics with biology has revolutionised the fieldand opened many opportunities for the advancement of genetics and disease research(Baxevanis and Ouellette, 2005). Biological research in bioinformatics is typicallycomposed of three main aspects, databases, tools and algorithms. Various databasesand tools have been used to complete this study.
1.7.1 Genome Sequencing Sequencing refers to the use of certain techniques to determine the order of geneticmaterial in either DNA or RNA or of amino acids in proteins. Automated techniques arenow used which can quickly and accurately sequence complete genomes (Lerner andLerner, 2008). Genetic sequences are the basis of bioinformatics research and many
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databases and tools have been developed to organise and analyse these sequences todiscover biologically relevant information.
1.7.1.1 Orthologs One of the most exciting aspects of the plethora of complete genomes available is theability to perform comparative analysis to find homologies, or a relationship of commondescent, between genes. A homologous gene can be classified into two categories: anortholog, genes related due to speciation or derived from a single common ancestor,and a paralog, genes related due to duplication, which can occur within one organismand/or between organisms (Koonin, 2005). The definition of ortholog has no directmeaning for functional characterisation of genes, but it does have implied meaning andoftentimes orthologs have equivalent function. One comparison between E. coli and B.
subtilis for one6to6one orthologs (only one protein in each genome) did not produce oneclear example of different functions between orthologs (Koonin, 2005). This does nothold true for organisms in different kingdoms, such as between bacteria and archaea oreukaryotes, which often show different functions. Additionally paralogs, though theymay retain their ancestral function, can also display functional diversification andspecialisation based on selective constraints. Lastly, although most orthologs haveequivalent function, the reverse statement is usually false; many examples exist wherenon6orthologous and even non6homologous proteins perform equivalent functions. Thefunctional equivalency of orthologs is often used to annotate genomes because it isimpossible to experimentally derive the function of all genes in all sequenced genomes.The characterisation of orthologs can be confounded in prokaryotes by the commonlyoccurring event called horizontal gene transfer (HGT), in which genes are acquiredfrom an outside source; these genes could appear to be orthologous but are not trueorthologs, and are rather called xenologs. Additionally, genes can appear to beorthologous when lineage6specific paralogous genes are lost, but these are in fact ratherknown as pseudoorthologs (Koonin, 2005).
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Figure 1.4 Pseudoorthology and xenoparalogy caused by horizontal gene transfer. Image (a) shows HGT
leading to xenology, in which gene XB is transferred from species C and appears to be orthologous to XA, with
XA being lost in species B due to displacement. Image (b) shows HGT leading to pseudoparalogy and
pseudoorthology, in which XB2 has been transferred from species C and appears paralogous to XB1, and
orthologous to gene XA (Koonin, 2005).Xenologs and pseudoorthologs may appear to be orthologous but in fact are not, andthus have important effects on predicting gene function. Orthologs can be identified inmultiple ways. First, orthologs are identified on the basis of phylogenetic analysis inwhich a gene tree is compared to the species tree and then are reconciled; HGT has anenormous effect on this method. Another method matches genes based on sequenceand assumes that orthologous proteins are more similar to one another than to othergenes in the genome and that matches are most likely formed between orthologs. Thiscan lead to false negatives and false positives, particularly for genes that are paralogs,pseudoorthologs and xenologs. While these methods are by no means perfect, certainassumptions such as these are necessary due to the computing time needed to processwhole genomes (Koonin, 2005).
1.7.2 Databases With the development of all the sequenced genomes now available, the organisation ofall this data has become essential. Thus a number of databases have developed toorganise data and compile it into easily accessible locations for researchers to add toand utilise. There are a number of databases relevant to this study including the KyotoEncyclopaedia of Genes and Genomes (KEGG) (www.genome.jp/kegg/) (Aoki6Kinoshitaand Kanehisa, 2007; Kanehisa et al., 2010; Ogata et al., 1999), Encyclopaedia of
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Metabolic Pathways (MetaCyc) (www.metacyc.org) (Caspi et al., 2012), Integr8 (nolonger operational) (http://www.ebi.ac.uk/integr8/), Universal Protein Resource(UniProt) (www.uniprot.org) (The UniProt Consortium, 2014) and Gene Ontology (GO)(www.geneontology.org) (The Gene Ontology Consortium, 2000).
1.7.2.1 KEGG The early development of KEGG began in 1995 as part of the Japanese Human GenomeProject (Ogata et al., 1999). The database stores and organises information in order tointegrate genomic, chemical and systemic functional information (Kanehisa et al.,2008). It has been widely used as a reference for the biological interpretation ofdatasets such as those produced from sequencing (Kanehisa et al., 2006) KEGG iscomposed of 15 main databases including KEGG PATHWAY (pathway maps), KEGGORTHOLOGY (KO) (manually defined ortholog groups), KEGG GENES (gene catalogues),KEGG ENZYME (information on enzyme nomenclature) and KEGG REACTION(metabolic reactions) (Kanehisa et al., 2010). Genome annotation is based on the KOsystem; using genes with known function, orthologous genes of organisms are assignedto orthology groups based on best6hit sequence matches. Once this annotation occurs,the genes with their new K numbers can be mapped to pathways (Kanehisa et al., 2012).KEGG contains 237 pathway maps, which are manually drawn graphical diagrams thatshow all the known reactions, no matter the organism or taxonomic group in whichthey function, related to a particular topic (for example phenylalanine metabolism).KEGG contains pathways that do not exist in MetaCyc such as xenobiotic degradation,glycan metabolism and metabolism of terpenoids and polyketides (Altman et al., 2013).KEGG also allows users to map their own data onto KEGG diagrams, for examplecolouring specific attributes (Kanehisa et al., 2012).
1.7.2.2 MetaCyc MetaCyc is similar to KEGG in that it is a reference source that integrates metabolicpathways and can be used for pathway prediction of organisms based on theirannotated genomes (Karp et al., 2002). It contains a searchable encyclopaedia ofenzymes, enzymatic reactions, non6redundant metabolic pathways, substrate6levelregulation, cofactor requirements, substrate specificity as well as a host of otherinformation (Caspi et al., 2006). MetaCyc contains a large number of reactions
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categorised into 296 superpathways, the MetaCyc equivalent of KEGG pathwaydiagrams (Altman et al., 2013). Additionally, all MetaCyc pathways are experimentallyderived, providing a high level of accuracy and reliability (Caspi et al., 2014). Theexpected taxonomic range of each is also included in the database, allowing users tofind pathways that are likely to exist in the organism being investigated. When aMetaCyc pathway is present for an organism then it is assumed that all the reactionswithin that pathway are present for that organism. Lastly, MetaCyc contains pathwaysthat do not exist in KEGG such as those in actinobacteria, plants, fungi and metazoan(Altman et al., 2013).
1.7.2.3 Integr8 Integr8, though no longer in use, provided a single entry location to complete genomeinformation (Kersey et al., 2005). It included all organisms with completely sequencedgenomes at the time of database retrieval. Integr8 also allowed this data to be searchedand for chosen components to be compared and extracted via downloads. Additionally,summary information for each genome could be accessed and downloaded for furtheranalysis. The database included CluSTr, which hierarchically clustered proteins basedon sequence similarity; this clustering proceeded via single6linkage clustering to createa similarity matrix, for which statistical significance was then assessed, creating ahierarchy of clusters (Petryszak et al., 2005). The CluSTr database formed the basis forthe prediction of orthologs for each protein from the genomes. Within Integr8, theortholog file for each sequenced genome could be downloaded; this file would includeall predicted orthologs across all organisms in the database for that genome (Mulder etal., 2008).
1.7.2.4 UniProt The goal of UniProt is to “provide a comprehensive, high6quality and freely accessibleresource of protein sequences and functional annotation” (The UniProt Consortium,2014). It compiles, interprets and standardises data from a variety of sources to providea highly comprehensive catalogue of protein information. The UniProt Knowledgebase(UniProtKB) is entirely curated with both a fully reviewed and manually annotatedsection known as UniProtKB/SwissProt and non6reviewed and automatically annotatedsection called UniProtKB/TrEMBL. UniProt is the world leader in the provision of
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comprehensive curation of literature6derive experimental data, and works with otherdatabases to ensure that time and effort is not wasted on the duplication of work. Eachpage in UniProt is filled with the record of one gene and all its protein products in oneorganism and includes names, function, catalytic activity, pathways and all relevantinformation to those proteins (The UniProt Consortium, 2014). Thus, UniProt provide ahighly accurate and reliable database of proteins along with corresponding relevantinformation regarding classification, function and activity.
1.7.2.5 Gene Ontology (GO) The GO resource classifies products of genes with functional information by usingstructured and controlled vocabularies. This resource aims to provide a standardterminology with which to annotate genomes to enable consistent and accuratecomparisons between information derived from a variety of sources. GO terms describehow (function) and where (process and location) gene products act and are composedof both the terms applied to a specific gene product as well as the evidence for theapplication of that term. Annotating gene products with GO terms proceeds by bothmanual (e.g. using literature sources) and automatic (e.g. using sequence similarity)methods. Terms are periodically reviewed for biological relevance in order to maximiseutility and ensure complete coverage (The Gene Ontology Consortium, 2013).
1.7.3 Tools One of the major tasks in bioinformatics is the development of user6friendly tools inorder to help analyse and interpret large6scale sets of data such as whole genomesequences. These tools are often designed to make bioinformatics analyses possible forthose without computational backgrounds such as biologists (Baxevanis and Ouellette,2005). A number of tools relevant for this study include Basic Local Alignment SearchTool (BLAST) (blast.ncbi.nlm.nih.gov/Blast.cgi) (Camacho et al., 2009), Pathway Tools(http://bioinformatics.ai.sri.com/ptools/) (Karp et al., 2010) and MultiExperimentViewer (MeV) (www.tm4.org) (Saeed et al., 2003).
1.7.3.1 BLAST BLAST is a program used to perform sequence similarity analyses (Johnson et al., 2008).These sequence alignments are typically the first method used to connect newlysequenced DNA to sequences that have already been characterised. BLAST takes a
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nucleotide or protein sequence and uses it to search across either a nucleotide orprotein database to find matches (Boratyn et al., 2013). BLAST can be accessed eitherthrough the web interface or by download and operation on the command line, anduses a heuristic that first locates short matches between sequences before attemptingalignments in order to shorten the required length of time to process the alignment(s).Once matches are found, BLAST provides statistics regarding the false6positive rate; thelower this rate, also known as the ‘expect’ value (e6value), the less likely the match is afalse positive. BLASTP attempts to perform protein alignments between querysequences and target genomes. Query sequences can take the form of a sequence inFASTA format or sequence identifiers such as GenBank accession number (Ye et al.,2006). The e6value threshold for matches is often taken at 1066, with any values lowerthan this taken to signify a positive match; however, higher e6values might beapplicable to find all possible positive matches or lower e6values might be necessary tosort orthologs and paralogs (Kerfeld and Scott, 2011).
1.7.3.2 Pathway Tools Pathway Tools (PT) uses the MetaCyc database in order to predict metabolic networksbased on genome sequence. PathoLogic uses ‘key reactions’ and taxonomic range(predicted in MetaCyc) to identify pathway memberships for a particular genome; ‘keyreactions’ are those that are unique, or do not also function in other pathways, and arealso defined in MetaCyc (Karp et al., 2011). The Cellular Overview tool in PT is used toshow all the metabolic pathways for a Pathway/Genome Database (PGDB) in oneintegrated diagram similar to the Global Map in KEGG (Caspi et al., 2013). Additionally,PT creates a list of pathway holes, or situations in which a genome seems to lack theenzymes needed to catalyse reactions within a pathway; the database uses certainmethods that combine evidence (such as homology, operons and context) to attempt tofill these holes, but remaining pathway holes are combined into a file available fordownload (Green and Karp, 2004).
1.7.3.3 MeV MeV is actually a tool developed for the visualisation and analysis of microarray data(used to determine expression patterns in organisms). The tool allows users to organisemicroarray data into heat maps in which expression levels are represented by various
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shades of two colours signifying the high and low values. It also allows user to analysesuch data by utilising clustering and statistical tools (Saeed et al., 2006). These heatmaps also allow for the visualisation and analysis of alternative types of data such asortholog information across a wide variety of species.
1.8 Annotations An annotation is composed of any type of additional information added on top of anyexisting data or document. Annotation incorporates additional layers of biologicallysignificant knowledge to help classify and analyse large6scale data such as thatgenerated by genome sequencing efforts (Gupta, 2009). Types of annotation forprokaryotes include structural, based on experimental evidence to find the physicalcharacteristics of a gene, and functional annotation, based on sequence similarity todetermine the function of the gene (Beckloff et al., 2012). Genome annotation isperformed via two methods: the first is manual annotation, in which a researcherphysically adds annotation information to a genome, and the second is automaticannotation, which takes advantage of various bioinformatics tools in order toautomatically add information to the genome.
1.8.1 Automatic Annotation Automatic annotation involves the automatic generation of annotations, usually basedon sequence similarity using various bioinformatics tools. For raw genome sequencesthese automatic annotations typically output a set of open reading frames (ORFs) withstart and stop codons, as well as predictions of function, metabolic pathways, geneontologies and phylogenetic information based on sequence alignments (Tummler,2010). A large proportion of these automatic annotations can be incorrect (14658% inone study), meaning that results must be evaluated for accuracy and further work mustbe done to provide correct biological interpretations (Ederveen et al., 2013). Automaticfunctional annotation can be performed through the use of either pairwise or multiplesequence alignments, usually with phylogenetically related organisms. Functionalannotations are assigned to genes based on alignments with already6annotatedreference genomes (Pirovano and Heringa, 2008). Automatic annotation is moreefficient and less labour intensive, but usually requires manual annotation to improveaccuracy and maximise biological analyses.
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1.8.2 Manual Annotation Manual annotation involves the review and curation of automatically generatedannotations by human experts (Richardson and Watson, 2013). This typically makesgreat use of the literature and assigns more specific information to genes based ondirect experiments on those genes and gene products and/or their orthologies withgenes characterised in substantial depth in the literature. When little functional data islocated, a more in depth analysis in performed via sequence analyses, database miningand literature searches. These annotations will either create or improve annotations orallow a hypothesis about the function to be generated (Tummler, 2010). Manualannotation will improve reliability and biological significance of annotation but is alsotime consuming. Most genome annotation processes involve a combination of bothautomatic and manual annotation to maximise accuracy and efficiency (Richardson andWatson, 2013).
1.9 Metabolic Pathways A metabolic pathway is a “series of enzyme6catalysed chemical reactions occurringwithin an organism, in which a principle chemical is modified” (Caspi et al., 2013). Theyare the true functional units of metabolic systems and enable an organism6wideinterpretation of cellular activities (Schilling et al., 2000). Pathway data includes threelevels of information including the metabolites that form the basis, the reactions, whichare built on metabolites, and pathways, which are composed of reactions (Altman et al.,2013). Metabolic pathway networks can provide information on organism response todifferent conditions and, for pathogenic bacteria, help elucidate disease progressionand interdependent mechanisms between host and microbe; the more complete ametabolic pathway is, the greater the biological relevance of its analysis andinterpretation (Papin et al., 2003). To enable analyses based on metabolic pathways,they first must be classified, and then they must be compared to identify biologicallyrelevant discoveries.
1.9.1 Functional Classification Functional annotation and classification of genes is usually accomplished via sequencealignments with highly characterised reference genomes such as E. coli. Accuracy ofpathway prediction is heavily based on the coverage of the reference pathway of the
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database. MetaCyc and KEGG share an estimated 3,600 reactions, leaving about 1,000reactions unique to each database. Pathway predictions performed using KEGG havebeen theorised to be less accurate than for MetaCyc, because MetaCyc providesadditional reaction attributes such as taxonomic range (Altman et al., 2013). Functionalannotation based on homology is a subject of debate, but multiple studies have shownthe functional equivalency of orthologs; while the fundamental functions of orthologssometimes change, these changes are rare and often associated with major evolutionarytransitions involving a significant acceleration of evolution (Koonin, 2005). It is usuallyassumed that paralogs are less likely to retain function and therefore have lower levelsof functional equivalency (Altenhoff et al., 2012; Chen and Zhang, 2012; Thomas et al.,2012); however, there is also some evidence to the contrary in that paralogs might havejust as much if not more functional equivalency as orthologs (Nehrt et al., 2011). In all,the ortholog conjecture seems to be supported, and it is likely that paralogs have lowerlevels of functional equivalency as compared to orthologs. Since basic sequencealignments do not distinguish between orthologs and paralog but simply analysehomology between sequences, the potential effects of paralogs must be taken intoaccount.
1.9.2 Comparison of Pathways The development of metabolic pathway networks for sequenced genomes has enabledthe comparison of these networks. For example, comparisons of genome6scalemetabolic pathway reaction content and networks have been used to performphylogenetic analyses on organisms (Hong et al., 2004). Additionally, thesecomparisons can help identify virulence factors that explain why certain organisms orstrains of organisms are more virulent during infection of hosts (O’Callaghan andStebbins, 2010). Network comparisons have also been performed in order to locatedifferences in metabolic phenotype. These network comparisons can also be used formany other purposes such as multi6species studies and host6pathogen interactions. Asof 2009 these last two uses of metabolic reconstructions were relatively representedthe least in the literature but can provide biologically relevant predictions of phenotypeand bacterial activity (Oberhardt et al., 2009). Lastly, many studies make use ofmycobacterial model systems such as M. smegmatis, M. bovis BCG and M. marinum;comparative analysis of genome6scale metabolic networks can assist in identifying
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pathways that are both similar and divergent between the model organisms and Mtb(Shiloh and Champion, 2010).
1.10 Pathway Holes A pathway hole, or ‘missing’ pathway, is a metabolic reaction within a pathway forwhich no catalysing enzyme has been located in the genome. Many possible pathwayholes result from situations in which genes coding these enzymes do exist but havesimply not been identified by the annotation methods, especially when one gene hasmultiple functions (Karp et al., 2010). Alternatively pathway holes can signify occasionswhen the bacteria might utilise, or hijack, the host metabolism in order to acquirecertain nutrients and accomplish certain metabolic needs. Bacteria belonging to
Chlamydiae, obligate intracellular pathogens that replicate within vacuoles, have beenshown to redirect vesicles and hijack organelles in order to ensure the acquisition ofessential nutrients (Saka and Valdivia, 2010). The identification of genuine pathwayholes can therefore provide important information regarding potential host6pathogeninteractions.
1.11 Need for New Drugs New drugs are urgently needed to address some of the concerns outlined above (Besteand McFadden, 2013). These drugs have several requirements in order to help end thisepidemic of tuberculosis. First, new drugs are required that can combat Mtb duringboth active and latent infection. Next, new drugs must be effective against resistantstrains of Mtb, meaning that they must have novel targets compared to currently useddrugs. Third, they must be able to treat patients with HIV coinfection, and thus have nointeractions with antiretroviral drugs. New drugs must also be able to shorten theduration of treatment to reduce issues with patient adherence to treatment regimens.Additionally, these drugs should be low6cost options in order to allow patients inresource6poor regions to have access to new treatment options. Lastly, new drugs donot necessarily need to function on their own as monotherapy but instead should beincluded in new, comprehensive regimens that accomplish all of the functions thusdescribed (Ma et al., 2010).
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1.12 Thesis Rationale Knowledge of the metabolism of Mtb will increase understanding of the disease as itdevelops within hosts and greatly assist in the rational development of drugs. With agreater understanding of the metabolome, or complete metabolism, doctors andresearchers will better understand the course of the disease, how to quickly diagnoseTB and better treatment regimens. One of the major steps in the drug developmentpipeline involves the identification and validation of appropriate targets, which ispresently a major bottleneck. Many currently used drugs have been developed withoutthe knowledge of targets, possibly because of the inability to use standardmethodologies to identify these targets on a large scale (Raman et al., 2008).Additionally, many drugs have bad side effects caused by polypharmacology, or whendrug molecules interact with multiple targets (Reddy and Zhang, 2013). Comparingpathway and reaction information over a broad spectrum of organisms (phylogeneticprofile) can assist in finding these new drug targets without affecting proteins in thehost or beneficial bacteria residing in the host. Proteins of Mtb without orthologs inother organisms can identify enzymatic reactions, which, if attacked, would not affectthe metabolism of host cells nor beneficial bacteria within the host. By finding theseproteins, potential drug targets can be identified for future drug development.Additionally, by using a phylogenetic profile to identify Mtb proteins with and withoutorthologs, essential pathways can be detected by observing orthologs inMycobacterium
leprae, a species with a highly reduced genome. Furthermore, by comparison with ananaerobic bacterium, potential pathways essential for anaerobic metabolism can beidentified, thereby finding potential drug targets for the persistent phase of infection.Lastly, mapping these pathways can help identify ‘missing’ pathways or pathway holes,possible circumstances in which Mtb uses the host metabolism to accomplish itsmetabolic needs.
1.13 Aims of the Study This study consists of three main steps:i. Completing the metabolic map by adding novel functional annotations to thegenome ofM. tuberculosis H37Rvii. Identifying reactions and pathways of interest using the phylogenetic profileiii. Identifying pathway holes, or missing pathways
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1.14 Road Map The remainder of the thesis is composed of the following chapters:
J Chapter 2 details the materials and methods used to complete the aims of thisstudy. This includes the steps taken to add manual annotations to the genome basedon both functional terms such as GO ontology and using KEGG mapping diagrams asa basis for protein matching with BLASTP.
J Chapter 3 details the results of the methods described above; this includes theadditional annotations and creation of tables recording pathway holes.
J Chapter 4 discusses the results. First the possible confounding factors of the resultsare considered. Secondly the results of the annotations are examined, with furtherexamination and mapping of three KEGG pathway diagrams with many newlycharacterised individual reactions and additional branches of pathways. Next thephylogenetic profile is analysed to discover important pathways and reactions,which include those in which Mtb shares both few and many orthologs with M.
leprae, few orthologs with E. coli and H. sapiens and many orthologs with C.
glutamicum, a facultative anaerobe. Lastly, pathway holes are considered to findthose for which Mtb may use the host metabolism to accomplish its metabolic needs.
J Chapter 5 reviews the important results found and summarises the conclusionsdrawn from these results. It evaluates the lessons learned and future research thatmust be done to advance the provided results.
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2 Materials and Methods 
2.1 Extraction of Ortholog Data The Mtb ortholog data was downloaded from Integr8, which has since been replaced byEnsembl genomes (Kersey et al., 2005). The ortholog .txt files were downloaded foreach of five different strains of Mtb on 21 May 2012. These five strains include ATCC25618 (H37Rv), ATCC 25177 (H37Ra), Oshkosh (CDC1551), F11 and KZN 1435. Each ofthe ortholog files show a list of all proteins encoded by the genome in the strain, alongwith all the known orthologs of that protein in all other species existing in the databaseat that time. Each ortholog entry includes the ortholog accession number, the speciesname and the taxonomic information.Information from these five ortholog files was then extracted and reorganised into aphylogenetic profile, along with pathway data downloaded from KEGG (Kanehisa et al.,2010). To do this, a script was written using Python (http://www.python.org/) tocreate a matrix with the GenBank accession number, EC number and pathway in theleft6hand columns and the ortholog information filling in the rest of the columns. In thismatrix, a ‘1’ indicates that an ortholog is present and a ‘0’ denotes that an ortholog isabsent. An example of this structure is shown in Table 2.1.
Table 2.1 Example structure of the compiled matrix. This shows the accession number of each protein, along
with the strain it has been derived from, its pathway membership, EC number and any orthologs it has across
the phylogenetic profile.AccessionNumber Strain PathwayLevel 1 PathwayLevel 2 Pathway Level 3 ECNumber Org1 Org2….P12345 H37Rv Metabolism EnergyMetabolism MethaneMetabolism EC:1.2.3.4 1 0P67890 KZN Metabolism CarbohydrateMetabolism Glycolysis/Gluconeogenesis EC:5.6.7.8 1 1To create this matrix, the Python script first processed the H37Rv ortholog file,extracting all the proteins and their orthologs. After running through H37Rv, the scriptran through the rest of the strains in the order of H37Ra, F11, CDC1551 and lastly KZN,extracting only those proteins that were not orthologs of H37Rv. These ‘unique’proteins and their orthologs were then appended to the matrix. Thus, the final matrixincludes all H37Rv proteins and those proteins of each strain that were not present inthe previously extracted strains. Theoretically, all of these proteins should be ‘unique’
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i.e. not orthologous to one another. This was done to retrieve a complete list of allpossible Mtb proteins.Pathway information was previously derived from a dataset created by a colleague inthe group using the KEGG database. This file contained information for M. tuberculosisH37Rv regarding the protein accession number, EC number(s), pathway(s) andfunctional description. Pathway membership and EC numbers were extracted from thisdataset and added to the matrix according to their protein accession number. Eachpathway is described by terms at three different levels, becoming more specific by thethird level. Thus columns were created for each pathway level in the final matrix, asshown by the example above.Many of the proteins with KEGG pathway information included multiple pathways perprotein. Thus, when creating the matrix, each protein (and corresponding orthologdata) with multiple pathway membership was duplicated so that those proteins filled asmany rows as they belonged to pathways. If the protein had more than one EC numberthen all were included for each protein entry.
2.2 Incorporating Additional Orthologs Once creation of the structure of the phylogenetic profile was completed, it was noticedthat some proteins showed no orthologs when in fact there was a known ortholog inthat strain or species. It was concluded that the Integr8 data must have used strictconditions when identifying orthologs in other species and strains, thus missing someorthologs. To remedy this, a reciprocal BLASTP was used to find additional orthologs inMtb strains H37Rv, H37Ra, F11 and KZN using CDC1551 as the reference (Boratyn etal., 2013).The additional ortholog data was then incorporated into the matrix. Anytime a ‘0’showed in the matrix for any of these strains, but the additional dataset showed a ‘1’,that entry was changed to ‘1’ in the matrix. After completing this, the matrix nowsignified that an ortholog is present when there was an ortholog shown in either theoriginal Integr8 data or the data obtained through the reciprocal BLASTP. This appliesonly to those five strains of Mtb: H37Rv, H37Ra, CDC1551, F11 and KZN.
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2.3 Removal of Orthologous Proteins in H37Ra, F11, KZN and CDC1551 The same strict conditions of Integr8 also mean that some of the added ‘unique’proteins for H37Ra, CDC1551, F11 and KZN, were in fact not unique. Thus, theseproteins were removed from the matrix. To do this, first a search was performed on theUniProt website using the GenBank accession number. All UniProt entries of the F11proteins included a link to the corresponding EMBL ENA (European NucleotideArchive) webpage (www.ebi.ac.uk/ena/) for the gene encoding that protein (Leinonenet al., 2010). For some of these, the ENA webpage included information about whichH37Rv protein that F11 protein was mapped to. In these cases, the matrix was checkedto make sure that the H37Rv protein was already included. If it was already present,then the F11 protein was removed from the matrix. EMBL ENA webpages for theproteins of the other three strains of Mtb (H37Ra, KZN and CDC1551) did not showmapping information. Therefore, once a UniProt search was performed for each of theseproteins, the ordered locus name was used to perform a search on the KEGG website. Insome cases, KEGG provided no additional information about that protein, often sayingonly that it was a hypothetical protein. When this occurred, the protein was left as is inthe matrix. In other cases, KEGG showed an orthology identifier. In these instances, theKEGG orthology number was used to find which H37Rv protein, if any, was its ortholog.When the protein showed an ortholog in H37Rv, and that H37Rv protein alreadyexisted in the matrix, then that protein from the other strain was removed from thematrix. Therefore, this left only unique proteins for each of the five strains in thephylogenetic profile.
2.4 Manual Annotation of Proteins without Pathway Data To increase pathway data coverage, the remaining proteins were manually annotatedusing the UniProt (www.uniprot.org) and KEGG websites (The UniProt Consortium,2014). Even though the KEGG pathway data was originally obtained from a colleague, itseems this data was incomplete, and many new annotations could be added from theKEGG database. In addition, the proteins added from the H37Ra, F11, KZN and CDC1151strains had as of yet no pathway information and were thus also manually annotated. Acolumn was added to the matrix in order to record additional information such as genename, function, Gene Ontology (GO) terms and other miscellaneous information. The
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following account describes the steps taken for each protein to manually add pathway,EC number and functional data.
2.4.1 UniProt Search The first step towards the addition of pathway data and EC numbers involvedperforming a search in UniProt. The UniProt entries provided information on the genename, gene function and GO terms. This information was copied into the ‘AdditionalInformation’ column. In some cases, the ‘General Annotation’ section included a notethat this protein was a high6confidence drug target. In these cases, the row of thatprotein was highlighted yellow. When a protein had an EC number, then that numberwas added to the matrix and the box was coloured blue to indicate the source. TheUniProt page also showed the ordered locus name, which could then be used for furtherenquiries.
2.4.2 KEGG Search Using the ordered locus name found in UniProt, a KEGG search was performed for eachprotein without pathway data. Some proteins displayed both EC numbers and pathwaymembership information. In these cases, all pathways were added to the matrix, againduplicating the row of the protein as many times as the number of pathways to which itbelongs. For proteins that already had EC numbers found on UniProt and for which theKEGG EC number was the same, nothing was changed. For proteins that did not have ECnumbers on UniProt, the KEGG EC number was added to the matrix and the cell wascoloured green to signify the source. For proteins that showed different EC numbers onUniProt and KEGG, both numbers were added to the matrix, with the UniProt ECnumber displayed first. For some proteins KEGG displays only pathway information orEC numbers. In these cases, the available information was added to the matrix.
2.4.3 KEGG BRITE Hierarchies KEGG BRITE is a collection of functional hierarchies using structured vocabularies andcan be used to represent functional information (Kanehisa et al., 2008). For someproteins, KEGG would provide no pathway information but would have assigned BRITEterms to a protein. These BRITE terms were included in the reference hierarchy foundon KEGG Orthology (KO) (http://www.genome.jp/kegg6bin/get_htext?ko00001.keg),and thus showed three levels in the same manner as the pathway terms. Many proteins
33
displayed BRITE terms only with no pathway information, and these BRITE termswould be included in the pathway cells for that protein. Examples of these BRITE termsinclude ‘Glycosyltransferases’, ‘Translation Factors’, ‘Transcription Machinery’, and‘Peptidases’, among others. This was performed to enable functional classification of asmany genes as possible, and so that the number of remaining unannotated genesneeding further investigation would be reduced.
2.4.4 Converting UniPathway Pathways Into KEGG Pathways UniProt provided pathway information for some proteins that did not have informationon KEGG. In these cases, the pathways were linked to UniPathway(http://www.grenoble.prabi.fr/obiwarehouse/unipathway), which does not use thesame naming structure as KEGG. On the UniPathway website some pathways showcross6references with KEGG or with MetaCyc pathways. If the pathways were cross6referenced with KEGG pathways, then those KEGG pathways were added to the matrix.Though some did not show KEGG cross6references, their KEGG pathway could beinferred due to name similarity or specific terms and would also be added. For a fewpathways, no appropriate match could be found in KEGG and thus these pathways wereadded to the matrix in the UniPathway naming structure. For example, protein O69670showed no pathway membership in KEGG but was assigned to the ‘amino6acidbiosynthesis; ergothioneine biosynthesis’ pathway in UniProt. When this pathway wasfound in UniPathway, there was no KEGG mapping information available (Figure 2.1).Therefore, the UniPathway terms were added to the matrix without conversion.
Figure 2.1 Example of UniPathway pathway membership information. This image shows the pathway
membership for a protein shown in UniPathway as acting within ergothioneine biosynthesis but for which no
KEGG pathway membership is available (Morgat et al., 2012). 
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Although no KEGG mapping data is provided, KEGG terms could sometimes be derivedvia another method. On the ‘Overview’ tab of these pathways there is a ‘Pathwayhierarchy: IsA relationships’ dropdown menu. By clicking on this dropdown menu, atree view of the pathway hierarchy is shown, with both UniPathway and GO terms. Inthis tree view, some of these pathways were nested in pathways that directlycorresponded to KEGG pathway terms. For example, the previous pathway‘ergothioneine biosynthesis’ is shown in the tree view (Figure 2.2).
Figure 2.2 Pathway membership tree view in UniPathway. These nested pathway trees could be used to
locate equivalent KEGG pathways and assign annotations to certain genes (Morgat et al., 2012). In this case ‘ergothioneine biosynthesis’ is nested within ‘sulfur metabolism’ and‘histidine metabolism’, which are both KEGG terms. Thus these two pathways were alsoadded in the matrix for proteins in the ‘ergothioneine biosynthesis’ UniPathwaypathway.
2.4.5 Using EC Numbers to Find Additional Pathway Memberships Many proteins were assigned EC numbers on UniProt and/or KEGG but did not showany pathway memberships. In these cases a search was performed on KEGG Enzyme forthat EC number. From the EC number’s webpage is a link to all KEGG reactions that areassociated with that EC number. Once on the webpage for all associated reactions, it ispossible to scroll through to see in which pathway(s) each reaction is involved. Allpossible pathways were added to the matrix for that protein, even though someundoubtedly did not apply to Mtb. The aim was to include all possible pathways inorder to not miss any potential memberships. Only certain pathways, such as‘Photosynthesis’ or ‘Insect Hormone Biosynthesis’ were excluded. Later on these
35
memberships would be investigated further in order to determine the veracity ofmemberships derived through this method.
2.4.6 Using GO Terms and Gene Names to Derive Additional Pathways UniProt provides a list of applicable Gene Ontology (GO) terms for each protein. In somecases, the GO terms for molecular function or biological process directly signifiedcertain pathway membership. For example, a GO term might be ‘histidine metabolism’and that pathway would be added to the protein’s pathway memberships.In other cases the GO term would signify a function that did not directly correlate withKEGG pathways. In this instance the reference hierarchy found on KEGG Orthology (KO)would be used to find proteins with the same function. By searching for keywords fromthe function of the protein, the protein name or from the GO terms, similar proteinscould sometimes be found in the reference hierarchy. When matching proteins ororthologies were found, whichever pathways it belonged to would be added to thematrix.
2.4.7 Additional Pathways from UniPathway In order to check if any of the still uncharacterised proteins had UniPathway data thathad been missed, or could not be converted into KEGG pathway mapping, the completelist of all 424 proteins with pathway data on UniPathway was downloaded. This list wasthen cross6referenced with all proteins without pathway data in the phylogeneticprofile. All proteins with UniPathway pathway membership but without KEGG pathwaymembership were highlighted. Then these proteins were manually searched on theUniPathway website. These pathways had no equivalent pathway in the KEGG pathwaymapping system, and so the pathways were recorded as they are found on theUniPathway website. Additional pathways added included ‘cell wall polysaccharidebiosynthesis,’ ‘coenzyme F0 biosynthesis,’ ‘molybdopterin biosynthesis,’ ‘trehalosedegradation,’ ‘lipoprotein biosynthesis’ and ‘mycolic acid biosynthesis.’By adding UniPathway membership data only to those proteins without KEGG pathwaymembership data, the pathways were not complete as shown on UniPathway. Thus, allproteins that belong to each added UniPathway pathway were found and then added tothe matrix, duplicating proteins that already had KEGG pathway data.
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2.5 Reordering of Matrix With all these proteins, EC numbers and pathway information added to the matrix, thenext step was to reorder the matrix. All proteins were reordered to cluster them intopathways with proteins having EC numbers but no pathway data beneath, followed byproteins without any EC number or pathway information at the bottom.
2.6 Mapping Proteins to KEGG Pathway Diagrams All proteins on the list characterised by pathways were then mapped to the KEGGpathway diagrams. Each protein already existing in the KEGG database was marked onthe diagrams. Then any additional proteins that were identified as enzymes ofparticular reactions were also mapped onto the pathways. This included proteins thatwere duplicates of reactions as well as proteins not already mapped into pathways.
2.7 Deriving Additional Pathways Using BLASTP The next step was to further characterise proteins without pathway information intounidentified KEGG reactions. Firstly, KEGG maps of each metabolic pathway werecompared between M. smegmatis, Mtb and M. leprae. The differences, in terms ofreactions filled in by proteins, between the pathways were noted. Since M. smegmatisusually had more characterised reactions, these were then used to find additionalinformation about the metabolome of Mtb. For each of the M. smegmatis proteinsidentified as belonging to a KEGG reaction, the NCBI6GI (genInfo identifier) accessionnumber was imported into BLASTP in order to find matches with Mtb proteins. A cut6off e6value of 1066 was used in most cases; in some cases where no results could befound, the cut6off value was increased to 1063. All sequences with a BLASTP hit wererecorded in a table along with sequences for which no results were found (can be foundon the CBIO website). These matched proteins of Mtb were then mapped onto theirreactions for each of the metabolic pathway maps. The BLASTP results include up to100 matches (for all Mtb strains) per sequence up to the cut6off value; all hits withinthese limits were recorded. All results were then added to the pathways both in thematrix and on the pathway maps.
2.7.1 Using BLAST on Other Organisms Each pathway map for H37Rv was compared with other closely related organisms inorder to annotate additional proteins with BLASTP matches and thus fill in pathway
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holes. For each metabolic pathway, maps for M. ulcerans, M. vanbaalenii, M. marinum M,
Corynebacterium glutamicum ATCC 13032 (Kyowa Hakko), Nocardia farcinica,
Rhodococcus jostii RHA1, Rhodococcus erythropolis PR4, Gordonia bronchialis and
Streptomyces coelicolorwere compared in the order thus stated. For reactions that werenot yet mapped to proteins in Mtb but showed proteins in any of the other organisms,NCBI6GIs of these proteins were searched against proteins in Mtb and mapped to thepathways when results were found. These BLASTP matches also used the cut6off e6value of 1066. Identified proteins were then added to their respective pathways in thematrix. The annotated proteins of three pathways were then evaluated using EnsemblGenomes (www.bacteria.ensembl.org) to identify possible operons between them andpreviously annotated proteins (Flicek et al., 2014). The genes encoding these proteinswere mapped to their location on the Mtb chromosome in order to see if they aresituated next to each other.
2.8 Analysing the Phylogenetic Profile MeV (http://www.tm4.org/index.html) was used to visualise the phylogenetic profileacross all organisms as a heat map (Saeed et al., 2003). The resulting image was quitelarge and so the total number of proteins for each organism in each pathway were usedrather then every single protein in M. tuberculosis H37Rv. After visualising (as a heatmap in MeV) the phylogenetic profile, it was observed that a number of organismsshowed very incomplete data; they displayed either none or extremely few orthologswith Mtb. Thus, these species were removed from the phylogenetic profile. Removalwas performed based on the total number of pathways. For example, any organism thatdid not have at least one ortholog in at least 50 of the 99 metabolic pathways containedin the profile was removed. This way only those organisms that were relatively wellcharacterised were included. To further reduce the size of the heat map all species withmultiple strains or variations were removed so that only one organism for each speciesremained in the heat map. Once, this was completed the proportion of orthologs foreach pathway in each organism was calculated by dividing the number of orthologs inthat pathway for that organism by the total number ofM. tuberculosis H37Rv proteins inthat pathway. Then the average proportions of all the organisms for each pathway wascalculated in order to rank pathways by most to least conserved across thephylogenetic profile.
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2.9 Deriving the Pathway Summary Totals for Escherichia coli In order to compare the pathway summary of Mtb, the pathway summary of E. coli, oneof the most well annotated genomes available, was derived from KEGG Orthology. Forthis the E. coli strain K612 MG1655 was chosen. All proteins within each pathway werecounted and the totals were entered into the matrix next to the totals from Mtb and M.
leprae for comparison.
2.10 Identifying ‘Missing’ Pathways or Pathway Holes Multiple methods were used to identify possible ‘missing’ pathways or pathway holeswithin the maps. A table of all possible ‘missing’ pathways was created which shows themissing reaction along with the evidence identifying it as a pathway hole (Appendix C).
2.10.1 Pathway Tools First, the pathway holes file was downloaded from version 16.5 of Pathway Tools (Karpet al., 2011). This file includes pathway holes for M. tuberculosis H37Rv as predicted byPathway Tools. For each possible pathway hole, the reaction and EC number isidentified. These reactions were then located on the pathway maps and marked aspossible holes needing to be filled.
2.10.2 KEGG The global map forM. tuberculosis H37Rv was observed to obtain additional evidence ofpathway holes. On the global map, some reactions were shown in colours while otherswere grey. Those in grey seemed to be reactions that were believed not to exist in Mtb.Of the coloured reactions, some were shown in dark colours and others in pale colours,signalling that the reactions probably did exist but had not been mapped to particularproteins within the genome. This evidence was not taken as conclusive but was used inconjunction with other methods to identify pathway holes.
2.10.3 Existence in Closely Related Organisms If reactions were observed to exist in closely related organisms but no matches werefound using BLASTP, then this could possibly serve as signifiers of pathway holes. Thisevidence was also not taken as conclusive but used in conjunction with other possibleindicators of pathway holes.
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2.10.4 Resemblance The final indicator for the identification of a reaction as missing or as a pathway holewas the existence of characterised reactions on either side of the reaction. For exampleif a reaction could not be mapped to a certain protein in Mtb but the preceding andsucceeding reactions have been mapped to proteins, then this is taken as evidence of ahole. This includes reactions where the immediately adjacent reactions were mapped aswell as reactions in which the adjacent reactions two and three steps away weremapped. Reactions of this type were observed for each of the pathways and thenincluded on the chart of missing pathways. An example of one of these reactions isshown in Figure 2.3.
Figure 2.3 Example of a pathway classified as ‘missing’ or a pathway hole. The evidence for this classification
is due to the characterised reactions on either side of this reaction, with only the one step missing in
between. This reaction was thus added to the missing pathways file.
2.11 Conclusion In this way we integrated data from a variety of sources to attempt to complete themetabolome of Mtb, prepare the data for comparison with other organisms and identifypathway gaps, such as pathway holes.
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3 Results 
3.1 Extraction of Ortholog Data  3,887 proteins were extracted from the original H37Rv ortholog file, with 294additional proteins from H37Ra, 574 from F11, 56 from CDC1551 and 384 from KZN. Intotal, the original extracted phylogenetic profile thus comprised 5,195 proteins from allfive strains of Mtb. All of these proteins should have been unique, or not orthologous toone another, but some were in fact orthologs and will be discussed later.A total of 1,161 organisms were included in the final phylogenetic profile. This includesall organisms in the downloaded Integr8 files that show at least one ortholog with anyof the five strains of Mtb. Some organisms included are Homo sapiens (humans) with595 orthologs shown, Escherichia coli MG1655 with 789 orthologs shown and
Streptomyces coelicolor with 1,014 orthologs. The five strains of Mtb included displayorthologs for only 66% of the total 5,195 proteins on average. Therefore, manyorthologous proteins were clearly missed using this dataset.The pathway data obtained from a colleague included pathway membership and ECnumber information for 855 M. tuberculosis H37Rv genes. Upon creation of the initialmatrix, pathways of these proteins were incorporated, leaving a substantial number ofgenes without pathway information or EC numbers.
3.2 Incorporating Additional Orthologs As mentioned before, the five strains of Mtb show orthologs for only about 66% ofgenes (using Mtb H37Rv as reference). After incorporating the additional data fromreciprocal BLAST results to find additional orthologs, many new orthologs were added,as shown in Table 3.1.
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Table 3.1 This shows the number of orthologs for the five strains of M. tuberculosis in the original and
updated phylogenetic profile.Number of Orthologs for EachStrain KZN1435 F11 ATCC25618 ATCC25177 CDC1551Number of Orthologs in Integr8Dataset 3,340 3,189 3,475 3,523 3,626Number of Orthologs With AddedBLASTP Dataset 4,008 3,827 4,022 3,889 3,812Therefore, a substantial number of orthologs were added for each of the five strains ofMtb, resulting in a more complete profile of orthologous proteins.
3.3 Removal of Orthologous Proteins in H37Ra, F11, KZN and CDC1551 This step is undertaken to ensure that all orthologous proteins should be removed fromthe dataset, leaving only unique proteins for the five strains of Mtb. Removing proteinsthat actually do have orthologs by using UniProt and KEGG orthology groups reducedthe number of proteins in the phylogenetic profile. A comparison of the numbers ofunique proteins before and after removal is shown in Table 3.2.
Table 3.2 Table showing the number of unique proteins from each strain in the phylogenetic profile. It
compares the number of unique proteins as extracted from the original Integr8 dataset with those remaining
after the data has been cleaned.Number of Unique Proteins for EachStrain H37Rv H37Ra F11 CDC1551 KZN TotalIn Original Dataset from Integr8 3,887 294 574 56 384 5,195After Manual Removal 3,887 109 45 39 99 4,179
Many duplicate proteins were therefore removed from the phylogenetic profile, and theremaining dataset should include only ‘unique’ proteins. On the other hand, someproteins that exist in the other strains might not be included. For example, the genomeof CDC1551 has 4,202 proteins in its complete proteome in UniProtKB while only 3,812of the proteins for this strain were in the ortholog file. Since we were primarily focusingon the well6characterised laboratory strain, H37Rv, we were not concerned about this.
3.4 Manual Annotation of Proteins without Pathway Data A number of proteins were added to the downloaded KEGG pathways by manualannotation using information derived from UniProt, KEGG and UniPathway. Theseinclude proteins that can fill current ‘pathway holes’ as well as proteins that can be
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assigned to reactions that have multiple enzymes within the genome that catalyse thatsame reaction. By using these various sources and databases, an additional 553proteins were annotated and characterised into pathways.
3.4.1 UniProt Search While the UniProt search itself did not add any pathways, it did allow for the addition ofmany EC numbers. In total, EC numbers were added to 1,115 proteins based on UniProtsearches. Some of these EC numbers were not found in KEGG and were thus added toproteins in the phylogenetic profile. In addition, proteins could be added to somepathways based solely on EC number.
3.4.2 KEGG Search KEGG searches were then performed on remaining proteins without pathway data. Atotal of 354 EC numbers (which were not included in the original dataset) were addedusing this method. For some reason some of these proteins belonged to pathways butwere not shown in the original pathway dataset obtained; therefore, these pathwayswere added to the matrix.
3.4.3 KEGG BRITE Hierarchies While KEGG showed no pathway information for many proteins, some of these proteinsdid display BRITE hierarchies. Added BRITE hierarchies include enzyme families,glycosyltransferases and polyketide biosynthesis proteins, among others. For proteinswithout pathway information but with BRITE hierarchies, these hierarchies were addedto the matrix. A total of 78 proteins were classified on the basis of KEGG BRITEhierarchies.
3.4.4 Converting UniPathway Pathways Into KEGG Mapping Pathways Some proteins could be added to pathways based on their UniPathway mappinghierarchy. These pathways were added to the KEGG pathways by matching termsbetween the two databases. These include those belonging to the citrate cycle (TCAcycle), glycerophospholipid metabolism and porphyrin and chlorophyll metabolism,among others. In sum, 14 proteins were added into pathways based on theirUniPathway pathway memberships.
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3.4.5 Using EC Numbers to Find Additional Pathway Memberships As mentioned previously, many EC numbers could be added to proteins in the matrixbased on the UniProt and KEGG searches. Some of these EC numbers were found inpathways, and so some proteins could be added to pathways based solely on ECnumber.
3.4.6 Using GO Terms and Gene Names to Derive Additional Pathways Using GO terms to map proteins to pathways allowed the characterisation of 49additional proteins into many different metabolic pathways. The GO terms could be anylevel of specificity as long as they matched groups within KEGG ORTHOLOGY. Thesepathway assignments were then confirmed or refuted, depending on whether theycould be mapped to specific locations in the pathways. GO terms were also often used inconjunction with EC numbers in order to determine functional characterisation. Inmany cases, protein pathway assignments based on GO terms were later refuted, but 49proteins were confirmed and mapped to specific pathways.
3.4.7 Additional Pathways from UniPathway Some UniPathway pathways had no equivalent pathway in KEGG, and so these wereadded to the matrix on their own. These include ergothioneine biosynthesis, L6argininebiosynthesis, L6cysteine biosynthesis, cell wall polysaccharide biosynthesis, coenzymeF0 biosynthesis, molybdopterin biosynthesis, quercetin degradation, trehalosedegradation, mycolic acid biosynthesis, polypeptide chain elongation and lipoproteinbiosynthesis. In all, 67 proteins were annotated with pathway information derived fromthe UniPathway database. Although these could not be mapped to KEGG pathwaydiagrams, they reduced the number of uncharacterised proteins requiring furtherinvestigation. Table 3.3 shows the numbers of proteins annotated by the manualannotation methods described thus far. Since many proteins function in multiplepathways, these numbers do not reflect the number of unique proteins added.
Table 3.3 Table showing the numbers of proteins annotated by each manual annotation method. The H37Rv
proteins that were annotated are often duplicates, meaning they have been assigned to multiple pathways
and so the counts are higher.
Annotation Method Number of Annotated Proteins (includes
proteins belonging to multiple pathways)












3.5 Reordering of Matrix The!reordering!of!the!matrix!put!all!proteins!in!order!of!their!pathways,!allowing!each!pathway!to!be!mapped!and!counted!across!all!organisms.!
3.6 Mapping Proteins to KEGG Pathway Diagrams All!metabolic!pathway!diagrams! shown! in!KEGG! for!M.-tuberculosis-H37Rv!were! then!used!to!map!both!pre6existing!proteins!(already!characterised!in!KEGG)!as!well!as!those!added! through! manual! annotation! onto! reactions! within! the! diagrams.! This! was!completed! for!a! total!of!89!KEGG!pathways!shown! to!exist! in!H37Rv!as!well! as! some!pathways!not!assigned!to!H37Rv!but!that!might!possibly!actually!exist.!When!proteins!were!mapped! to!pathways,! some!proteins! identified!using!GO! terms!were! then! found!not! to!be!applicable! to! the!assigned!pathways;! this!was!especially! found!true! in!cases!
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where! GO! terms! were! general! terms! without! specific! application! to! particular!pathways.!
3.7 Annotating Additional Reactions Using BLASTP There!is!a!well6established!idea!that!sequence!similarity!suggests!functional!similarity!(Koonin,!2005;!Yu!et!al.,!2004).!It!is!therefore!assumed!that!sequence!similarity!can!be!used!to!identify!function.!This!study!used!BLASTP!to!match!proteins!between!Mtb!and!closely! related! organisms! in! order! to! find! additional! functional! homologs! (no!distinction!was!made!between!orthologs!and!paralogs)! that! could! then!be!mapped! to!pathways.!Since!these!BLASTP!matches!only!looked!at!sequence!similarity!and!did!not!take!into!account!the!origins!of!these!matches!(whether!via!orthology!or!paralogy),!only!closely!related!organisms!were!used.!Using!only!closely!related!organisms!reduces!the!chance! for! major! evolutionary! divergence,! and! thus! corresponding! functional!divergence,! between! homologs.! These! matches! enabled! the! annotation! of! additional!reactions!within!the!metabolome!of!Mtb.!!In! total,! 1,217! H37Rv! proteins! had! matches! from! the! BLASTP! runs,! completing! 288!reactions! in! 78! metabolic! pathways.! Some! of! these! proteins! were! proteins! already!found!in!other!reactions!within!the!pathway!and!were!simply!annotated!with!additional!functions.! Others! were! matched! multiple! times! with! different! proteins! from! related!organisms,!resulting!in!the!assignment!of!multiple!EC!numbers!to!these!proteins.!Many!other!proteins!were!previously!uncategorised!into!pathways!but!did!have!GO!terms,!EC!numbers!or!gene!names!assigned.!Lastly,!32!proteins!were!previously!uncharacterised!or!putative!but!could!be!assigned!to!pathways!based!on!these!BLASTP!matches.!
3.7.1 Using BLASTP on Other Organisms Of!the!288!reactions!completed!using!BLASTP!matches,!136!were!matches!to!proteins!in!M.-smegmatis!MC2!155.-The!remaining!152!reactions!were!completed!with!matches!to!proteins!in!eight!other!organisms.!18!reactions!were!completed!with!matches!in!M.-
vanbaalenii,! 6!with!C.-glutamicum! ATCC! 13032!Kyowa!Hakko,! 20!with!N.- farcinica,! 1!with! N.- brasiliensis,! 81! with! R.- jostii- RHA1,! 4! with! R.- erythropolis- PR4,! 1! with! G.-
bronchialis! and! 21! with! S.- coelicolor.! When! checking! the! BLASTP! results,! organisms!were!compared!in!the!order!written!above!because!this!is!the!order!in!which!they!are!most!closely!related!to!Mtb.!Thus,!if!a!protein!matched!a!protein!in!M.-vanbaalenii-then!
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that! reaction! would! not! be! investigated! for! any! of! the! other! organisms.! Since! M.-
vanbaalenii! is!the!most!closely!related!of!the!proteins!and!the!second!best!match!with!
M.-tuberculosis-H37Rv!after!M.-smegmatis!MC2!155,!the!highest!proportion!of!matches!should! thus! be! with! this! organism.! The! larger! number! of! Mtb- proteins! matching!proteins! of! R.- jostii! RHA1! could! be! due! to! the! greater! number! of! its! proteins! being!characterised!in!KEGG;!KEGG!has!more!complete!pathways!for!R.-jostii-RHA1!compared!to!the!other!organisms.!This!influences!the!results!because!all!proteins!used!to!identify!BLASTP!matches!with!Mtb-were! derived! from! the!KEGG!pathway!diagrams! for! those!organisms.! However,! this! did! not! always! prove! true! as! other! organisms! such! as! S.-




those,added,by, the,annotation,methods,described,previously.,The, third, column, includes,all,proteins,added, through, the,
annotation,methods,for,each,of, the,pathways,(duplicates,are,not,recorded).,(EC),means,that,the,protein,was,categorised,
into,that,pathway,based,on,its,EC,number,,(GO),means,it,was,categorised,based,on,its,GO,terms,,and,the,rest,are,based,on,
BLASTP, matches., The, organism, in, which, the, protein, was, matched, is, shown, in, parentheses:, (Msmeg), =,M./ smegmatis,/
(Mvan),=,M./vanbaalenii,,(Cglut),=,C./glutamicum,/(Nfarc),=,N./farcinica,/(Nbra),=,N./brasiliensis,/(Rjost),=,R./jostii,/(Rery),=,R./
erythropolis,/(Gbron),=,G./bronchialis/and,(Strep),=,S./coelicolor.,Proteins,marked,with,colour,signify,two,types,of,proteins:,




































































































3.8 Analysing the Phylogenetic Profile The!phylogenetic!profile!originally!contained!1,161!organisms!with!ortholog!data!from!99!different!metabolic!pathways.!After!removing!species!with!orthologs!in!less!than!50!pathways!(showing!incomplete!data)!and!removing!multiple!strains!of!the!same!species!so!that!only!one!entry!for!each!species!remained!(to!reduce!the!image!sizes),!the!matrix!contained!371!organisms.!The!number!of! orthologs! for! each! species! in! each!pathway!was! then!divided!by! the! total! number! of! proteins! for! that! pathway! in!M.-tuberculosis!H37Rv,! resulting! in! the! frequency! of! orthologous! proteins! for! each! species! in! each!pathway.!The!resulting!data!was!assembled!into!a!heat!map,!shown!in!Figure!3.1!(pages!51652).! The! average! frequency! across! all! species! (except! for! organisms! showing!incomplete!data)!for!each!pathway!was!also!calculated!in!order!to!compare!pathways.!These!averages!are!shown!in!Figure!3.2.!
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Figure' 3.2' These' charts' show' the' average' frequency' of' homologs' for' all' species' in' the' phylogenetic' profile'
according' to' pathway.' Those'with' the' highest' averages' show'pathways' in'which' relatively' higher' numbers' of'
orthologs'were'found'across'all'species'within'the'phylogenetic'profile.'
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Using# these# graphs# notable# pathways# were# identified# with# at# least# one# of# five#characteristics:# those# for# which# Mtb# and# M.# leprae# share# both# many# and# very# few#orthologous#proteins,#those#for#which#the#pathway#totals#are#very#different#between#M.#
tuberculosis#H37Rv#and#E.#coli,#those#for#which#Mtb#and#C.#glutamicum,#as#a#facultative#anaerobe,# share#many#orthologs,# and# those# in#which#Mtb#and#H.#sapiens# do#not# share#many# orthologs.# In#many# cases,# the# totals# found# for#M.# tuberculosis#H37Rv# are#much#higher# than#E.#coli#and# the#other#organisms.#This# is# likely#due# to# the#acceptance#of#all#BLASTP#matches#with#an#eJvalue#lower#than#10J6;#some#matches#could#simply#be#closely#related# proteins# that# function# in# other# similar# pathways.# While# this# could# bias# the#results# towards# higher# counts# for# proteins# in# pathways# of#M.# tuberculosis#H37Rv,# in#some# cases# the# results# for#E.# coli# or# other# organisms#were# substantially# higher# than#those# of# M.# tuberculosis# H37Rv.# Pathways# that# fulfil# one# or# more# of# the# five#aforementioned#characteristics#will#be#discussed#in#the#following#chapter.#
3.10 Identifying ‘Missing’ Pathways or Pathway Holes Using#all#methods#previously#described#to#identify#‘missing’#pathways#or#pathway#holes,#meaning# essential# reactions# for# which# no# gene# has# been# identified,# a# total# of# 363#possible# pathway# holes# were# identified# (shown# in# Appendix# C).# Pathway# holes# have#been#identified#for#almost#all#metabolic#pathways,#and#particular#notable#pathway#holes#are#discussed# in# the# following# chapter.#Only# one#pathway#hole#has#been# identified# as#missing# in# multiple# pathways,# the# rest# of# the# 361# pathway# holes# are# all# ‘unique’#reactions.# These# pathway# holes#might# occur# in# instances#where#Mtb# utilises# the# host#metabolome# in# order# to# accomplish# certain# metabolic# needs.# Alternatively,# enzymes#might#simply#not#yet#be#identified#for#these#reactions#in#the#genome#of#Mtb.##
3.10.1 Pathway Tools The#Pathway#Tools#“pathway#holes”#file#contained#198#missing#reactions#for#which#no#corresponding# enzyme# had# been# identified# for# these# metabolic# pathways# in# M.#
tuberculosis#H37Rv#by#the#Pathway#Tools#software.#100#of#these#pathway#holes#were#in#fact#filled#by#enzymes#in#KEGG#and#identified#using#the#annotation#methods#described#above,#resulting#in#only#98#pathway#holes#for#which#no#corresponding#enzyme#has#been#identified#in#M.#tuberculosis#H37Rv.#
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3.10.2 KEGG The! KEGG! global! map! for! M.# tuberculosis# H37Rv! was! checked! for! possible! missing!pathways.! Certain! reactions! on! this! global! map! are! grey! in! colour! and! others! show!colours,! either! pale! or! bright.! Bright! colours! show! instances! in!which! enzymes! have!been! identified! for! reactions! in!M.#tuberculosis#H37Rv.! It! is! believed! that!pale! colours!show! reactions!which! are! thought! to! exist! but! are! uncharacterised!by! enzymes.!Grey!reactions! are! those! that! are! thought! not! to! exist! in! M.# tuberculosis# H37Rv.! Thus,!reactions! that! were! shown! in! pale! colours! when! the! pathways! were! highlighted! are!marked! as! possible!missing! reactions.! This! pale! colour!was! displayed! for! 125! of! the!possible!missing!reactions.!This!information!is!used!in!conjunction!with!other!evidence!to!determine!pathway!holes!for!Mtb.!
3.10.3 Existence in Closely Related Organisms Of! all! the! identified! possible! pathway! hole! reactions,! 61! had! corresponding! enzymes!identified! in!M.# smegmatis.! As!M.# smegmatis! is! a! closely! related! organism!within! the!Mycobacteria,!it!is!possible!that!these!uncharacterised!pathways!are!in!fact!‘missing’!or!holes!in!Mtb.!This!is!also!assumed!true!for!characterised!pathways!in!the!other!closely!related!organisms.!
3.10.4 Visual Evidence for Pathway Holes For!112!reactions,!none!of!the!first!three!instances!were!fulfilled!but!yet!reactions!were!still!classified!as!‘missing’!based!on!observational!evidence.!These!occur!in!cases!where!an! uncharacterised! reaction! might! be! surrounded! by! other! reactions! with! identified!enzymes.!For!example,!in!pathway!chains!or!branches!in!which!enzymes!characterised!multiple! reactions!but!yet! some!were!uncharacterised! it!would! seem!most! likely! that!these!uncharacterised!reactions!were!in!fact!missing.!
3.11 Conclusion Thus,!a!substantial!number!of!Mtb!H37Rv!proteins!have!been!annotated!using!the!methods!described!in!this!paper.!Additionally,!these!annotations!have!been!used!to!compare!the!metabolic!map!of!Mtb!across!the!phylogenetic!profile!and!identify!pathway!holes,!or!functional!gaps!that!remain!to!be!completed!either!by!Mtb!or!the!host.!
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4 Discussion The!metabolic!network!characterisation!efforts!and!creation!of!the!phylogenetic!profile!elucidates!a!number!of!interesting!aspects,!and!these!will!be!discussed!in!this!chapter.!First,! an! evaluation! of! the!methods! used! to! annotate! pathways! as!well! as! determine!important!pathways!reveals!some!strengths!and!weaknesses!of!this!research.!These!are!discussed!below,!followed!by!an!examination!of!the!interesting!results!of!these!various!methods.! Firstly,! the! manual! annotation! plus! the! BLASTP! results! from! multiple!organisms!show!a!number!of!interesting!pathways!that!could!be!filled!and/or!possibly!completed.!Secondly,!the!comparison!of!total!proteins!per!pathway!between!organisms!shows! an! additional! number! of! interesting! pathways,!which!will! be! described! below.!Lastly,! the!missing!pathway! chart! shows!even!more! interesting!pathways! in! terms!of!the! reactions! still! classified! as! missing! after! using! several! methods! to! characterise!pathways.!
4.1 Assessment of Methods Used The! methods! used! to! add! annotations! to! the! M.# tuberculosis! H37Rv! genome! and!compare!the!organisms!within!the!phylogenetic!profile!provide!a!number!of!interesting!results.! However,! some! of! these!methods! also! cause! potential! confounding! factors! in!terms!of!the!interpretation!of!results.!One!of!the!first!potential! factors!affecting!this!work!is!the!choice!of!KEGG!as!the!main!pathway!database!(Ogata!et!al.,!1999).!The!choice!of!pathway!database!can!have!a!huge!effect!on!the!results!for!a!number!of!reasons.!Firstly,!pathway!description!and!naming!varies!widely!across!databases!and!literature.!Many!pathways!overlap!and!this!causes!discrepancies! as! well! as! repetition! within! databases.! Additionally,! some! reactions!marked! as! missing! may! in! fact! only! be! artefacts! of! other! pathways.! For! example,! if!reactions! are! replicated!within!other!pathways,! they!may! show!up! in! a!pathway!or! a!branch!of!a!pathway,!even!if!that!section!of!a!pathway!doesn’t!exist!within!the!organism.!This!may! also! cause!problems! in! cases!where! compounds! or!metabolites! are! used! in!other!pathways.!For!example,! reactions!may!produce!a!particular!metabolite!within!a!pathway,!with!all! following! reactions! showing!as!nonJannotated;! it! could!be!assumed!that! the! subsequent! reactions! might! be! missing! in! the! organism.! However,! this!
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compound!may!be!used!in!another!pathway,!and!might!not!prove!to!be!actually!missing.!Unlike! KEGG,! MetaCyc! unlinks! commonly! repeated! reactions,! thus! reducing! the!redundancy!in!the!database.!KEGG!pathway!maps!include!all!known!reactions!related!to!a!particular! topic!or! goal,! regardless!of! the! species!or! kingdoms! in!which! they!occur.!Since!many!pathway!variants!occur,!when!different!organisms!use!different! reactions!or! pathways! in! order! to! achieve! the! same! metabolic! goal,! many! reactions! in! KEGG!diagrams!are!specific! for!unrelated!organisms,! such!as!perhaps!mammals,!and!do!not!exist! in!Mtb! (Caspi!et!al.,!2013).!The!main!annotations!and!pathways! in! this! research!were! extracted! from! the!KEGG!database,! because! the!diagrams! in!KEGG!were! clearer!and!more!manageable.!Since!many!of!these!KEGG!diagrams!were!quite!large,!some!were!broken! into! pieces! of! pathways! derived! from! the!MetaCyc! database.! Since! functional!annotations! were! obtained! from! KEGG,! there! could! be! false! negatives! in! that! some!MetaCyc! reactions! are!not! included! in! the!KEGG!database.!Additionally,! and!probably!having!a!stronger!effect!on!the!results,!there!could!be!false!positives!for!characterised!and! missing! reactions! due! to! the! overlap! between! pathways.! Reactions! that! were!characterised!or!found!to!be!missing!could!rather!be!artefacts!of!other!pathways.!This!could! affect! certain! pathways! by! enabling! them! to! be! characterised! and! deemed!functional! in!M.# tuberculosis#H37Rv! when! in! fact! they! are! only! present! because! the!reactions! are! shared! with! other! pathways.! Thus! the! obtained! results! might! require!further!experimentation!in!order!to!confirm!or!refute!them.!A! second! potential! issue! is! the! use! of! primary! sequence! structure! to! determine!homology! and! EC! number! to! determine! functional! characterisation.! Protein! matches!were!made!to!annotate!the!genome!of!M.#tuberculosis#H37Rv!by!using!BLASTP!to! find!protein! matches! for! already! annotated! enzymes! in! KEGG.! Studies! have! found! that!proteins!in!pathway!alignments!(aligning!pathways!from!two!or!more!organisms!to!find!proteins)!did!not!necessarily!pair!with!the!best!sequence!match!of!the!other!pathway.!This!suggests!that!if!a!multifunctional!protein!of!one!organism!experiences!duplication!and! specialisation! in! another! organism,! then! it! could! have! different! orthologs! in!different! metabolic! pathways! (Kelley! et! al.,! 2003).! This! could! have! an! effect! on! the!research!conducted!here,!since!additional!reactions!were!annotated!based!on!sequence!similarity!and!not!on!proteinJprotein!interactions.!In!addition!to!sequence!similarity,!EC!number! assignments! were! used! to! characterise! some! proteins.! A! previous! study!
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aligning!the!metabolic!pathways!of!Escherichia#coli!and!Saccharomyces#cerevisiae!used!EC! number! rather! than! sequence! similarity! to! form! alignments;! this! allowed! the!authors! to! locate! functional! orthologs! resulting! from! both! convergent! evolution,! in!which!nonJhomologous!proteins!evolved!the!same!function,!or!divergent!evolution,! in!which! orthologous! proteins! diverge! in! sequence! while! retaining! the! same! function.!Thus!they!showed!the!efficacy!of!using!functional!classification!in!addition!to!sequenceJbased!classification! in!order!to!compare!pathways!(Pinter!et!al.,!2005).! In! the!current!study,!functional!classification!(for!example!EC!numbers!and!GO!terms)!has!been!used!in! addition! to! sequenceJsimilarity! in! order! to! complete! functional! gaps! in! the!metabolism!of!Mtb.!This!also!provides!a!basis!for!the!technique!of!using!a!protein’s!EC!number!to!assign!that!protein!to!a!pathway!or!reaction.!However,!this!means!that!these!functional!classifications!rely!on!the!accuracy!of!the!EC!numbers!and!GO!terms.!The!phylogenetic!comparison!itself!can!be!affected!by!the!use!of!the!KEGG!database.!It!is!hard!to!compare!KEGG!maps!phylogenetically!because!of!the!fact!that!they!encompass!all!reactions!related!to!a!particular!topic;!if!one!organism!has!less!coverage!of!a!pathway!it! could! be! because! of! different! branches! within! the! pathway.! Alternatively,! two!organisms! could! show! the! same! number! of! reactions! for! a! pathway,! but! the! actual!mapping! shows! entirely! different! metabolisms,! with! the! two! organisms! utilising!completely!different!portions!of!the!map!with!no!or!little!overlap!(Altman!et!al.,!2013).!While!this!means!that!pathway!comparisons!are!more!uncertain!and!less!predictive!in!KEGG,!the!larger!structure!of!KEGG!maps!makes!it!easier!to!compare!all!pathways!of!the!metabolome! as! a! whole.! In! this! study,! this! factor! should! not! be! a! major! problem! in!comparing!pathway!totals!of!organisms!to!M.#tuberculosis#H37Rv!since!these!totals!were!calculated!using!only!orthologous!proteins!of!M.#tuberculosis#H37Rv.!On!the!other!hand,!organisms!(besides!M.#tuberculosis#H37Rv)!shown!to!have!the!same!number!of!proteins!in!pathways!might!have!different!parts!of!the!pathways!and!thus!cannot!be!compared!to!one! another.! Additionally,! the! protein! counts! of! proteins! derived! from! the! KEGG!orthology! lists! include! duplicates! of! proteins;! when! a! protein! catalyses! multiple!reactions!within! one! pathway,! it! is! counted! twice! in! these! summary! totals.! This!will!sometimes!lead!to!the!KEGG!protein!counts!being!greater!than!those!summarised!from!the!matrix,!and!so!this!must!be!taken!into!account!when!evaluating!these!results.!
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The!prediction!of!missing!proteins!can!also!be!effected!by!the!used!of!BLASTP!to!find!protein! matches! with! proteins! from! closely! related! organisms! and! characterise!pathways!in!M.#tuberculosis!H37Rv.!In!previous!research,!wellJcharacterised!pathways!of! model! organisms! have! been! used! to! predict! homologous! pathways! in! other!prokaryotes!(Mao!et!al.,!2012).!Pathway!holes!are!missing!pieces!in!a!mapped!pathway,!and! can! result! from! two! conditions! when! performing! pathway! prediction! in! this!manner.!Firstly,!genes!of!the!template!pathways!may!not!always!map!to!any!gene!in!the!organism.!Secondly,!the!organism!may!possess!reactions!or!pathways!that!the!template!pathways!do!not!have.!Thus,!some!‘missing’!reactions!may!be!false!positives!while!other!reactions!not!classified!as!‘missing’!may!prove!to!be!false!negatives.!
4.2 Interesting Pathways Filled in M. tuberculosis These!pathways!are!interesting!due!to!their!completion!where!they!previously!had!gaps!or! because! of! their! functions! within! the! genome.! Benzoate! degradation! was! chosen!because!it!belongs!to!the!xenobiotics!biodegradation!and!metabolism!category,!to!which!many!pathways! have! been! added! and!partially! completed.! Xenobiotic! biodegradation!and! metabolism! is! also! particularly! interesting! because! many! of! the! reactions!comprising! this! category! do! not! exist! in!MetaCyc,! the! other!major! pathway! database!(Altman!et!al.,!2013).!Next!phenylalanine!metabolism!was!chosen!from!the!amino!acid!metabolism! category,! because! the! major! amino! acid! pathways! are! highly! conserved!among!organisms,!and!it!has!been!suggested!that!these!pathways!evolved!prior!to!the!divergence!of!organisms!into!the!kingdoms!of!Archaea,!Bacteria!and!Eukarya!(Hochuli!et! al.,! 1999;! Pinter! et! al.,! 2005).! The! last! pathway! examined,! glyoxylate! and!dicarboxylate! metabolism,! belongs! to! the! carbohydrate! metabolism! category,! chosen!because!of!its!necessity!for!survival!and!essentiality!for!growth.!
4.2.1 Benzoate Degradation Aromatic! compounds! are! incredibly! widely! distributed! in! nature! and! comprise! oneJquarter!of!the!biomass!on!Earth!(Valderrama!et!al.,!2012).!The!degradation!of!aromatic!compounds!can!provide!a!source!of!nutrients!and!energy!(Caspi!et!al.,!2012).!One!of!the!most! distinctive! steps! in! the! degradation! of! aromatic! compounds! is! ring! cleavage!although! not! all! aromatic! compound! modifications! cause! fission! (Evans,! 1963).!Degradation! of! aromatic! compounds! can! occur! in! both! aerobic! and! anaerobic!
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conditions!via!four!pathways!including!aerobic,!hybrid,!anaerobic!and!strict!anaerobic!metabolism!pathways.!Hybrid!metabolism!occurs!in!aerobic!conditions!but!uses!similar!reactive! steps! as! anaerobic! metabolism,! while! strict! anaerobic! metabolism! uses! a!different!reduction!reaction!that!is!not!ATPJdependent,!compared!to!typical!anaerobic!metabolism! (Fuchs,! 2008).!However,! these! two!pathways!do!not! appear! in! the!KEGG!diagram!for!benzoate!degradation!and!thus!will!not!be!discussed!further.!!Aerobic! degradation! of! aromatic! compounds! requires! extensive! use! of! molecular!oxygen!and!a!huge!number!of!oxygenases!have!evolved!to!act!on!aromatic!compounds!(Harwood! et! al.,! 1998).! The! initial! goal! of! aerobic! aromatic!metabolism! is! to! remove!constituent! groups! and! replace! them! with! hydroxyl! groups,! thus! hydroxylating! the!aromatic!compound!into!central!intermediates.!Consequently,!the!central!intermediates!of! aerobic! aromatic! degradation! are! easily! attacked! via! oxidation,! and! a! dioxygenase!then!cleaves! the! ring!by! incorporating! two!oxygen!atoms! from!O2! (Heider!and!Fuchs,!1997).!!
!
Figure! 4.1! This! image! shows! the! general! aerobic! metabolism! of! aromatic! compounds.! The! first! reaction!
shown! is! the! hydroxylating! step! in!which! two! hydroxyl! groups! are! added! to! the! ring.! Next! two! hydrogen!
atoms!are! removed! to! reform! the!benzene! ring.!The! last! reaction! shows! the! ring! cleavage! step! in!which!a!
dioxygenase!utilises!O2!to!cleave!the!benzene!ring!(Fuchs,!2008).!Aerobic! degradation! of! benzoate! relies! on! oxygen! as! an! essential! coJsubstrate! of! the!oxygenases! that! hydroxylate,! or! activate,! and! cleave,! or! dearomatise,! the! benzoate.!Aerobic!degradation!is!the!classical!form!by!which!bacteria!degrade!benzoate!and!relies!on! the! intermediary! compound! known! as! catechol! (Valderrama! et! al.,! 2012).! An!alternative! pathway! to! metabolise! benzoate! relies! on! the! intermediary! compound!known!as!protocatechuate,!or!3,4Jdihydroxybenzoate!(Fuchs,!2008).!Two!pathways!are!available!to!degrade!catechol,! ‘catechol!degradation!II’!and! ‘catechol!degradation!to!βJketoadipate’! (Williams! and!Murray,! 1974).!Together,! these! two!pathways! account! for!the! degradation! of! benzoate! via! catechol.! Aerobic! degradation! can! also! occur! via! the!intermediate!protocatechuate!using!parallel!reactions!with! ‘catechol!degradation!to!βJketoadipate’! which! then! converge! at! ‘3Joxoadipate! degradation’.! These! two! aerobic!
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pathways! are! widely! distributed! in! soil! bacteria! and! have! been! shown! to! be! highly!conserved!in!diverse!bacteria!(Harwood!and!Parales,!1996).!Biodegradation!of!aromatic!compounds!also!commonly!occurs!in!anoxic!conditions!and!has!been!observed! in!proteobacteria,!sulfate!reducing!bacteria,! ironJreducing!bacteria!and!fermentative!bacteria.!It!requires!an!entirely!different!strategy!in!which!all!oxygenJdependent! steps! must! be! replaced! by! new! reactions! and! alternative! central!intermediates! (Heider! and! Fuchs,! 1997).! It! typically! occurs! via! reduction! to! break!aromaticity!followed!by!hydrolytic!ring!opening!(Harwood!et!al.,!1998).!The!first!step!in!the! anaerobic! metabolism! of! aromatic! compounds! generally! begins! with! the!transformation!of!the!compound!to!an!acyl!coenzyme!A!(acylJcoA)!derivative!(of!which!benzoylJCoA!is!the!most!common),!which!could!then!be!reduced!(Schuhle!et!al.,!2003).!Anaerobic! degradation! of! benzoate! relies! on! the! activation! of! benzoate! by! an! ATPJdependent!benzoateJcoA!ligase!to!produce!benzoylJcoA!(Valderrama!et!al.,!2012).!From!benzoylJcoA! there! are! two! mechanisms! to! degrade! the! molecule! anaerobically;! one!possible!anaerobic!pathway!involves!ring!hydrolysis!of!cyclic!6JketoxycyclohexJ1JeneJ1JcarboxylJcoA!while!the!other!proceeds!through!ring!hydrolysis!of!2JketocyclohexaneJ1JcarboxylJcoA.!The!two!anaerobic!pathways!then!converge!at!3JhydroxyJpimeloylJcoA!and! is! then! converted! into! glutarylJCoA,! which! then! undergoes! glutarylJcoA!degradation!to!produce!two!molecules!of!acetylJcoA.!Overall,!benzoylJcoA!metabolism!produces!three!molecules!of!acetylJcoA!and!one!molecule!of!CO2!(Harwood!et!al.,!1998).!Benzoate!degradation!is!particularly!interesting!to!examine!because!many!proteins!and!reactions!have!been!added!to!the!pathway!in!Mtb!through!the!methods!described!thus!far.!Of! these!annotated! reactions,!PT!had!marked!many!of! these!as!pathway!holes,!or!reactions!where!Mtb#either!needed!the!enzyme!catalysing!that!reaction!or!used!the!host!metabolism!to!complete!that!reaction.!Also,!since!Mtb!can!survive!in!both!aerobic!and!anaerobic!conditions,!benzoate!degradation!is!of!potential! interest! for! investigation!of!potential!drug!targets!during!the!persistent!(hypoxic)!phase!(Valderrama!et!al.,!2012).!Thus,!the!pathway!was!investigated!for!notable!added!reactions.!The!KEGG!diagram!for!the!M.#tuberculosis#H37Rv!benzoate!degradation!pathway!shows!only!nine!reactions!as!being!annotated!with!enzymes!within!the!genome.!Of!these,!eight!enzymes! also! catalyse! reactions! in! other! pathways! leaving! only! one! enzyme! that! is!
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As!can!be!seen!in!the!diagram,!many!additions!were!made!to!the!pathway.!The!aerobic!degradation!of!benzoate!has!been!observed!through!three!separate!pathways:!‘catechol!degradation! to! β@ketoadipate’! and! ‘protocatechuate! degradation! II’! coupled! with! ‘3@oxoadipate! degradation’! and! ‘catechol! degradation! II.’! Evidence! for! the! existence! of!these! pathways! varies,! but! the! ‘benzoate! degradation! I’! pathway! is! necessary! for!degradation!through!the!intermediate!catechol.!The!‘benzoate!degradation!I’!pathway!has!been!completed!using!BLASTP!matches!with!the!toluate!1,2@dioxygenase!electron!transfer!unit!of!M.#smegmatis#MC2!155!and!the!1,6@dihydrocyclohexa@2,4@diene@1@carboxylate! dehydrogenase! of! R.# jostii! RHA1.! The! e@values! for! these!protein!matches!are!1e@47! and!5e@29,! respectively,! signalling! relatively!high! confidence! matches.! This! pathway! is! central! for! the! aerobic! degradation! of!benzoate! through! catechol! and! thus! its! annotation! could! be! highly! important! for! the!functional!characterisation!of!M.#tuberculosis#H37Rv.!The! other! aerobic! intermediate,! protocatechuate,! or! 3,4@hydroxybenzoate,! is! shown!within!the!benzoate!degradation!pathway!to!be!produced!via!a!benzoate!4@hydroxylase!from!benzoate.!However,!no!matches!were!found!to!annotate!this!reaction.!Additionally,!none!of!the!organisms!used!in!the!BLASTP!analyses!showed!proteins!for!this!reaction.!The! production! of! protocatechuate! is! also! possible! from! chorismate! and! the! enzyme!catalysing! this! reaction! has! been! found! in! M.# tuberculosis# H37Rv,! identified! as! a!chorismate! pyruvate@lyase! (Stadthagen! et! al.,! 2005).! Because! the! production! of!protocatechuate! can! occur! through! alternative!means,! it! is! possible! that! the! reaction!using! the! substrate! benzoate! to! produce! protocatechuate! does! not! occur! in! M.#
tuberculosis#H37Rv.!The! convergent! ‘catechol! degradation! to! β@ketoadipate’! and! ‘protocatechuate!degradation! II’! pathways! were! also! partially! annotated.! Most! of! the! reactions!proceeding!from!catechol!had!previously!been!classified!as!pathway!holes! in!Pathway!Tools,!and!these!holes!have!now!been!completed!through!matches!with!proteins!in!both!
M.#smegmatis#MC2!155!and!R.# jostii#RHA1.! !All! four!enzymes!have!been! found! for! the!pathway!proceeding! from! catechol,!while! two! of! three! enzymes! in! the! pathway! from!protocatechuate!are!annotated.!A!protocatechuate:!oxygen!3,4@oxidoreductase!has!still!yet! to! be! identified! for! this! pathway.! Lastly,! one! additional! enzyme,! a! β@
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ketoadipate:succinyl! CoA! transferase,! has! also! not! yet! been! identified! within! the! ‘3@oxoadipate! degradation’! pathway.! Coupled! with! the! ‘benzoate! degradation! I’! and! ‘3@oxoadipate! degradation’! pathways,! the! ‘catechol! degradation! to!  @ketoadipate’!pathway! allows! for! the! aerobic! degradation! of! benzoate,! and! there! is! additional!evidence! that! ‘protocatechuate! degradation! II’! also! exists! in! M.# tuberculosis# H37Rv!although! it! is! unknown! whether! this! pathway! involves! the! degradation! of! benzoate!itself!as!a!source!of!energy.!The!anaerobic!degradation!of!benzoate!is!shown!as!only!partially!completed!for!Mtb!in!the! KEGG! diagram.! Certain! reactions! have! been! annotated! with! enzymes,! but! many!have!not!been!identified.!Of!those!that!are!currently!annotated,!all!of!them!exist!in!other!pathways,! meaning! that! their! existence! in! this! pathway! could! simply! be! an! artefact.!Thus,!it!is!still!questionable!as!to!whether!Mtb#can!anaerobically!degrade!benzoate.!The!first! major! step! in! the! anaerobic! degradation! is! the! transformation! of! benzoate! to!benzoyl@coA!(Schuhle!et!al.,!2003).!No!benzoate@coA!ligase!was!found!in!Mtb!or!for!any!of! the! compared! closely! related!organisms,! and! thus! this!might! indicate! the! lack! of! a!mechanism! for!anaerobic!benzoate!degradation! in!Mtb.!The!main!anaerobic!benzoate!degradation!pathway,!labelled!benzoyl@coA!degradation!III,!shows!only!three!identified!enzymes! of! the! eight! required! by! the! pathway.! Among! the!missing! enzymes! include!those! required! for! ring! reduction! and! cleavage.! The! last! section! in! the! anaerobic!mechanism! for! benzoate! degradation! is! glutaryl@coA! degradation.! This! pathway! is!annotated! with! three! of! the! five! enzymes! required,! all! of! which! function! in! other!pathways.! While! the! results! shown! demonstrate! the! existence! of! some! enzymes!catalysing!reactions!within!the!anaerobic!degradation!of!benzoate,!there!is!by!no!means!conclusive!evidence!that!this!pathway!exists!in!Mtb.!In!fact,!due!to!the!lack!of!enzymes!found! catalysing! anaerobic! benzoate! degradation! it! is! quite! possible! that!Mtb#cannot!degrade!benzoate!in!the!absence!of!oxygen.!Overall! the! results! show! that! Mtb! is! able! to! degrade! benzoate! aerobically.! This! is! a!common!ability! among! soil! bacteria,! a! group! to!which!most! species!within! the! genus!






Figure' 4.3' Figures' showing' the' chromosome' location' of' four' newly' annotated' Mtb' H37Rv' genes' to' two'
reactions' that'have'one' reaction' in'between.' Image'A' shows' the' locations'of' two'genes'encoding'proteins'
(Rv0768'(P71823,'EC:1.2.1.85)'and'Rv0769'(P71824,'EC:1.3.1.25))'for'the'two'reactions'while'image'B'shows'
the' locations' of' genes' encoding' two' different' annotated' proteins' (Rv2857c' (O33339,' EC:1.3.1.25)' and'
Rv2858c'(O33340,'EC:1.2.1.85))'for'the'same'two'reactions.'Image'C'shows'another'of'the'newly'annotated'




4.2.2 Phenylalanine Metabolism Amino! acid! metabolism! is! an! interesting! category! of! pathways! to! examine,! because!most!of!the!genes!involved!in!amino!acid!biosynthesis!are!highly!conserved!across!the!genomes,!with!only!M.#leprae! showing! some! loss!of! genes! (Marri! et! al.,! 2006).!Amino!acids!are!protein!building!blocks!and!have!vital!functions!in!cell!metabolism.!The!amino!acid! phenylalanine! is! a! precursor! of! tyrosine! and! is! essential! for! its! synthesis! (Wu,!2009).!Phenylalanine! concentrations! in! mycobacteria! have! been! found! to! be! relatively! low!compared! to! other! amino! acids! and! compared! to! its! reported! concentrations! in!vertebrates! and! other! microorganisms! (Ginsburg! et! al.,! 1956).! The! phenylalanine!metabolism! pathway! involves! the! production! of! various! compounds! including!phenylpropanoids! and! benzenoids,! most! common! in! plants! but! shown! to! have!counterparts!in!bacteria;!these!can!have!important!roles!in!defence!and!signalling.!It!has!been! found! that! Streptomyces! can! even! produce! benzoyl@coA! in! a! plant@like! manner!from!phenylalanine!(Moore!et!al.,!2002).!Phenylacetate,!produced!from!phenylalanine,!is!a!common!aromatic!intermediate!that!is!often!degraded!into!common!metabolites!in!order!to!produce!energy!(Luengo!et!al.,!2001).!The!phenylalanine!metabolism!pathway!in!KEGG!comprises!a!number!of!branches!and!parts! that! can! be! identified! with! MetaCyc! identifiers.! Those! marked! as! potentially!existing! in! M.# tuberculosis! H37Rv! include! ‘phenylalanine! degradation! I! (aerobic)’,!‘phenylethanol! biosynthesis’,! ‘phenylethylamine! degradation! I’,! ‘phenylacetate!degradation! I! (aerobic)’,! ‘cinnamate! and! 3@hydroxycinnamate! degradation! to! 2@oxopent@4@enoate’,! phenylpropanoid! biosynthesis,! initial! reactions’,! ‘phenylpropanoid!biosynthesis’!and!‘capsaicin!biosynthesis’.!
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Many! Mtb! proteins! were! identified! for! reactions! in! the! phenylalanine! metabolism!pathway.! The! section! labelled! ‘phenylethanol! biosynthesis’! originally! showed! an!enzyme!for!one!reaction,!but!here!one!more!reaction!was!characterised!using!BLASTP,!leaving! one! reaction! unannotated.! In! E.# coli#K12! ‘phenylethanol! biosynthesis’! can! be!used!as!a!sole!source!of!energy!by!degrading!2Hphenylethylamine!to!phenylacetic!acid.!The!reaction!converting!phenylethylamine!to!phenylacetaldehyde!also!functions!within!the!‘phenylethylamine!degradation!I’!pathway,!along!with!the!subsequent!conversion!to!phenylacetate! (Parrott! et! al.,! 1987).! Phenylethyl! alcohol! is! mainly! classified! as! an!aromatic! plant! product! and! has! been! reported! to! exhibit! antibacterial! action,!particularly! in! gramHnegative! bacteria! (Lilley! and! Brewer,! 1953).! Since! this! enzyme!functions! in! four! other! pathways! as! well,! it! is! possible! that! its! annotation! within!phenylalanine!metabolism!is!simply!an!artefact.!The!missing!enzyme!shown!within!the!pathway!is!a!general!aromatic!amino!acid!decarboxylase!which!also!degrades!tyrosine,!histidine!and!tryptophan!(Kanehisa!et!al.!2012).!Thus!it!could!be!an!important!enzyme!that!remains!to!be!elucidated.!Phenylacetate! is! an! important! intermediate! in! the! degradation! of! multiple! aromatic!compounds!(Luengo!et!al.,!2001).!Thus!phenylacetate!degradation!is!an!important!part!of! the! metabolism! of! aromatic! compounds! for! use! as! energy.! It! can! occur! both!aerobically! and! anaerobically,! although! no! enzymes! were! found! for! the! anaerobic!degradation! of! phenylacetate,! and! so! it! probably! does! not! occur! in! Mtb.! Aerobic!degradation!of!phenylacetate!in!Mtb#has!been!elucidated;!importantly,!intermediates!of!this!pathway!can!contribute!to!virulence,!evidence!of!which!has!been!found!in!multiple!bacterial!species!and!suggested! in!M.#abscessus.!Accumulation!of! the!early!products!of!phenylacetate! degradation! can! have! toxic! effects! on! the! host! (Teufel! et! al.,! 2010).!Phenylacetate! degradation! involves! multiple! CoA! thioesters,! epoxide! formation,!isomerisation!to!an!oxepin!and!hydrolytic!ring!cleavage,!resulting!in!succinylHCoA!and!acetylHCoA! (Teufel! et! al.,! 2010).! This! is! very! similar! to! one! of! the! pathways! used! by!bacteria! to! aerobically! (hybrid! aerobic)! degrade! benzoate! (Teufel! et! al.,! 2010),! and!could! be! important! in! Mtb.! However,! the! entire! aerobic! hybrid! phenylacetate!degradation!pathway! could!be! characterised! in!Mtb!using!BLASTP!matches!primarily!with!R.# jostii! RHA!1! but! also!with!M.#smegmatis!MC2!155! and!N.# farcinica.! Of! the! ten!enzymatic! reactions! necessary! for! aerobic! degradation! of! phenylacetate! only! two!
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enzymes! in!Mtb#were!previously!annotated.!All!of! the!eight! remaining!reactions!were!characterised!using!BLASTP!matches,!thus!completing!the!pathway.!These!results!show!that!Mtb!might!utilise!phenylalanine!as!an!energy!source.!The!‘phenylpropanoid!biosynthesis,!initial!reactions’!includes!two!reactions,!neither!of!which!could!be!characterised.!Phenylpropanoids!are!compounds!typically!produced!by!flowering! plants,! and! thus! they! are! most! likely! not! synthesised! in! Mtb# (Caspi! et! al.,!2012).!However,!the!reactions!following!the!initial!reactions,!including!‘cinnamate!and!3Hhydroxycinnamate! degradation! to! 2HoxopentH4Henoate’! and! ‘phenylpropanoid!biosynthesis’!have!been!characterised!using!BLASTP!matches.!Matches! have! been! found! for! eight! of! eleven! reactions!within! the! ‘cinnamate! and! 3Hhydroxycinnamate!degradation!to!2HoxopentH4Henoate’!pathway.!This!pathway!involves!the!degradation!of!phenylpropanoids,!compounds!found!in!abundance!in!nature!as!the!breakdown!products!of!plant!materials!and!soil!proteins!(Caspi!et!al.,!2012).!Bacterial!degradation!plays!an!important!role!in!the!carbon!recycling!of!phenylpropanoids!in!the!environment!(Vicuña,!1988).!It!is!unclear!whether!phenylpropanoids!would!exist!in!the!macrophage;!however,!since!the!biosynthesis!of!these!compounds!is!typically!attributed!to! plants,! it! is! unlikely! they! are! common! in! the! host.! The! discovery! of! matches! for!enzymes!involved!in!this!pathway!might!therefore!be!due!to!evolutionary!relics,!since!many!species!in!the!genus!Mycobacterium#are!soil!dwellers.!The!reactions!following!this!pathway! already!have! characterised! enzymes! in!KEGG.!However,! these! two! reactions!are!common!intermediates!in!aromatic!degradation!and!thus!could!also!be!involved!in!other!pathways.!Lastly,! the! initial!phenylpropanoid!biosynthesis!reactions!are! followed!by!reactions! in!the! ‘phenylpropanoid! biosynthesis’! and! ‘capsaicin! biosynthesis’! pathways.!Within! the!first! pathway,! one! of! two! reactions! has! been! characterised! in! Mtb# using! BLASTP!matches.!Since!lignins!are!typically!plant!compounds!associated!with!cellulose!(Boerjan!et!al.,!2003)!and!the!enzyme!found!also!functions!in!another!pathway,!it!is!probable!that!this! pathway! does! not! actually! exist! in! Mtb.# The! ‘capsaicin! biosynthesis’! pathway!follows!the! ‘phenylpropanoid!biosynthesis’!pathway!and!one!of!three!reactions!in!this!pathway!has!been!characterised!with!a!BLASTP!match.!Capsaicin!has!only!been!found!in!
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the! fruits! of! plants! in! the!Capsicum! genus! so! it! is! unlikely! that! this! pathway! actually!exists!in!Mtb#(Sukrasno!and!Yeoman,!1993).#Thus,!22!reactions!of!the!phenylalanine!pathway!have!been!assigned!enzymes!from!the!genome!of!M.#tuberculosis#H37Rv!using!BLASTP!matches.!These!matches!show!complete!or!almost!complete!pathways!that!enable!the!degradation!of!phenylalanine!through!the!bacterial! aerobic! hybrid! pathway! as!well! as! the! degradation! of! the! phenylpropanoid!transHcinnamate,! both! as! sources! of! energy.! To! provide! further! evidence! for! the!annotated! proteins,! Ensemble! Bacteria! was! used! to! locate! the! genes! encoding! these!proteins! on! the! chromosome! (Flicek! et! al.,! 2014).! Images! showing! five! of! these! gene!locations!are!in!Figure!4.5.!
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4.2.3 Glyoxylate and Dicarboxylate Metabolism Central! carbon! metabolism,! including! glycolysis/gluconeogenesis,! the! pentose!phosphate! shunt! and! tricarboxylic! acid! (TCA)! cycle,! has! been! identified! as! a! key!determinant! of! the! pathogenicity! of!Mtb# (Rhee! et! al.,! 2011).!While!microbes! can! use!nonHcarbohydrate! sources! of! carbon! and! energy! including! fatty! acids,! lipids,! amino!acids,! nucleotides! and! others,! the! degradation! of! these! alternative! sources! typically!proceeds! through! intermediates! which! are! then! processed! through! the! central!carbohydrate!metabolism!pathways!(Moat!et!al.,!2003).!Because!Mtb!resides!in!such!a!narrow!environmental!niche!within!the!human!host,!carbon!metabolism!is!particularly!important!for!its!survival!and!growth;!the!bacteria!can!simultaneously!process!multiple!substrates!of!carbon,!an!ability!not!seen!in!many!other!bacterial!species!(de!Carvalho!et!al.,!2010).!Glyoxylate!and!dicarboxylate!metabolism!allows!microorganisms!to!grow!on!acetate!as!a!sole!source!of!carbon!during!growth!(Moat!et!al.,!2003).!Additionally,!this!pathway!is!part! of! those! of! central! metabolism,! which! together! produce! the! 13! precursor!metabolites! for! all! cellular! biosynthesis.! This! pathway! can! also! generate! energy! for!growth!(Caspi!et!al.,!2012).!MetaCyc! pathways! which! form! sections! of! the! KEGG! ‘glyoxylate! and! dicarboxylate!metabolism’! pathway! include! the! ‘glyoxylate! cycle,’! ‘glycolate! and! glyoxylate!degradation! I,’! ‘glycolate! and! glyoxylate! degradation! II,’! ‘oxalate! degradation! III,’!‘oxalate! degradation!V,’! ‘formaldehyde! assimilation! I! (serine! pathway),’! ‘ethylmalonyl!pathway’!and!‘methylmalonyl!pathway’.!These!pathways!are!shown!in!Figure!4.6. !
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Figure' 4.6:' The' KEGG' pathway' for' M.' tuberculosis' H37Rv' glyoxylate' and' dicarboxylate' metabolism.' Red' boxes' show' MetaCyc' pathways.' The' boxes' contain' EC'
numbers'and'are'different'colours.'Green'indicates'reactions'already'annotated'in'KEGG,'blue'are'those'annotated'in'this'project,'yellow'are'reactions'with'proteins'
in'other'organisms'but'for'which'no'BLASTP'matches'could'be'found'in'Mtb,'orange'are'reactions'classified'as'missing'while'pale'orange'shows'possible'additional'
missing'reactions'without' further'evidence' (such'as'pathway'holes' in'PT'or' characterised' in' closely' related'organisms)' (Caspi'et'al.,'2012;'Kanehisa'et'al.,'2004;'
Ogata'et'al.,'1999).'
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One! of! the! most! important! metabolic! functions! within! this! pathway! involves! the!reactions!belonging! to! the! ‘glyoxylate! cycle’,!part!of! the!central! carbon!metabolism!of!microorganisms.! This! cycle! utilises! acetate! for! growth! and! energy,! and! results! in! the!formation!of!malate!from!two!molecules!of!acetate.!Both!glucose!and!fatty!acids!can!be!converted! into!acetate! for!use! in! the!glyoxylate! cycle,!which! is!particularly! important!for! use! of! fatty! acids! as! substrates! for! growth.! The! glyoxylate! cycle! resembles! the!tricarboxylic!acid!(TCA)!cycle!except!that!it!bypasses!those!steps!of!the!cycle!which!lead!to! a! loss! of! carbon! in! the! form!of! CO2!(Moat! et! al.,! 2003).! The! cycle! also! includes! the!enzyme!isocitrate!lyase,!shown!to!be!essential! for! in#vivo#growth!and!virulence!of!Mtb!(MunozJElias! and! McKinney,! 2005).! All! of! these! reactions! have! already! been!characterised! with! enzymes! in! KEGG,! and! thus! no! additions! were! made.! However,!MetaCyc!shows! two!different!enzymes! for!malate! synthase! (EC:2.3.3.9),!one!of!which,!malate! synthase! A,! functions! in! the! ‘glyoxylate! cycle’! in!E.# coli! and! the! other,!malate!synthase!G,!functions!in!the!‘glycolate!and!glyoxylate!degradation!II’!pathway,!discussed!later! (Clark! and! Cronan,! 2005).! Only! the! gene! encoding!malate! synthase! G! has! been!identified!in!Mtb,!meaning!that!this!step!is!actually!missing!or!uncharacterised!for!the!glyoxylate!cycle.!No!protein!for!malate!synthase!A!could!be!located!within!the!genome!of!Mtb.!Even! though! alternative! degradation! pathways! exist! for! glycolate! and! glyoxylate,! the!‘glycolate! and! glyoxylate! degradation! I’! pathway! is! essential! for! growth! on! either!compound! in!E.# coli! possibly! because! its! products! cycle! into! glycolysis.! Through! this!pathway!E.#coli#can!use!either!of!these!two!substrates!as!the!lone!source!of!carbon!and!energy.! The! glyoxylate! utilised! in! this! degradation! pathway! can! come! from! either!exogenous!or!endogenous!(i.e.J!via!other!pathways)!sources!(Clark!and!Cronan,!2005).!Of! the! four! reactions! belonging! to! this! pathway! in!Mtb,! two! have! been! characterised!using!the!BLASTP!matches,!one!is!already!characterised!in!KEGG!and!the!fourth!has!not!been! identified! for! any! organism! in! KEGG.! Of! the! two! BLASTP!matches,! the! enzyme!found!matching!glyoxylate!carboligase!(EC:4.1.1.47)!exhibits!a!low!eJvalue![3eJ86]!but!is!described!as!an!acetolactate!synthase;!therefore!the!match!could!be!inaccurate!for!this!reaction.! The! fourth! reaction,! for! which! an! enzyme! does! not! exist! in! KEGG! for! any!organism,!could!be!characterised!based!on!data! from!MetaCyc!and!UniProt.!Using! the!protein! name! found! in!MetaCyc,! a!UniProt! search! found! one! of! three! subunits! of! the!
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enzyme! required! to! catalyse! this! reaction.! Thus,! this! reaction! is! in! fact! partially!characterised! for!Mtb.! Although! a! protein! catalysing! the! reaction! between! glyoxylate!and!tartronate!semialdehyde!has!yet!to!be!found!with!confidence,!the!characterisation!of!the!other!enzymes!within!this!pathway!would!suggest!that!the!pathway!does!exist!in!Mtb.!This!enables!the!bacteria!to!utilise!glyoxylate!as!a!sole!source!of!energy!and!carbon!when!nutrients!are!scarce,!such!as!probably!occurs!within!the!macrophage.!The! ‘glycolate! and! glyoxylate! degradation! II’! pathway! also! functions! in! degrading!glyoxylate!as!a!source!of!carbon!and!energy;!however,! it! is!not!essential! in!E.#coli!and!instead!cycles!into!the!TCA!cycle!rather!than!glycolysis!(Clark!and!Cronan,!2005).!This!pathway!shares! the! first!step!with! ‘glycolate!and!glyoxylate!degradation!I’,!which!was!characterised!using!the!protein!name!and!function!in!order!to!identify!a!gene!encoding!one!of!three!subunits!of!the!enzyme!catalysing!this!reaction.!The!second!reaction!in!this!pathway! was! already! characterised! in! KEGG.! Thus,! this! pathway! is! only! partially!complete,!requiring!the!identification!of!the!genes!encoding!the!remaining!two!subunits!of!glycolate!oxidase!in!order!to!be!completed.!None!of!the!closely!related!organisms!had!characterised!genes! for! these! two! subunits! and! thus!no! attempts! at!BLASTP!matches!could!be!performed.!Most!of! the! ‘formaldehyde!assimilation!I!(serine!pathway)’!pathway!is! included!in!the!KEGG! ‘glyoxylate! and! dicarboxylate! metabolism’! diagram! apart! from! two! steps.!Formaldehyde! is! a! compound! derived! from!methanol! via! oxidation.! In! one! study,! all!mycobacteria!tested!were!found!to!be!methylotrophic,!meaning!they!could!grow!solely!on!singleJcarbon!sources!of!carbon!and!energy!such!as!methanol!and!carbon!monoxide;!this! is! unique! among! taxonomic! groups!of! bacteria.! The! singular! outlier! of! the! study,!Mtb#was!only!able!to!grow!on!carbon!monoxide!(CO)!and!not!on!methanol!(Park!et!al.,!2003).!Of!the!nine!reactions!from!this!pathway!shown!in!the!KEGG!diagram,!four!were!previously! characterised! in! KEGG,! one!was! characterised! using! BLASTP!matches! and!four!remain!uncharacterised.!Of!these!four!uncharacterised!reactions,!two!are!catalysed!by!the!same!enzyme!in!a!coupled!reaction.!Thus!only!about!half!the!pathway!has!been!characterised,!and!it!is!unclear!whether!this!pathway!is!functional!in!Mtb.!Additionally,!‘formaldehyde! assimilation! I! (serine! pathway)’! begins! by! utilising! formaldehyde! as! a!substrate,! itself! produced! from! methane! using! either! a! methanol! dehydrogenase! or!
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ribulose! bisphosphate! carboxylase/oxygenase! (RuBisCO).! A! pathway! enabling! the!production!of!formaldehyde!from!CO!was!not!found!during!a!literature!review;!the!use!of! CO! as! a! source! of! carbon! and! energy! rather! proceeds! via! a! carbon! monoxide!dehydrogenase!to!produce!CO2,!which!then!progresses!into!the!TCA!cycle.!The!inability!of!Mtb#to!grow!on!methanol!combined!with!the!four!uncharacterised!reactions!suggests!that! this!pathway!might!not!be! functional! in!Mtb.!Because!many!other! species!within!
Mycobacterium! are! able! to! grow! on! methanol,! perhaps! the! existence! of! enzymes!catalysing! the!characterised!reactions! is!simply!an!evolutionary!artefact!rather! than!a!sign!that!the!pathway!is!functional.!The!‘ethylmalonyl!pathway’!is!an!alternative!pathway!for!the!metabolism!of!fatty!acids!via! acetate.! As! opposed! to! the! ‘glyoxylate! cycle’,! the! ‘ethylmalonyl! pathway’! enables!organisms! to! metabolise! acetate! when! isocitrate! lyase! (ICL),! a! key! enzyme! in! the!‘glyoxylate!cycle’,!is!not!available.!This!pathway!functions!in!organisms!that!are!unable!to! produce! ICL! and! proceeds! through! acetoacetylJCoA! and! other! intermediates! to!produce! glyoxylate,! recycled! back! into! (S)Jmalate,! and! propionylJCoA,! which! is!carboxylated!to!succinate!via!the!‘methylmalonyl!pathway’!(Alber!et!al.,!2006).!The!key!step! in! this! pathway! is! the! conversion! from! crotonoylJCoA! to! (2S)JethylmalonylJCoA,!catalysed!by!crotonylJCoA!carboxylase/reductase!(Erb!et!al.,!2007).!Of!the!13!reactions!within!the!ethylmalonyl!and!methylmalonyl!pathways,!four!were!already!characterised!in! Mtb,! four! were! characterised! using! BLASTP! matches,! and! five! are! still!uncharacterised.!The!key!enzyme!crotonoylJCoA!carboxylase/reductase!was!not!found!in!Mtb! or! any! of! the! examined! closely! related! organisms.! Since! this! pathway! is! only!partially!characterised,!and!since!Mtb#can!utilise!the!glyoxylate!cycle!to!metabolise!twoJcarbon! substrates,! it! is! unclear! whether! this! pathway! is! functional.! While! the!‘ethylmalonyl! pathway’! is! still! incomplete,! the! ‘methylmalonyl! pathway’! has! been!completed.! This! pathway! succeeds! the! ‘ethylmalonate! pathway’! and! begins! with!propionylJCoA.!Mtb! can! obtain! propionate! from! its! environment! and! uses! it! to! form!methylmalonate,! an! important! component! in! the! synthesis! of!mycobacterial! cell!wall!lipids!(Matsunaga!et!al.,!2004).!Thus,!the!completion!of!the!‘methylmalonyl!pathway’!is!not!necessarily!evidence!of!the!existence!of!a!functional!‘ethylmalonyl!pathway’,#and!it!is!unclear!whether!the!latter!operates!in!Mtb.!
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The! ‘oxalate! degradation! V’! and! ‘oxalate! degradation! III’! pathways! enable! the!metabolism!of!oxalate,!a!compound!commonly!found!in!the!soil!and!produced!by!some!plants!and!fungi!(Allison!et!al.,!1995).!Two!reactions!producing!oxalate!from!glyoxylate!are!shown!in!KEGG!but!neither!of!them!have!an!assigned!enzyme!in!any!organism!in!the!KEGG! database.! Thus,! it! is! unknown! whether! Mtb! might! produce! oxalate! from!glyoxylate,! metabolise! exogenous! sources! or! not! use! oxalate! at! all.! Two! different!pathways! show! possible! evidence! that! oxalate! degradation! exists! in! Mtb! for! oxalate!degradation,! with! ‘oxalate! degradation! V’! using! an! oxalate! decarboxylase! to! produce!formate! directly! from! oxalate! and! ‘oxalate! degradation! III’! utilising! an! oxalateJCoA!transferase! and! oxalylJCoA! decarboxylase! to! convert! oxalate! first! to! oxalylJCoA,! then!formylJCoA! and! finally! to! formate.! However,! both! of! these! pathways! remain! largely!uncharacterised!in!KEGG,!even!for!other!organisms;!thus!BLASTP!could!not!be!used!to!find! matches! for! these! enzymes! in! the! genome! of! Mtb.! Since! no! reactions! could! be!characterised!for!‘oxalate!degradation!III’!and!only!one!reaction!is!already!characterised!in!KEGG,!it!is!unclear!whether!this!pathway!is!functional.!While!several!other!organisms!contained!the!oxalate!decarboxylase!catalysing!the!reaction!of! ‘oxalate!degradation!V’,!no! matches! could! be! identified! in! Mtb.! Additionally,! because! oxalate! is! a! common!compound! in! soil! and! many! Mycobacteria! are! soilJdwellers,! it! is! possible! that! the!existence!of!portions!of!these!pathways!is!an!evolutionary!artefact.!Overall,!several!reactions!within!the!‘glyoxylate!and!dicarboxylate!metabolism’!pathway!were!characterised! in!Mtb!using!BLASTP!matches.!These!matches!reveal!evidence! for!the! existence! of! several! MetaCyc! pathways! including! ‘glycolate! and! glyoxylate!degradation’!I!and!II,!‘formaldehyde!assimilate!I!(serine!pathway)’!and!‘methylmalonyl!pathway’.!Additionally!there!is!partial!but!not!strong!evidence!for!the!existence!of!the!‘methylmalonyl! pathway’! and! ‘oxalate! degradation’! III! and! V.! As! before,! Ensembl!Bacteria!was! then! used! to! find! additional! evidence! for! the! newly! annotated! proteins!(Flicek!et!al.,!2014).! Images!shown!in!Figure!4.7!represent! the! locations!of! two!newly!annotated!Mtb!H37Rv!proteins.!
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Figure'4.7' Image'showing'the' location'of' two'genes'encoding'proteins' in' the' ‘glyoxylate'and'dicarboxylate'
metabolism’'pathway.' It'shows'the'genes'Rv1322A'(Q8VK36,'EC:5.1.99.1)'and'Rv1323'(P66926,'EC:2.3.1.9)'(Flicek!et!al.,!2014).'The!proteins!shown!in!Figure!4.7!function!in!the!‘ethylmalonyl!pathway’!and!‘methylmalonyl!pathway’.!Located!next!to!one!another!on!the!chromosome,!their!expression!is!likely!controlled!by!the!same!regulatory!proteins.!These!are!both!newly!annotated!proteins,!and!although!not!coJlocated!with!others!in!the!pathway!they!are!coJlocated!with!each!other.!!
4.3 Comparing Pathways between Organisms The!phylogenetic!profile!allowed! for! the!comparison!of!protein!numbers!belonging! to!the! different! metabolic! pathways! over! a! large! range! of! different! organisms.! By!comparing! Mtb! with! M.# leprae,! a! pathogenic! mycobacterial! species! with! a! highly!reduced! genome,! and! E.# coli,! often! used! as! a! model! organism! and! thus! well!characterised! functionally,! certain! interesting! pathways! have! emerged.! These!interesting! pathways! include! one! or! more! of! five! particular! characteristics:! those! in!which!many!proteins!have!been!added!to!both!Mtb#and!M.#leprae,!those!in!which!many!proteins! have! been! characterised! for!Mtb#and! not! for#M.# leprae,! those! for! which! the!pathway!totals!are!very!different!between!Mtb#H37Rv!and!E.#coli,!those!for!which!Mtb#and!C.#glutamicum,! a! facultative! anaerobe,! share!many!homologs,! and! those! in!which!Mtb!and!H.#sapiens!do!not!share!many!homologs.!Proportions!were!calculated!for!the!number!of!homologous!proteins!for!each!organism!in! each! of! the! metabolic! pathways.! These! were! calculated! by! taking! the! number! of!homologous!proteins! for! each!organism!and!dividing!by! the! total!number!of!proteins!for!that!pathway!in!M.#tuberculosis!H37Rv.!This!was!done!so!that!all!pathways!could!be!compared!on!the!same!scale!(for!example,!zero!to!one)!for!visualisation!in!the!heat!map.!The!pathways!were!then!compared!to!one!another!by!averaging!the!proportions!of!all!organisms!for!each!pathway.!Those!with!the!highest!average!are!those!pathways!which!are! most! conserved! among! the! analysed! genomes! and! vice! versa! for! those! with! the!
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lowest!averages.!This!should!confirm!or!refute!research!examining!the!most!and!least!conserved! pathways! among! organisms.! One! study! found! that! all! examined! genomes!showed! similar! (conserved)! pathways! for! amino! acid! biosynthesis,! cofactor!biosynthesis,! nucleotide! metabolism! and! macromolecule! metabolism! (Marri! et! al.,!2006).! The! top! five! pathways! according! to! average! frequency! include! ‘DJalanine!metabolism’!(metabolism!of!other!amino!acids),! ‘thiamine!metabolism’!(metabolism!of!cofactors! and! vitamins),! ‘DJglutamine! and! DJglutamate! metabolism’! (metabolism! of!other! amino! acids),! ‘lysine! biosynthesis’! (amino! acid! metabolism)! and! ‘LJcysteine!biosynthesis’! (amino!acid!biosynthesis).!Of! these!pathways,! four!belong!to!amino!acid!biosynthesis!and!metabolism;!this!aligns!with!the!previous!research!(Marri!et!al.,!2006).!The! fifth!pathway,! ‘thiamine!metabolism’,!belongs!to! the! ‘metabolism!of!cofactors!and!vitamins’!category;!genes!involved!in!folic!acid,!pantothenate,!pyridoxine!and!thiamine!biosynthesis! have! also! been! shown! to! be! highly! conserved! among! Mycobacterium!(Marri!et!al.,!2006).!These!results!support!the!methods!used!in!so!far!as!they!agree!with!previous!research!regarding!evolutionary!conservation!of!pathways.!On! the! other! hand,! the! pathways!with! the! lowest! averages! show! the! least! conserved!pathways! across! the!phylogenetic! profile.!The! five!pathways!with! the! lowest! average!frequencies! across! the! phylogenetic! profile! include! ‘glycerolipid! metabolism’! (lipid!metabolism),! ‘ether! lipid! metabolism’! (lipid! metabolism),! ‘linoleic! acid! metabolism’!(lipid! metabolism),! ‘DJarginine! and! DJornithine! metabolism’! (metabolism! of! other!amino!acids)!and!‘carotenoid!biosynthesis’!(metabolism!of!terpenoids!and!polyketides).!Lipid!metabolism,! cell!wall! proteins! and!polyketide! synthases! showed!wide! variation!across!strains!of!Mycobacterium,!and!both!lipid!metabolism!and!cell!wall!proteins!could!be! related! to! virulence! as! many! lipids! function! in! the! cell! membrane,! the! interface!between! host! and! pathogen! (Marri! et! al.,! 2006).!Many! of! the! low! average! frequency!pathways! found!here! belong! to! lipid!metabolism,! showing! that! these!pathways!differ!quite!extensively!not! just!among!mycobacteria!but!also!across!the!entire!phylogenetic!profile.!Three!of!these!bottom!five!have!very!few!characterised!proteins!(between!one!and! five! in!Mtb#out! of! two! to! twenty! in! the!KEGG! reference! pathway)! and! this! could!have!skewed!the!results.!However,!when!looking!at!the!bottom!16!pathways!in!terms!of!average!frequencies,!six!of!those!pathways!belong!to!the!lipid!metabolism!category.!Of!the!remaining,!three!are!part!of!the!metabolism!of!terpenoids!and!polyketides,!two!are!
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part!of!xenobiotics!biodegradation!and!metabolism,!and!one!pathway!each!belongs!to!carbohydrate! metabolism,! metabolism! of! cofactors! and! vitamins,! and! metabolism! of!other!amino!acids.!The!other! two!pathways!are!UniPathway!pathways!added! into! the!profile!in!order!to!increase!coverage!and!include!cell!wall!polysaccharide!biosynthesis!and!mycolic!acid!biosynthesis.!Pathways!with!low!conservation!across!the!phylogenetic!profile!are!particularly!important!to!examine!because!they!have!potential!as!future!drug!targets.! For! example,! drugs! could!possibly! target! an!Mtb#pathway! that!does!not!have!protein! homology! with! pathways! in!H.# sapiens! without! causing! disruption! of! human!metabolism.! These! pathways! with! low! average! frequencies! were! then! selected! for!further!examination.!In!addition!to!the!bar!graphs!created!to!compare!numbers!of!proteins!characterised!for!Mtb,#M.# leprae,# C.# glutamicum,! E.# coli,#and!H.# sapiens# (Figure! 3.3),#which! includes! the!protein!counts!for!both!KEGG!pathways!as!well!as!those!in!the!profile,!a!heat!map!was!created! of! the! phylogenetic! profile! as! shown! in! Figure! 3.1! (some! organisms! were!removed! to! fit! the! heat! map! onto! two! pages).! This! heat! map! shows! the! number! of!proteins!belonging!to!each!pathway!for!each!organism!as!a!proportion!of!the!number!of!proteins!for!each!pathway!in!M.#tuberculosis!H37Rv.!Thus!each!of!these!proportions!are!calculated!out!of! a! score!of!one!and!shown!across! the! list!of!392!organisms.!The! two!figures! enable! a! visual! interpretation! of! the! data! to! find! pathways! that! might! be!possible!drug!targets.!Pathways! matching! each! of! the! five! characteristics! were! found! using! the! heat! map!(Figure!3.1),!frequency!comparison!graph!(Figure!3.2)!and!bar!graph!(Figure!3.3).!Many!of!these!pathways!satisfied!more!than!one!of!the!desired!characteristics!for!the!purpose!of!this!study.!
4.3.1 Many Proteins Added to Both M. tuberculosis and M. leprae Two!pathways!for!which!a!number!of!proteins!were!added!in!both!Mtb!H37Rv!and!M.#
leprae! TN! are! ‘arginine! and! proline! metabolism’! and! ‘glycine,! serine! and! threonine!metabolism’.!Both!these!pathways!show!relatively!equal!numbers!of!proteins!added!in!the!two!species!of!mycobacteria.!These!pathways!are!part!of! ‘amino!acid!metabolism’,!and!most!of!the!genes!involved!in!amino!acid!biosynthesis!are!highly!conserved!across!the! genomes! (Marri! et! al.,! 2006).! The! results! shown! in! Figure! 3.2! for! these! two!
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pathways! suggest! that! the! characterised! proteins! found! might! be! functionally!important! for!mycobacteria.! Additionally,! the! results! from! the! compiled! phylogenetic!profile! shown! in! Figure! 3.1! show! relatively! high! levels! of! homology! for! proteins!involved!in!‘arginine!and!proline!metabolism’.!The!frequency!of!homology!is!lower!for!‘glycine,! serine! and! threonine! metabolism’! but! still! shows! relatively! high! homology.!Arginine!degradation!is!a!common!ability!among!organisms!from!all!kingdoms,!and!as!such! performs! an! important! role! in! organisms! (Jenkinson! et! al.,! 1996).! Arginine! and!proline! can! both! be! degraded! via! glutamate! or! alternative! pathways! as! a! source! of!carbon! or! nitrogen.! Previous! studies! have! shown! the! existence! of! arginases! in!mycobacteria! and! the! discovery! of! additional! proteins! in! the! pathway! are! likely! the!result!of!the!characterisation!of!additional!segments!of!the!pathway!(Zeller!et!al.,!1954).!These!additions!do!not!show!homology!with!either!E.#coli!or!H.#sapiens#and!thus!could!be!possible!drug!targets.! ‘Glycine,!serine!and!threonine!metabolism’,!as!another!amino!acid! pathway,! also! has! important! functions! and! can! be! used! as! a! source! of! carbon.!Serine! is!produced!from!an! intermediate!of!glycolysis,!which!then! is! transformed!into!glycine;! threonine! is! produced! from! aspartate.! Glycine! can! also! be! produced! from!betaine!and!can!be!used!as!a! sole! source!of! carbon!and!nitrogen! (Smith!et! al.,! 1988).!Threonine! itself! is! indispensable,! can! proceed! through! both! aerobic! and! anaerobic!pathways!and!can!be!used!as!a!solitary!substrate!for!growth!(Sawers,!1998).!Therefore,!all! of! these!amino!acid!metabolism!pathways! can!be!used!as! sources! for! growth,! and!since! they! share! many! proteins! with! M.# leprae,! might! be! essential! for! growth! and!survival.!This!essentiality!could!make!these!pathways!potential!new!drug!targets.!Many!proteins!have!also!been!added!to!the! ‘glycerolipid!metabolism’!pathway!in!both!Mtb#and!M.#leprae.!Many!bacteria!can!directly!absorb!glycerol!from!the!environment!to!use!as!a!source!of!carbon!and!energy.!While!some!bacteria!have!been!found!to!grow!on!glycerol! aerobically,! others! can! metabolise! the! compound! anaerobically! (Rush! et! al.,!1957).!Additionally,!phospholipids!are!important!components!of!the!membrane!and!cell!wall! of!Mtb;!metabolism! of! glycerol! proceeds! through! phosphoglycerides! and! can! be!important! in! building! constituents! of! cell!wall! proteins.! Proteins! that! are! part! of! this!pathway!could!be!important!drug!targets!for!multiple!reasons.!First,!Mtb!shifts!from!a!carbohydrateJbased!to!a!lipidJbased!metabolism!while!within!the!macrophage!(Yang!et!al.,! 2011).! Second,! Mtb! shares!many! orthologous! proteins! with!M.# leprae,! suggesting!
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that! these! proteins! would! be! essential! for! growth! in! the! host.! Lastly,! glycerolipid!metabolism! has! a! very! low! number! of! orthologous! proteins! across! the! phylogenetic!profile! meaning! it! likely! does! not! share! many! enzymes! with! other! organisms! and! if!drugs! were! to! target! these! enzymes! then! they! would! not! simultaneously! affect! the!metabolism! of! human! cells! or! other! organisms! within! the! host.! All! of! these! factors!warrant!a!closer!examination!of!this!pathway!and!the!newly!characterised!proteins!for!potential!targets!of!new!drugs.!
4.3.2 Many Proteins Added to M. tuberculosis But Not M. leprae ‘Fructose! and! mannose! metabolism’! is! a! pathway! in! which! the! number! of! proteins!characterised! in! Mtb! is! far! higher! than! the! number! of! proteins! characterised! in!M.#
leprae.!This!pathway!also!shows!very!few!homologous!proteins!between!Mtb!and!E.#coli.!Additionally,!when!looking!across!the!phylogenetic!spectrum!(Figure!3.1),!this!pathway!shows! relatively! few! homologous! proteins! except! for! very! closely! related! organisms!such! as!Rhodococcus.! That! there!were!many!proteins! added! in!Mtb! that!did!not!have!homologs!in!the!highly!reduced!genome!of!M.#leprae!suggests!that!these!added!proteins!are! not! absolutely! necessary! for! survival.! In! all! mycobacteria! mannoseJcontaining!glycolipids!are!an! important!component!of!cell!walls,!but!have!also!been!shown!to!be!essential! for!growth!and!cell!division! in!M.#smegmatis.!The!same!study!also!suggested!that!enzymes!involved!in!the!production!and!metabolism!of!mannose!could!be!possible!drug! targets,! especially! due! to! the! fact! that! they! share! few! homologous! genes! with!animal! cells! (Patterson! et! al.,! 2003).! Figures! 3.1! and! 3.2! also! show! the! low! levels! of!homology!between!Mtb!genes!involved!in!fructose!and!mannose!metabolism!and!genes!from! other! organisms! including! H.# sapiens.! These! results! suggest! that! ‘fructose! and!mannose!metabolism’!could!be!a!potential!drug!target!for!preventing!the!growth!of!Mtb.!On! the! other! hand,! the! lack! of! orthologous! genes! in!M.# leprae! could!mean! that! these!reactions!are!not!necessary!for!survival!and!thus!may!not!make!good!drug!targets.!Another! pathway! in! which! many! proteins! were! added! to! Mtb! H37Rv! but! not! to!M.#
leprae#TN!is! ‘limonene!and!pinene!degradation’.! ‘Limonene!and!pinene!degradation’! is!part! of! the!metabolism! of! terpenoids! and! polyketides! category! in! KEGG;! polyketides!have!been!shown!to!vary!greatly!among!the!species!within!the!MTBC!and!thus!may!have!proteins!unique!to!Mtb!(Marri!et!al.,!2006).!This!pathway! is!also! important! to!note! in!
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that! it! does! not! have! many! orthologs! in! either! E.# coli! or!H.# sapiens.! Limonene! is! an!incredibly! widespread! compound! produced! by! many! different! species! of! plants.! R.#
erythropolis,!a!closelyJrelated!organism!to!Mtb,!can!grow!on!limonene!as!a!sole!source!of! carbon! and! energy! (van! der! Werf! et! al.,! 1999).! Pinene! is! also! a! common!monoterpenoid!produced!by!certain!plants!(Caspi!et!al.,!2012).!The!phylogenetic!profile!shows!that! this!pathway!has! the!characteristics! that!are!necessary! for!drug! targets! in!terms! of! the! lack! of! homology! with! H.# sapiens! and! other! organisms;! however,! the!compounds! upon!which! this! pathway! operates! are! not! likely! to! be! found!within! the!macrophage.! Thus,! the! pathway! is! probably! not! essential! for! Mtb! H37Rv! and! may!simply!be!an!artefact!due!to!the!soilJdwelling!nature!of!many!mycobacteria.!
4.3.3 Large Differences Between M. tuberculosis and E. coli Pathways! for! which! proteins! differ! significantly! between! Mtb# and! E.# coli# could! also!signify!potential!drug!targets.!If!there!are!few!orthologous!proteins!between!these!two!organisms! then! there! is! a! good! chance! that! there! are! also!many!differences! between!Mtb# and! other! organisms,! including! those! likely! to! be! affected! by! drugs! given! to! a!patient.! Pathways! that! show! few! orthologous! proteins! between! these! two! organisms!include!‘histidine!metabolism’,!‘butanoate!metabolism’!and!‘phenylalanine!degradation’.!‘Histidine! metabolism’! is! another! amino! acid! pathway! and! thus! expected! to! be!conserved!across!the!phylogenetic!profile.!However,!this!does!not!seem!to!be!the!case.!In!fact,!Figures!3.1!and!3.2!show!very!few!orthologous!proteins!for!this!pathway.!Part!of!this!pathway!involves!the!biosynthesis!of!histidine!from!PRPP,!and!is!the!same!pathway!for! all! organisms! studied! so! far,! with! only! small! differences! in! some! of! the! enzymes!used!(Caspi!et!al.,!2012).!This!section!of!the!pathway!was!already!characterised!in!KEGG!and! thus!no!proteins!were!added.!On! the!other!hand,! the!metabolism!of!histidine!can!proceed!via!multiple!pathways!using!different!enzymes!and!histidine!can!be!used!as!a!source! of! nitrogen! and! carbon! (Borek! and!Waelsch,! 1953).! If! histidine!metabolism! is!essential! for! growth! then! reactions! of! this! histidine! degradation! pathway! could! be!possible! new! drug! targets.! In! fact,! a! recent! study! demonstrated! the! essentiality! of!histidine! biosynthesis! for! growth! and! suggested! that! enzymes! within! this! pathway!would! make! attractive! drug! targets! (Lunardi! et! al.,! 2013).! The! phylogenetic! profile!
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strengthens! the! attractiveness!of! this!pathway!as! a!potential! drug! target,! and! further!research!could!be!done!to!determine!whether!these!enzymes!would!be!viable!targets.!!Another! pathway! in! which! E.# coli#and!Mtb#H37Rv! share! few! orthologous! proteins! is!‘butanoate!metabolism’.!Of!the!many!proteins!added!to!this!pathway,!parts!of!multiple!pathways!were!characterised.!These!include!aerobic!and!anaerobic!pathways!involved!in!carbon!metabolism!as!a!source!of!carbon!and!energy.!Additional!reactions!have!been!characterised,! allowing! the!partial! completion!of! the! interconversion!of! pyruvate! and!succinate! as!well! as! the! production! of! butanoylJCoA! from! acetoacetate! through! both!acetoacetylJCoA! and! (R)J3Jhydroxybutanoate.! The! bar! graph! shows! many! added!proteins! for! this!pathway,!with!very! few!added!proteins! in!E.#coli#and!H.#sapiens.! The!pathway! also! has! a! substantial! number! of! added! proteins! for!M.# leprae.! Even! though!some!of!the!reactions!belong!to!anaerobic!pathways,!C.#glutamicum#and!Mtb!share!very!few!orthologous!proteins.!Additionally,!Figure!3.2!shows!‘butanoate!metabolism’!in!the!lower!half!of!pathways,!meaning!that!it!is!not!very!conserved!evolutionarily.!The!results!from! the!phylogenetic!profile! thus!point! to! ‘butanoate!metabolism’!as!a!pathway! that!merits!further!investigation!as!a!potential!drug!target.!Another!pathway!that!shows!relatively!few!shared!orthologs!between!Mtb!and!E.#coli#is!‘phenylalanine!metabolism’.!As!stated!earlier,! ‘phenylalanine!metabolism’!can!function!as! a! sole! source! of! carbon! and! energy! (Caspi! et! al.,! 2012).! Additionally,! amino! acid!metabolism! pathways! are! typically! highly! conserved! among! organisms! (Marri! et! al.,!2006).!However,!when!observing!this!pathway!across!the!phylogenetic!profile,!very!few!orthologs! are! found! between! Mtb# and! E.# coli.! Additionally,! Figure! 3.3! shows! many!orthologs!between!Mtb#and!M.#leprae! and! few!orthologs!between!Mtb!and!H.#sapiens.!These!findings!suggest!first!that!these!newly!characterised!proteins!may!be!important!aspects!of!Mtb!metabolism.!Secondly,!the!lack!of!orthologs!between!Mtb#and!E.#coli#and!
H.#sapiens!indicates!that!these!enzymes!might!not!be!common!either!in!the!human!body!or! in! beneficial! bacteria! that! reside! within! the! host.! Both! of! these! factors! warrant! a!closer!look!at!the!reactions!of! ‘phenylalanine!metabolism’!as!targets!for!potential!new!drugs.!Thus! a! number! of! pathways! including! ‘histidine!metabolism’,! ‘butanoate!metabolism’!and!‘phenylalanine!metabolism’!show!relatively!few!orthologs!between!Mtb!and!E.#coli.!
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The! lack!of!orthologs!between!these!two!organisms!provides!pathways!and!reactions,!which,! if! targeted! by! drugs,! would! not! affect! pathways! and! reactions! essential! for!beneficial!bacteria!within!the!human!body.!
4.3.4 Many Similarities Between M. tuberculosis and C. glutamicum 
C.# glutamicum! is! a! closely! related! bacteria! to! Mtb! which! functions! as! a! facultative!anaerobic!bacterium!(Nishimura!et!al.,!2007).!Since!Mtb#also!survives! in!an!anaerobic!state! during! persistence! in! the! host,! comparison! of! the! phylogenetic! profile! between!this! organism! and! Mtb! could! show! pathways! that! are! particularly! important! for!bacterial! survival! in!an!anaerobic!environment.!Pathways! that!were!observed! to! fulfil!this! characterisation! are! ‘xylene! degradation’! and! ‘porphyrin! and! chlorophyll!metabolism’.!Xylene!is!a!polycyclic!aromatic!hydrocarbon!that!can!be!found!in!the!environment,!and!is! a! major! petrochemical.! Another! species! of! mycobacteria,! Mycobacterium#
austroafricanum! IFP! 2012,! can! grow! solely! on! xylene! (Francois! et! al.,! 2002);! M.#
cosmeticum!has!also!been!found!to!degrade!benzene,!toluene,!ethylbenzene!and!xylene!(Zhang! et! al.,! 2013).! Xylene! is! degraded! via! reactions! shared!with! the!degradation!of!other! polycyclic! aromatic! hydrocarbons! such! as! toluene,! benzene! and! ethylbenzene.!Xylene!degradation!does!not!show!a! large!number!of!orthologs,!as!seen! in!Figure!3.2;!however,!it!is!one!of!the!few!pathways!which!shows!a!greater!number!of!orthologs!than!are!characterised!for!that!pathway!in!KEGG.!The!phylogenetic!profile!shows!relatively!low!conservation!of!proteins!across!all!organisms,!as!shown!in!Figure!3.1.!The!ability!to!degrade!xylene!has!not!been!directly!shown!in!Mtb,!but!these!results!suggest!that!this!is!functionally! possible! for! the!microorganism.! However,! its! importance! as! an! essential!pathway!for!anaerobic!metabolism!is!inconclusive!in!this!case.!Another!pathway!in!which!Mtb#and!C.#glutamicum!share!many!orthologs!is! ‘porphyrin!and! chlorophyll! metabolism’.! The! pathway! results! in! the! production! of! cobalamin!(vitamin! BJ12),! one! of! the! most! structurally! complex! molecules! found! in! nature!(Martens! et! al.,! 2002).! Mtb# is! one! of! a! select! group! of! bacteria! that! can! synthesise!cobalamin!de#novo,!but!it!can!also!uptake!cobalamin!from!the!host!environment.!It!has!even!been!suggested!that!the!organism!can!regulate!core!metabolic!functions!based!on!the! availability! of! cobalamin! (Gopinath! et! al.,! 2013).! This! similarly! complex! pathway!
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proceeds! via! both! aerobic! (late! cobalt! incorporation)! and! anaerobic! pathways! (early!cobalt!incorporation)!(Warren!et!al.,!2002),!both!of!which!have!been!added!to!through!manual! annotation! and! BLASTP! matches.! The! aerobic! pathway! has! been! completed!while! the! anaerobic! pathway! now! has! only! two!missing! enzymes.! In! Figure! 3.3! this!pathway!shows!more!orthologs!for!C.#glutamicum!than!for!M.#leprae.!On!the!other!hand,!Figure! 3.1! shows! that! this! pathway! is! relatively! conserved! across! the! phylogenetic!profile.! Because! the! number! of! orthologs! between! Mtb# and! C.# glutamicum# are! quite!high,!this!suggests!that!certain!of!these!proteins!are!important!in!anaerobic!metabolism.!It!has!been!proposed!that!there!is!a!strong!role!for!cobalamin!in!pathogenesis!(Gopinath!et!al.,!2013).!Further!examination!of!this!pathway,!in!particular!the!anaerobic!section!of!this!pathway,!could!thus!be!warranted!during!the!search!for!potential!drug!targets!that!would!inhibit!Mtb!functioning!in!the!persistent!phase,!during!which!the!bacteria!is!able!to!survive!in!an!anaerobic!environment.!Both! ‘xylene! degradation’,! including! other! pathways! that! are! part! of! xenobiotics!biodegradation! and! metabolism,! and! ‘porphyrin! and! chlorophyll! metabolism’! show!many! shared! proteins! between! Mtb# and! C.# glutamicum.#Due! to! this! similarity,! these!pathways!might!possibly!be!targets!for!new!drugs!that!attack!Mtb!during!the!persistent!phase!of!infection.!
4.3.5 Large Differences Between M. tuberculosis and H. sapiens For!reactions!and!pathways! to!be! labelled!as!potential!drug! targets,! they!must!not!be!catalysed!by!the!same!enzymes!in!Mtb#and!H.#sapiens.!Using!the!phylogenetic!profile!of!Figure! 3.1! and! 3.2,! pathways! were! noted! which! showed! few! orthologous! proteins!between! these! two! organisms.! Certain! pathways!were! noted! in! this! regard! including!‘biotin! metabolism’,! ‘glyoxylate! and! dicarboxylate! metabolism’,! ‘sulfur! metabolism’,!‘geraniol!degradation’!and!‘polycyclic!aromatic!hydrocarbon!degradation’.!The! ‘biotin! metabolism’! pathway! has! only! two! reactions! added;! however,! these!reactions!partially!complete!the!biosynthesis!of!biotin,!an!essential!cofactor!for!carboxyl!group!transfer!enzymes!required!by!all!forms!of!life!(Caspi!et!al.,!2012).!In!E.#coli!biotin!is!synthesised!through!a!number!of!reactions!belonging!to!a!slightly!altered!fatty!acid!synthetic!pathway.!These!reactions!add!a!methyl!ester!to!the!intermediates!to!disguise!them! so! that! they! can! be! substrates! for! the! fatty! acid! synthesis! reactions.! After! two!
! 89!
reiterations!of!these!fatty!acid!elongation!cycles,!pimeloylJ[acp]!is!produced,!which!then!proceeds!via!8JaminoJ7Joxononanoate!to!produce!biotin!in!reactions!that!have!already!been!characterised! in!KEGG! for!Mtb! (Lin!et!al.,!2010).! In! the!phylogenetic!profile! this!pathway!was! found! to! share! few!orthologs!with!H.#sapiens,! although! it! shares! a! large!proportion!with!both!M.#leprae!and!E.#coli.!The!high!proportion!of!shared!orthologs!with!
M.# leprae! suggests! that! this! pathway! is! important! for! growth! and! survival,! a! finding!supported!by!the!literature!(Caspi!et!al.,!2012;!Lin!et!al.,!2010).!The!low!proportion!of!shared!orthologs!with!H.#sapiens! suggests! these!organisms!share! few!similarities!with!regards! to! the! biosynthesis! of! biotin.! These! results! indicate! that! reactions! of! this!pathway!might!be!potential!drug!targets!for!future!research.!Another! pathway! that! deserves! further! investigation! is! ‘glyoxylate! and! dicarboxylate!metabolism’.! As! mentioned! previously! this! pathway! is! incredibly! important! for! the!metabolism! of! fatty! acids! as! a! source! of! carbon! and! energy! (Moat! et! al.,! 2003).!Additionally,! these! reactions! are! important! for! the! use! of! glycolate! and! glyoxylate! as!sources! of! carbon! and! energy! (Clark! and! Cronan,! 2005).! Figure! 3.3! shows! that! only!about! one! quarter! of! the!Mtb#proteins! involved! in! this! pathway! have! orthologs! in!H.#
sapiens.! Those! proteins! shared! between! the! two! organisms! mostly! comprise! the!‘methylmalonyl!pathway’,!‘glyoxylate!cycle’!and!‘glycolate!and!glyoxylate!degradation!I’!pathway.! Of! these! three! pathways,! only! the! ‘methylmalonyl! pathway’! is! predicted! by!MetaCyc! to! function! in! H.# sapiens.! However,! when! viewing! the! ‘glyoxylate! and!dicarboxylate!metabolism’!pathway!across!the!phylogenetic!profile!shown!in!Figure!3.1,!it!seems!to!be!relatively!well!conserved!among!bacteria.!While!the!lack!of!orthologous!proteins! in! H.# sapiens#might! warrant! further! examination! of! these! proteins! as! drug!targets,! their! conservation! in! other! bacteria! might! prove! difficult! in! the! actual!application!of!drugs.!The! reactions!belonging! to! ‘sulfur!metabolism’! also! show! few!orthologs!between!Mtb#and!H.# sapiens.! Sulfur! and! sulfite! can! be! used! as! sources! of! energy! and! electrons! in!organisms!able!to!metabolise!it!(Kappler!and!Dahl,!2001).!The!bars!representing!‘sulfur!metabolism’! in! Figure! 3.3! show! close! to! even!numbers! of! orthologs! in!C.#glutamicum#and!E.#coli.!This!also!shows!very!few!shared!orthologs!in!H.#sapiens.!Lastly,!many!of!the!proteins! added! for! Mtb# also! have! orthologs! in! M.# leprae.! The! heat! map! of! the!
! 90!
phylogenetic!profile!shown!in!Figure!3.1!shows!that!is!pathway!is!relatively!conserved!across!the!genome.!However,!most!of! those!proteins!that!were!added!to!this!pathway!using!BLASTP!matches!do!not!have!orthologs!across! the!phylogenetic!profile.!Most!of!these!added!proteins!are!involved!in!first!the!transport!of!taurine!and!alkanesulfonate!from!extracellular!sources!and!second!their!conversions!into!sulfite.!This!would!suggest!that! these! proteins! involved! in! transport! and! conversion! of! compounds! that! are!precursors! of! sulfite! might! require! further! examination! as! drug! targets,! particularly!since!these!proteins!are!not!shared!across!the!phylogenetic!profile!but!have!orthologs!in!the!genome!of!M.#leprae.!The! ‘geraniol! degradation’! pathway! also! shows! few! orthologs! between! Mtb# and! H.#
sapiens.!In!fact,!Mtb#proteins!involved!in!this!pathway!share!orthologies!with!very!few!proteins!across!the!entire!phylogenetic!profile!and!the!pathway!is!in!the!bottom!third!in!terms! of! average! frequency! as! shown! in! Figure! 3.2.! This! pathway! involves! the!degradation! of! citronellol,! a! compound! produced! by! plants! and! found! in! the!environment!(Caspi!et!al.,!2012).!Pseudomonas#citronellolis!can!use!citronellol!as!a!sole!source!of!carbon!and!energy!(Seubert,!1960).!Mtb#shows!many!more!proteins!assigned!to!this!pathway!than!any!of!the!organisms!compared!in!Figure!3.3!suggesting!that!this!pathway!may!be!important!for!the!organism.!On!the!other!hand,!Mtb#also!shares!very!few!orthologs! for! this!pathway!with!M.#leprae,! indicating!that!perhaps!these!reactions!are!not! essential! for! central!metabolism.!However,! the!much!greater!numbers!of!Mtb!proteins! belonging! to! this! pathway,! compared! to! other! organisms,! warrants!investigation! into! the! potential! competitive! advantages! this! pathway! might! provide!within! the! host.! Since! citronellol! is! a! common! plantJderived! compound! in! the!environment,! the! existence! of! proteins! catalysing! reactions!within! this! pathway!may!simply! be! an! evolutionary! artefact! of! a! soilJdwelling! ancestor.! However,! the! large!differences!in!numbers!of!orthologous!proteins!seen!between!Mtb#and!other!organisms!warrant!further!attention.!Lastly! the! ‘polycyclic! aromatic! hydrocarbon! degradation’! pathway,! along! with! many!other! pathways! involved! in! ‘xenobiotics! biodegradation! and!metabolism’,! shows! few!orthologs!between!Mtb#and!H.#sapiens.!Additionally!Mtb#shares!few!orthologs!with!any!other! examined! organism! for! this! pathway! (Figure! 3.3);! this! pathway! ranks! in! the!
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bottom!20%!of!pathways,! signifying! that! it! is! one!of! the! least! conserved!as! shown! in!Figure!3.2.!These!results! identify!this!pathway!as!being!notable!and!worthy!of! further!investigation.! Many! of! the! added! proteins! to! this! pathway! are! involved! in! the!degradation!of!phenanthrene,!a!compound!found!in!cigarette!smoke.!The!most!common!way!by!which!phenanthrene,!along!with!many!other!polycyclic!aromatic!hydrocarbons!(PAHs),!enters!the!body!is!by!breathing!air!contaminated!with!fumes!from!coal,!asphalt,!wildfires,!vehicle!exhaust!or!even!grilled!food!(Phenanthrene).!A!number!of!species!of!mycobacteria!have!been!shown!to!be!able!to!grow!on!phenanthrene!(and!other!PAHs)!as! a! sole! source! of! carbon! and! energy! (Boldrin! et! al.,! 1993;! Moody! et! al.,! 2001;!Willumsen!et!al.,!2001).!Interestingly,!exposure!to!tobacco!has!been!shown!to!increase!TB! infection,! active! disease! and!mortality! (Bates! et! al.,! 2007;!Wen! et! al.,! 2010).! This!correlation! is! thought! to!occur!because!smoking!suppresses! the! immune!system,! thus!allowing!greater!chance!of!infection!and!progression!of!the!disease!as!well!as!a!reduced!ability! of! the! body! to! fight! back! against! infection.! However,! these! newly! annotated!proteins! in! Mtb! offer! another! possibility:! perhaps! smoking! increases! virulence! and!survival! of! Mtb! by! providing! a! source! of! carbon! and! energy.! The! findings! of! the!phylogenetic! profile! thus! suggest! that! reactions!within! this! pathway! could! represent!potential!drug!targets!that!must!be!examined!further.!An!examination!of!the!number!of!H.#sapiens!proteins!that!have!orthologs!in!Mtb#results!in! the! identification! of! a! number! of! interesting! pathways.! These! pathways,! including!‘biotin! metabolism’,! ‘glyoxylate! and! dicarboxylate! metabolism’,! ‘sulfur! metabolism’,!‘geraniol! degradation’! and! ‘polycyclic! aromatic! hydrocarbon! degradation,! signify!pathways! that! could! be! targeted! by! novel! drugs! without! adversely! affecting! human!cells.!
4.4 Missing Pathway Results After! annotating! as!many! reactions! as! possible!with! proteins! from!Mtb#H37Rv,! some!reactions! remained! uncharacterised.! These! ‘missing’! reactions! were! compiled! into! a!table! showing! the! pathway!membership,! reaction! and! evidence! that! shows! they! are!missing!(see!Appendix!C).!This!evidence!includes!the!existence!of!the!reaction!in!closely!related!organisms,! its! classification! as! ‘missing’! in!Pathway!Tools! and! its! existence! in!the! KEGG! global! map.! Certain! reactions! have! all! three! types! of! evidence! supporting!
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their!status!as! ‘missing’!and!these!can!provide!interesting!cases.! ‘Missing’!reactions!or!pathway! holes! result! from! one! of! two! conditions.! First! enzymes! catalysing! these!reactions!may! in! fact!exist!but! their!sequence!structure!differs! to!a! large!degree! from!enzymes!in!closely!related!organisms.!Secondly,!these!can!be!cases!in!which!Mtb#does!not!possess!an!enzyme!catalysing!this!reaction!and!rather!uses!the!host!metabolism!to!accomplish!these!conversions.!One!such!reaction!is!for!the!interconversion!of!glycine!and!threonine.!This!is!a!central!reaction!within! the! ‘glycine,! serine!and! threonine!metabolism’!pathway! that!has!been!characterised!in!other!related!organisms!and!is!classified!as!a!pathway!hole!in!Pathway!Tools.!It!has!been!reported!that!a!wide!variety!of!bacteria!have!the!ability!to!grow!on!LJthreonine!as!a!sole!source!of!carbon!and!nitrogen!(Bell!and!Turner,!1977).!Additionally!many!organisms!have!been!found!to!possess!the!LJthreonine!aldolase!that!catalyses!this!reaction! (Morris,! 1969).! However,! the! physiological! relevance! of! this! enzyme! in!bacteria! has! not! been! established! and! many! organisms! do! not! exhibit! high! aldolase!activity!(Bell!and!Turner,!1977).!Its!absence!from!Mtb!could!mean!that!either!it! is!not!essential!(due!to!the!existence!of!alternative!pathways!between!the!two!compounds)!or!the!microbe!utilises!the!host!to!achieve!this!interconversion.!A!missing!reaction!belonging!to!the!‘one!carbon!pool!by!folate’!pathway!converts!5,10JmethyleneJTHF! into! 5JmethylJTHF.! This! reaction! is! classified! as! a! pathway! hole! in!Pathway!Tools!and!has!been!characterised!in!closely!related!organisms.!The!reaction!is!involved!in!both!methionine!biosynthesis!and!1Jcarbon!metabolism!(Caspi!et!al.,!2012).!The! enzyme! catalysing! this! reaction,! methylenetetrahydrofolate! reductase,! has! been!identified! in! E.# coli! as! well! as! other! bacteria! and! eukaryotes! including! humans!(Sheppard!et!al.,!1999).!The!widespread!distribution!of!this!enzyme!suggests!that!it! is!very! important! for! survival! and! growth.! The! inability! to! characterise! this! reaction! in!Mtb! suggests! that! the! enzyme! either! does! not! exist! or! has! a! different! amino! acid!sequence!compared!to!enzymes!from!closely!related!organisms.!If!the!enzyme!does!not!exist! in!Mtb! it! is!possible!that! the!microbe!utilises!the!host!metabolism!to!accomplish!this!conversion.!Another!reaction!that!has!been!classified!as!a!missing!reaction!in!Pathway!Tools,!shows!on! the! KEGG! global! map! and! has! been! characterised! in! closely! related! organisms!
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belongs! to! the! ‘folate! biosynthesis’! pathway.! Very! little! information! could! be! found!regarding!the!enzyme!catalysing!this!reaction,!alkaline!optimum!2JaminoJ4JhydroxyJ6J(erythroJ1,2,3Jtrihydroxypropyl)!dihydropteridine!triphosphate!phosphohydrolase,!but!it! catalyses! the!only!missing! reaction! in! the! ‘folate!biosynthesis’!pathway.!Folates! are!essential! cofactors!of!many! reactions! in!which!oneJcarbon!units! are! transferred! from!donor!molecules! to! important! biosynthetic! pathways! involved! in! the! biosynthesis! of!methionine,! purine! and! pyrimidine,! the! conversion! of! histidine! catabolism! and!interconversion! of! serine! and! glycine! (Caspi! et! al.,! 2012;! Lucock,! 2000).! Thus! the!absence! of! an! enzyme! catalysing! this! essential! reaction! in! Mtb# could! be! due! to! a!divergent!sequence!for!this!enzyme!in!Mtb!or!to!the!utilisation!of!the!host!metabolism!to!accomplish!this!biosynthesis.!The! reaction! with! the! substrate! 6Jhexanolide! and! product! 6Jhydroxyhexanoate,!catalysed!by!epsilonJcaprolactone!gluconolactonase!(also!6Jhexanolide!hydrolase)!and!part!of!the!‘caprolactam!degradation’!pathway,!is!also!classified!as!‘missing’!on!the!basis!of! all! three! types! of! evidence.! Multiple! other! reactions! were! characterised! for! this!pathway,!and!Figure!3.3!shows!that!many!of!these!proteins!have!no!orthologs!in!other!organisms! including! C.# glutamicum,# E.# coli! and! H.# sapiens.! The! pathway! is! common!within! the! phylum! actinobacteria! and! typically! the! five! enzymes! converting!cyclohexanol! to! adipate,! including! this! ‘missing’! reaction! function! in! one! operon.!Although!the!four!other!enzymes!were!characterised!in!Mtb!using!BLASTP!matches,!this!reaction!has!yet!to!be!found.!It!is!thus!likely!that!this!enzyme!exists!in!Mtb#but!simply!has!not!been!assigned!a!protein!from!the!genome.!These!few,!as!well!as!many!other,!reactions!have!been!classified!as! ‘missing’!reactions!or!pathway!holes!and!are! shown! in! the!appendix! (Appendix!C).!These!pathway!holes!deserve! further! attention! to! discover! certain! cases! where! Mtb! may! utilise! the!metabolome!of!the!human!host!in!order!to!accomplish!its!metabolic!needs.!
4.5 Conclusion This! study! has! identified! a! number! of! pathways! and! reactions! that! deserve! further!attention! as! potential! drug! targets.! First,! certain! pathways! for! which! many! proteins!have! been! assigned! were! investigated.! Second,! pathways! showing! interesting!
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characteristics!across!the!phylogenetic!profile!were!identified.!Interesting!pathways!in!this!case!include!those!in!which!Mtb#shares!both!many!and!very!few!orthologs!with!M.#
leprae,! many! orthologs! with! C.# glutamicum,! and! few! orthologs! with! E.# coli# and! H.#
sapiens.!Lastly,!the!compiled!table!of!‘missing’!reactions!or!pathway!holes!was!examined!to! find!reactions!which!deserve! further!attention!as!possible!cases!where!Mtb!utilises!the!host!genome!to!accomplish!its!metabolic!requirements.!These!strategies!have!aided!in!the!further!characterisation!of!the!genome!of!M.#tuberculosis!H37Rv.!
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5 Conclusion Although! many! efforts! have! been! made! to! reduce! the! burden! of! the! disease,!tuberculosis! remains! a!major! global! health! problem.!An! estimated! 1.3!million! people!died! of! TB! in! 2012,! including! 88,000! people! in! South! Africa! alone! (World! Health!Organization,!2013c,!2013f).!In!addition,!the!deadly!combination!of!HIV!and!TB!affects!1.1! million! or! the! 8.6! million! people! infected! with! TB! in! 2012,! with! 75%! of! these!instances! occurring! in! subJSaharan! Africa.! Lastly,! the! World! Health! Organization!estimates!that!globally!3.6%!of!new!cases!and!20%!of!previously!treated!cases!of!TB!are!MDRJTB,!with!9.6%!of!MDRJTB!cases!are!actually!XDRJTB!(World!Health!Organization,!2013f).!TB!treatment!and!prevention!urgently!needs!to!be!addressed!in!order!to!reduce!this!significant!burden!of!the!disease!both!around!the!world!and!in!South!Africa.!Several!factors!contribute!to!the!high!incidence!and!prevalence!of!TB!around!the!world.!One!complication! involved! in! the! treatment!of!TB! includes! the! lack!of!drugs!affecting!the! bacteria! during! the! persistent! phase! (Ma! et! al.,! 2010).! Mtb# persists! in! an! early!phagosome!within!macrophages!where! it!resides! in!either!a!nonJreplicating!or!slowly!replicating!state,!and!no!currently!available!drugs!are!effective!against!Mtb#in!this!state!(Kaufmann! and! Parida,! 2008;! Wakamoto! et! al.,! 2013).! Secondly,! poor! diagnosis!methods!with!low!sensitivity!such!as!sputum!smear!microscopy!delay!the!treatment!of!TB! and! thus! allow! the! disease! to! spread! further! (Abubakar! et! al.,! 2013;! Jassal! and!Bishai,! 2009).! Third,! the! long! treatment! periods! and! many! side! effects! of! currently!available! drugs! reduce!patient! compliance,! causing! increased! risk! of! reactivation! and!development!of!drug!resistance!(Ma!et!al.,!2010).!HIV!coinfection!also!makes!treatment!more!difficult!and!carries!with!it!an!increased!risk!of!reactivation!of!the!disease!(Jassal!and! Bishai,! 2009;! Ma! et! al.,! 2010).! Lastly,! drug! resistance! requires! longer! treatment!periods! with! both! first! and! secondJline! drugs! (which! have!more! side! effects)! and! is!more! difficult! to! cure! (Jassal! and! Bishai,! 2009).! All! of! these! factors! complicate! the!treatment!of!TB!and!underscore!the!need!for!new!drugs.!New! drugs! are! urgently! needed! to! address! these! issues! and! improve! treatment!outcomes! for! patients.! In! order! to! efficiently! and! rationally! design! these! new! drugs,!more! research!needs! to!be! completed! regarding! the!metabolism!of!Mtb.!With! further!
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understanding!of!its!metabolism,!drugs!can!be!developed!that!target!specific!reactions!or!pathways!in!the!metabolome.!The!identification!and!validation!of!appropriate!targets!is! currently! a! bottleneck! in! the!drug!development!pipeline.! In! fact,!many!drug! in!use!today! have! been! developed! without! specific! drug! targets! in! mind,! probably! because!there!are!no!standard!methodologies!to!identify!these!targets!on!a!large!scale!(Raman!et!al.,! 2008).! These!drug! targets! need! to! be! essential! for! the! survival! of!Mtb,! preferably!functional! in! Mtb# during! the! persistent! state! and! not! have! equivalent! reactions! or!enzymes! in!H.# sapiens#and! other! beneficial! bacteria! that!will! be! affected! by! the! same!drugs.!In! order! to! find! these! new! drug! targets,! this! study! first! aimed! to! improve! the!characterisation! of! the! Mtb! metabolome,! and! then! compared! pathway! and! reaction!information! over! the! phylogenetic! profile,! which! includes! a! large! spectrum! of!organisms.! Orthologs,! or! genes! in! different! species! with! shared! ancestry! by! vertical!descent,! were! used! to! make! this! comparison! across! the! various! species! by! finding!pathways! showing! different! numbers! of! orthologs.! This! study! has! attempted! to! first!further!characterise!the!metabolism!of!Mtb,#second!compare!its!metabolism!across!the!phylogenetic! spectrum! to! find! notable! pathways! that! can! be! deemed! potential! drug!targets,!and!third!to!classify!pathway!holes,!or!reactions!without!an!assigned!enzyme!in!the!genome!of!Mtb.#!The! first! step! of! this! study! involved! the! addition! of! functional! annotations! to! the!genome!of!Mtb.!A!combination!of!annotation!methods!using!EC!number,!GO!terms!and!BLASTP!matches!were!used!to!help!complete!the!metabolic!map.!A!total!of!553!proteins!were!added!to!pathways!based!on!GO!terms!and!EC!numbers.!In!addition,!288!reactions!were!annotated!within!the!metabolism!of!Mtb!using!BLASTP!matches.!Some!pathways!in! particular! had! many! newly! annotated! reactions! and! thus! were! examined! further.!Benzoate! degradation,! phenylalanine! metabolism! and! glyoxylate! and! dicarboxylate!metabolism!displayed!a!relatively!high!number!of!added!annotations!and!were!mapped!to! KEGG! diagrams! to! identify! important! newly! characterised! pathway! sections.! It! is!unclear!why! so!many!additional! annotations! could!be!made! for!M.#tuberculosis,!when!the!genome!should!already!be!fully!annotated.!One!possible!cause!is!that!the!annotation!is!simply!out!of!date!and!needs!to!be!updated!for!this!organism.!Another!possibility!is!
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based! on! the! genomes! used! for! annotation.! Typical! automatic! annotation! uses! wellJcharacterised! genomes! to! generate! functional! annotations! for! newly! sequenced!genomes.! The! genomes!used! to! locate!BLASTP!matches! in! this! study!were! all! closely!related!organisms,!and!it!is!possible!that!these!genomes!were!annotated!after!Mtb,!and!thus! not! used! to! annotate! the! genome! of! Mtb! as! they! were! in! the! current! study.!Whatever! the! reason,! a! substantial!number!of! additional! genes!were!annotated!using!the!methods!described!thus!far,!and!the!study!highlights!the!need!to!keep!annotation!as!current!as!possible.!The! metabolic! map! with! the! novel! functional! annotations! was! then! used! to! identify!pathways!and!reactions!of!interest!by!comparing!the!number!of!orthologs!per!pathway!for! 392! organisms! across! the! phylogenetic! profile.! Five! characteristics! of! interesting!pathways! include!Mtb#having!both!many! and!very! few!orthologs!with!M.# leprae,#very!few! orthologs! with! E.# coli# and!H.# sapiens# and! many! orthologs! with! C.# glutamicum,! a!facultative! anaerobe.! Comparisons! of! the! number! of! orthologs! with! M.# leprae,! an!organism! with! a! highly! reduced! genome,! can! show! reactions! that! are! likely! to! be!essential! in!Mtb.!Proteins!of!Mtb!without!orthologs! in!other!organisms,!such!as!E.#coli#and!H.#sapiens!can!classify!enzymatic!reactions,!which,!if!attacked,!would!not!affect!the!metabolism!of!host!cells!nor!beneficial!bacteria!within!the!host.!Lastly,!by!comparison!with! an! anaerobic! bacterium! such! as!C.#glutamicum,! potential! pathways! essential! for!anaerobic!metabolism!can!be! identified,! thereby! finding!potential!drug!targets! for! the!persistent! phase! of! infection.! A! number! of! interesting! pathways! were! identified!fulfilling! these! characteristics! including! arginine! and! proline! metabolism! and!glycerolipid!metabolism!(many!orthologs!shared!between!Mtb#and!M.#leprae),!histidine!metabolism!and!butanoate!metabolism!(few!orthologs!shared!between!Mtb#and!E.#coli),!xylene!degradation!and!porphyrin!and!chlorophyll!metabolism!(many!orthologs!shared!between! Mtb# and! C.# glutamicum)! and! lastly! biotin! metabolism,! sulfur! metabolism,!geraniol!degradation!and!polycyclic!aromatic!hydrocarbon!degradation!(few!orthologs!between! Mtb! and! H.# sapiens).! Important! functions! of! these! pathways! were! then!described! to! assess! the! essentiality! of! the! pathway! and! significance! during! infection.!These! pathways! have! therefore! been! identified! as! potential! drug! targets! for! the!development!of!novel!drugs.!
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The! third! and! final! goal! of! this! project! was! to! identify! pathway! holes,! or! essential!reactions!either!without! annotated!enzymes!or! instances! in!which!Mtb#might!use! the!host! metabolism! to! accomplish! its! metabolic! needs.! Pathway! holes! were! located! by!mapping! the! enzymes! of! Mtb! onto! KEGG! pathway! diagrams.! Reactions! without!annotated! enzymes! in! the! genome! of!Mtb!were! crossJreferenced!with! pathway! holes!identified!by!Pathway!Tools!and!reactions!that!have!annotated!enzymes!in!the!genomes!of!closely!related!organisms!but!for!which!no!BLASTP!matches!could!be!found.!A!total!of!363!pathway!holes!were! classified,!which! can!help! elucidate! the! interaction! between!host!and!microbe!during!infection.!The! use! of! sequence! similarity! as! a! proxy! for! functional! similarity,! while! being!supported! in! the! literature,!also!has! its! limitations.!Some!proteins!with!highly!similar!sequences! may! not! share! function,! especially! if! they! have! experienced! duplication!events!and!horizontal!gene! transfer!such!as!has!occurred! in!Mtb! (Kelley!et!al.,!2003).!The! use! of! EC! number! and! GO! terms! to! annotate! the! genome! of! Mtb! relies! on! the!accuracy! of! these! classifications! and! this! also! limits! the! accuracy! of! the! annotations.!Lastly,! the! use! of! KEGG! as! the! reference! database! can! have! a! major! effect! since!functional!characterisation!of! the!metabolome!relies!on! the!precision!of! the!database.!Repetitious! reactions! and! the! lack! of! taxonomic! predictors! for! pathway! function! in!different! organisms! can! cause! false! positives! in! terms! of! pathway! membership! and!pathway! hole! prediction.! Additionally! since! KEGG! pathway! diagrams! include! all!reactions!pertaining!to!a!particular! topic,!comparison!of! the!number!of!proteins! in!M.!tuberculosis! H37Rv! for! each! pathway! with! the! number! of! orthologous! proteins! for!organisms!across! the!phylogenetic!profile!might!not!always!be!effective.!For!example,!two!organisms!might!show!the!same!number!of!orthologous!proteins!but!have!entirely!different!pathway!branches!within!the!diagram,!and!this!must!be!taken!into!account.!In!summary,!many!new!annotations!were!added!to!the!genome!of!Mtb!and!a!number!of!pathways!were!identified!as!potential!drug!targets!for!future!drug!development.!These!annotations!should!be!added!to!the!genome!of!Mtb#in!the!KEGG!database!by!updating!the! genome! annotation.! Future! research! should! be! directed! toward! those! pathways!identified!as!potential!drug!targets.!Enzymes!within!these!identified!pathways!must!be!investigated! further! to! evaluate! this! potential.! A! combination! of! expression! data! (to!
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New!Proteins!Found! #!Missing!Pyrimidine!Metabolism! 49! P0A616! &! P65548! (GO);! O53217! (GO);! O53590! (GO);! P68911!(Msmeg);!L0TED1/O05791!(Msmeg);!P71809!(Msmeg)! 5!Purine!Metabolism! 79! P65548! (GO);! O07732! (GO);! O50399! (GO);! O33230! (GO)(dup);!O53707! (GO);! O53699! (GO);! Q7D4M2! (GO);! C6DMB2! (GO);!A5U160! (GO);! P68911! (Msmeg);! P71809! (Strep);! O53772! &!Q11058!(Mvan)!
9!(maybe!8)!Tyrosine!Metabolism! 58! P0A678!(GO);!O53904!&!P95153!(GO);!O53303!&!O53533!&!Q7DAC8!&!P71818!&!O53904!&!P0A4X0!&!P95153!&!O07737!(Msmeg);!O86346!(Rjost);!Q8VK36!(Rjost);!P95275!(Rjost);!P71865!(Rjost);!O53242!&!O86346!(Rjost);!P63937!&!P96405!&!O33340!&!P71823!&!O53816!&!P71989!&!P96417!&!Q7D5R7!&!P96824!&!O50443!(Nfarc);!C6DW56!(GO)(KZN)!
13!




Cysteine! and!Methionine!Metabolism! 29! P96847?! (GO);! P66875! &! P95199! &! O53390! (Msmeg);! P95075!(Nfarc)! 8!Valine,!Leucine! and!Isoleucine!Degradation!




Lysine!Biosynthesis! 16! P63509!(EC);!O53407!(GO);!O53176!&!P95139!(Msmeg)! 11!Lysine!Degradation! 50! Q7D529! (GO);! O53176! &! P95139! (Msmeg);! O05820! (Rjost);!O50463!(Strep)! 3!Alanine,!Aspartate!and! 32! P96847! (GO);! O53446! (Msmeg);! Q10896! &! L0TB18! &! O05819!(Rjost);!O69644!(Rery)! 1!
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Glutamate!Metabolism!Steroid!Biosynthesis! 1! ! Unknown!Fatty! Acid!Metabolism! 70! Q10878!!&!Q7D5D8!&!O53551!&!O07797!(GO/EC);!O06544!(GO);!O07737! (EC);! O05893! (GO);! O06164! &! P95186! &! O86319! &!P63429! &! P95208! &! P96842! &! O33331! &! P96831! &! P96397!(Msmeg);! O33229! &! O86319! &! O06164! &! P63427! &! O53815! &!P96397! &! P71539! &! O33331! &! P95208! &! O53549! &! P71858! &!P95280! &! P63429! &! P95186! &! P96831! &! P96855! &! P96808! &!O53577! (Msmeg);! P77900! &! O08447! &! P63719! &! O69653! &!P0A512! &! P63717! &! P95099! &! P63715! &! O33180! (Nfarc);!P95034! &! P95146! (Mvan);! P63427! &! P96397! &! O06164! &!O53815!&!O33229!&! P95208!&! P63429!&!O33331!&!O86319!&!P96831! &! P71539! &! P95208! &! O53549! &! P95186! &! P96808! &!O53577! &! P96844! &! P71858! &! P96842! &! P95228! &! O53926!(Rjost)!
0!
Synthesis!and!Degradation!of! Ketone!Bodies!






Glycerophospholipid!Metabolism! 23! O07427!&!P0A642!(GO)! 11!Ether! Lipid!Metabolism! 7! None! Unknown!Fatty! Acid!Biosynthesis! 33! P71980!(EC);!P0A5Y4!(EC);!P0A574!(Msmeg);!P63456!&!P63454!&!O53579!&!Q10977!&!O86335!&!P96284!&!P94996!&!L0TA10!&!O53901! &! P96202! &! P96291! &! L0T5X5! &! P71718! &! O06586! &!O65933! &! P96204! &! O07798! (Msmeg);! P0A5Y6! &! P71871! &!O05919!&!P71824!(Strep)!
0!
Linoleic! Acid!Metabolism! 5! None! Unknown!Sphingolipid!Metabolism! 4! None! Unknown!Steroid!Biosynthesis! 1! None! Unknown!Glycolysis/!Gluconeogenesis! 42! O07737!(EC);!A5U5J3!&!C6DMY5!(EC)(CDC!&!KZN);!P0A4X0!(EC)! 3!Citrate! Cycle!(TCA!Cycle)! 37! O53671!(GO);!O50463!(EC);!O50463!(Strep)! 0!
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Pyruvate!Metabolism! 48! P64261!(EC);!P96886!(EC);!P65684!&!O06579!(Msmeg);!P95040!(Msmeg);! P0A622! &! P66946! &! O06335! &! O53639! &! O53554!(Msmeg)! 3!Propanoate!Metabolism! 80! O86318!&!O53578!&!O06165!&! P63407! (EC);! P66984! (Msmeg);!O06831!&! P95227!&! O07411!&! P96396!&! O53306!&! P96843!&!P96283!&!P71716!&!Q7D5D8!&!O06417!&!O53406!&!O06168!&!Q10878! &! Q50586! (Msmeg);! Q8VK36! (Msmeg);! P0A5H3! &!O07718!(Msmeg)!
9!
Pentose!Phosphate!Pathway! 20! P71825!(EC);!P65154!(Msmeg)! 6!Pentose! and!Glucuronate!Interconversions!
44! P95286! &! P0A5Y4! &! O53927! &! P95033! &! P66781! &! P71824! &!O33339!&! P95273!&! O33292!&! P69167!&! P66777!&!O06348!&!O05919!&! P96841!&! O33263!&! P95101!&! P71852!&! O06544!&!P71564! &! P71853! &! O53863! &! P71871! &! P96825! &! O53665! &!Q7D6M3! &! O53547! &! O53302! &! O50460! &! P95150! &! O53398!(Msmeg);! O69664! (Msmeg);! P71821! &! Q11150! &! O50417!(Msmeg);!O06413!(Msmeg);!P95075!(Msmeg)!
5! (or!13)!
Ascorbate!and! Aldarate!Metabolism! 7! P95075!(Msmeg)! 6!Starch! and!Sucrose!Metabolism! 28! O07242!(GO);!P71741!(EC)! 4!Amino! Sugar!and!Nucleotide!Sugar!Metabolism!
38! P64905!(GO);!Q50685!(EC);!P63338!(Msmeg);!P95277!&!Q7ARS9!&!O05875!&!P96853!&!P71846!&!O86347!(Msmeg)! 4!
C5JBranched!Dibasic! Acid!Metabolism! 10! P0A666!(Msmeg)! 1!Galactose!Metabolism! 14! P67475!(Msmeg)! 0!Inositol!Phosphate!Metabolism! 16! Q7D6W6!(GO);!P96283!&!P66946!&!O53639!&!O53865!(Msmeg);!O86352!(Msmeg)! 4!Oxidative!Phosphorylation! 49! P64947!(EC);!O53671!(GO)! 0!Nitrogen!Metabolism! 46! P71753!(EC);!P63627!(EC);!O06179!(EC);!A5TYS2!&!P71994!(EC);!Q7D4Q3!(EC);!P96218!(Msmeg);!Q11146!(Rjost)! 3!Methane!Metabolism! 57! P64118! &! P65408! (EC);! A5UBZ1! (EC);! A5TZ90! (EC);! P65573! &!P65567! &! P95175! &! P65408! &! O06817! &! O06560! &! L0T2Z1!(Msmeg);! O53294! &! P64745! &! P71662! &! O53762! &! P96223! &!O53300! (Msmeg);! P96253! &! Q10814! &! P96809! &! O07914! &!P95140! &! P95159! &! O53565! &! P71701! &! P64769! (Msmeg);!P65684! &! O06579! (Msmeg);! O53533! (UniPathway);! O07737! &!O53904!&!Q7DAC8!&!P72043!&!P0A4X0!&!P95153!(Strep)!
16!




Terpenoid!Backbone!Biosynthesis! 27! None! 0!Carotenoid!Biosynthesis! 1! None! Unknown!Ubiquinone!and! Other!TerpenoidJQuinone!Biosynthesis!
21! P96843!&!O06168!&!O07411!&!O53306!&!O53406!&! P95227!&!O06417!&!O05295!&!P96396!&!O07169!&!O06831!&!O53551!&!O53521!&!Q7D5D8!(Rjost);!Q8VK36!(Rjost)! 3!
Thiamine!Metabolism! 10! None! 2!Riboflavin!Metabolism! 11! P95275!(GO)! 1!Vitamin! B6!Metabolism! 11! O53240!&!A5WM18!&!O07171!&!O50398!&!O06553!(EC);!P66913!(Msmeg)! 4!Nicotinate!and!Nicotinamide!Metabolism!
18! P96394!(EC);!P68911!(Msmeg)! 2!
Pantothenate! and! CoA!Biosynthesis! 19! P71809!(Msmeg)! 3! (or!5)!Lipoic! Acid!Metabolism! 2! None! Unknown!Peptidoglycan!Biosynthesis! 27! P71707!(GO);!O33346!(Strep)! 3!Lipopolysaccharide!Biosynthesis! 6! P95231!(Rjost)! 2! (or!9)!Taurine! and!Hypotaurine!Metabolism! 21! O53379! &! P63504! &! P63568! &! P0A4X6! &! P63506! &! P63509! &!P71890! &! P71891! (Msmeg);! Q50685! &! Q11061! &! O07406! &!L0TBR2!&!P72056!(Rjost)! 3!BetaJAlanine!Metabolism! 48! P71809!(Msmeg);!Q8VKI0!(Msmeg);!O53379!&!P63504!&!P63568!&!P0A4X6!&!P63506!&!P63509!&!P71890!&!P71891!(Msmeg)! 6!Selenocompound!Metabolism! 12! P95199!&!O53390!(Msmeg)! 1!DJGlutamine!and! DJGlutamate!Metabolism!
4! O69644!(Rjost)! 1!
DJArginine!and! DJ 1! None! 2!
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Ornithine!Metabolism!Cyanoamino!Acid!Metabolism! 7! Q11146!(Rjost)! 1!(could!be!many!more)!DJAlanine!Metabolism! 2! None! 0!Glutathione!Metabolism! 18! O05915!&!O53356!(EC);!P0A5M4!(Nfarc)! 3!Penicillin!and!Cephalosporin!Biosynthesis!
2! None! Unknown!
Novobiocin!Biosynthesis! 3! None! Unknown!Streptomycin!Biosynthesis! 11! None! 3! (but!could!be!more)!Fluorobenzoate!Degradation! 37! P95277! &! P66781! &! P71871! &! O33339! &! P71824! &! P96841! &!Q7ARS9!&! P69167!&!O33292!&! P95286!&!O05919!&!Q11150!&!O53398!&!P95033!&!P96853!&!P95273!&!O33263!&!Q7D6M3!&!P71846!&! O53863!&! P0A5Y4!&! P95101!&! O06413!&! P71853!&!P71821! (Msmeg);! O53665! &! P71852! &! O53927! &! P96825! &!O50417!&!O50460!&!O53302! (Rjost);!P65425! (Rjost);!O65936!&!O53772!(Rjost);!P95118!(Rjost);!P65083!(Rjost)!
0!
Chlorocyclohexane! and!Chlorobenzene!Degradation!
35! P96850! (Msmeg);! P65425! (Rjost);! O50405! (Msmeg);! P96811! &!O06266! &! P0A572! &! P95276! &! O06576! (Msmeg);! P95034! &!P95146! (Mvan);! O53311! &! O53674! &! P66006! &! O07927! &!O06598!&!O53641!&!P96839!(Rjost);!O65936!&!O53772!(Rjost);!P95118! (Rjost);!P66777!&!O69638!&!O53321!&!O06420! (Rjost);!P65083!(Rjost);!O05301!&!O06339!(Rjost)!
2!
Nitrotoluene!Degradation! 6! O50431!&!O50388!(Mvan)! 2!Styrene!Degradation! 21! Q11146! (Rjost);! P96850! &! O33319! &! O86347! (Rjost);! O86346!(Nfarc);!P71850!(Nfarc);!O33340!&!P96405!&!P96417!&!P63937!&!P71823! &! P71989! &! O53816! &! Q7D5R7! &! P96824! &! O50443!(Strep)!
4! (or!7)!
Atrazine!Degradation! 11! O69719! (GO);! P0A676! &! P0A660! &! P0A662! (EC);! O53258! &!P63490! &! P63494! &! P63496! &! O53325! &! P63492! (Msmeg);!P71809!(Rjost)! 4! (or!2)!Naphthalene!Degradation! 69! P96825! &! P71853! &! O53547! &! P66781! &! P71824! &! P95033! &!O33292!&!O53863!&!P96841!&!O53398!&!O50417!&!P0A5Y4!&!O53665!&! O53302!&! P69167!&! O50460!&! P95101!&! P66777!&!P95273!&! P95286!&! P71821!&! O33263!&! O33339!&! O05919!&!Q7D6M3!&!P71871!&!P71852!&!O53927!&!P66779!&!O06348!&!P95150!&!O06413!&!O53533!&!O69693!&!O53146!&!P0A4X0!&!P72043!&! P95185!&!O05842!&!O53613!&!O53726!&!O53537!&!O07230! &! O53324! &! Q11150! &! Q10782! &! P96202! (Msmeg);!
4!
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O53772!&!Q11058!(Rjost/Strep);!O53311!&!P95034!&!P95146!&!O53674! &! P66006! &! O07927! &! O06598! &! O53641! &! P96839!(Rjost)!Steroid!Degradation! 14! Q50616!&!O53670!(Msmeg)! 0!Aminobenzoate!Degradation! 108! O53580! (EC);! Q11146! (Rjost);! O06335! &! P0A622! &! O53639! &!P66946! &! O53554! (Msmeg);! P96405! &! P71823! &! O33340! &!P96417!&! P71989!&! P63937!&!O53816!&!Q7D5R7!&! P96824!&!O50443! (Msmeg);! P95034! &! P95146! &! O53674! &! Q79FW1!(Msmeg);!O65936!(Cglut);!P71825!&!O86347!&!P96853!&!P71846!&! O05875! (Cglut);! P96283! &! O07411! &! O05295! &! O53306! &!O06831!&! P95227!&!O69635!&!O06168!&! P96396!&!O06417!&!O53406! &! P96843! &! P71716! &! O07169! &! Q7D5D8! &! Q10878!(Nfarc);!O50388!&!O50431!(Nfarc);!P77900!&!O08447!&!P63719!&! O69653!&! P0A512!&! P63717!&! P95099!&! P63715!&! O33180!(Nfarc);!O53555!(Rjost);!P95034!&!P95146!(Mvan)!
3!
Chloroalkane! and!Chloroalkene!Degradation!
68! O07737!(EC);!P96825!&!P71853!&!O53547!&!P66781!&!P71824!&!P95033!&!O33292!&!O53863!&! P96841!&!O53398!&!O50417!&!P0A5Y4!&!O53665!&!O53302!&! P69167!&!O50460!&! P95101!&!P66777! &! P95273! &! P95286! &! P71821! &! O33263! &! O33339! &!O05919!&!Q7D6M3!&!P71871!&!P71852!&!O53927!&!P66779!&!O06348!&! P95150!&!O06413!&!O69693!&!O53146!&! P95185!&!O05842!&!O53613!&!O53726!&!O53537!&!O07230!&!O53324!&!Q11150! &! Q10782! &! P96202! (Msmeg);! O06266! &! P0A572! &!P95276!&!O06576!(Msmeg);!O50405!(Msmeg);!P95034!&!P95146!(Mvan);!O53533!&!P72043!&!P0A4X0!(Strep)!
4!
Toluene!Degradation! 36! O53671!(EC);!O53303!&!O53533!&!Q7DAC8!&!P71818!&!O53904!&!P0A4X0!&!P95153!&!O07737!(Msmeg);!P95118!(Rjost);!P65425!(Rjost);! P65083! (Rjost);! P95034! &! P95146! (Mvan);! O65936!(Cglut);!Q50685!(Rjost);!O53311!&!O53674!&!P66006!&!O07927!&!O06598!&!O53641!&!P96839!(Rjost)!
7!
Ethylbenzene!Degradation! 24! O53567!(EC);!P95034!&!P95146!&!O53674!&!Q79FW1!(Msmeg)!P96850!(Rjost);!P96851!&!P0A572!&!P64303!&!O06266!&!O53327!&!P95276!&!P64301!&!P96811!&!O69638!&!O06420!(Rjost)! 1!Bisphenol!Degradation! 89! P96825! &! P71853! &! O53547! &! P66781! &! P71824! &! P95033! &!O33292!&!O53863!&!P96841!&!O53398!&!O50417!&!P0A5Y4!&!O53665!&! O53302!&! P69167!&! O50460!&! P95101!&! P66777!&!P95273! &! P95286! &! P71821! &! O33263! &! O33339! &! O05919!(Msmeg);! Q7D6M3!&! P71871!&! P71852!&! O53927!&! P66779!&!O06348!&!P95150!&!O06413!&!O07737!&!O53303!&!O53533!&!O69693!&!P71818!&!Q7DAC8!&!O53904!&!P95153!&!O53146!&!P0A4X0!&! P72043!&! P95185!&!O05842!&!O53613!&!O53726!&!O53537! &! O07230! &! O53324! &! Q11150! &! Q10782! &! P96202!(Msmeg);! O53294! &! P71662! &! P64745! &! P96223! &! O53762! &!O53300!(Mvan)!
2!




List of Organisms from Figure 3.1 1. M.tuberculosis!Oshkosh!2. M.tuberculosis!KZN!1435!3. M.tuberculosis!F11!4. M.tuberculosis!ATCC!25618!5. M.tuberculosis!ATCC!25177!6. M.bovis!Tokyo!172!7. M.bovis!Pasteur!1173P2!8. M.bovis!AF2122/97!9. Mycobacterium!sp.!MCS!10. Mycobacterium!sp.!KMS!11. Mycobacterium!sp.!JLS!12. M.vanbaalenii!13. M.ulcerans!14. M.smegmatis!15. M.paratuberculosis!16. M.leprae!TN!17. M.leprae!Br4923!18. M.gilvum!19. M.avium!20. Rhodococcus!sp.!21. R.erythropolis!22. N.farcinica!23. C.jeikeium!24. C.glutamicum!Nakagawa!25. C.glutamicum!Kalinowski!26. C.efficiens!27. C.diphtheriae!28. T.whipplei!Twist!29. T.fusca!30. S.tropica!31. S.coelicolor!32. S.avermitilis!33. P.acnes!DSM!16379!34. Nocardioides!sp.!35. L.xyli!36. K.radiotolerans!37. Frankia!sp.!EAN1pec!38. Frankia!sp.!CcI3!39. F.alni!
40. Arthrobacter!sp.!41. A.cellulolyticus!42. B.longum!NCC!2705!43. R.xylanophilus!44. Z.mobilis!CP4!45. Y.pseudotuberculosis!I!46. Y.pestis!91001!47. X.oryzae!MAFF!311018!48. X.fastidiosa!9a5c!49. X.campestris!vesicatoria!50. X.axonopodis!51. X.autotrophicus!52. Wolbachia!sp.!Brugia!malayi!53. W.succinogenes!54. W.pipientis!wMel!55. V.vulnificus!YJ016!56. V.parahaemolyticus!57. V.fischeri!ATCC!700601!58. V.eiseniae!59. V.cholerae!ATCC!39315!60. Thermoanaerobacter!sp.!X514!61. T.thermophilus!HB8!62. T.tengcongensis!63. T.pseudethanolicus!64. T.maritima!65. T.erythraeum!66. T.elongatus!67. T.denticola!68. T.denitrificans!69. T.crunogena!70. Synechocystis!sp.!71. Synechococcus!sp.!CC9311!72. Silicibacter!sp.!73. Shewanella!sp.!MRJ4!74. S.wolfei!75. S.usitatus!76. S.typhimurium!ATCC!700720!77. S.typhi!ATCC!700931!
78. S.thermophilum!79. S.sonnei!80. S.schwarzengrund!81. S.saprophyticus!82. S.ruber!DSM!13855!83. S.pyogenes!MGAS5005!84. S.putrefaciens!CNJ32!85. S.pomeroyi!86. S.pneumoniae!ATCC!BAAJ255!87. S.paratyphi!SARB42!88. S.oneidensis!89. S.newport!90. S.mutans!ATCC!700610!91. S.medicae!92. S.loihica!93. S.heidelberg!94. S.haemolyticus!95. S.glossinidius!96. S.gallinarum!97. S.fumaroxidans!98. S.frigidimarina!99. S.flexneri!5b!100. S.epidermidis!ATCC!35984!101. S.enteritidis!102. S.elongatus!103. S.dysenteriae!104. S.dublin!105. S.denitrificans!OS217!106. S.degradans!107. S.choleraesuis!108. S.boydii!4!109. S.baltica!OS195!110. S.aureus!Mu50!111. S.amazonensis!112. S.alaskensis!113. S.agona!114. S.agalactiae!Ia!115. S.aciditrophicus!116. Roseiflexus!sp.!
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117. R.sphaeroides!ATCC!17023!118. R.solanacearum!119. R.rubrum!120. R.palustris!HaA2!121. R.metallidurans!122. R.meliloti!123. R.loti!124. R.leguminosarum!bv.!viciae!125. R.ferrireducens!126. R.etli!CFN!42!127. R.denitrificans!128. R.baltica!129. Psychrobacter!sp.!130. Polynucleobacter!sp.!131. Polaromonas!sp.!132. P.vibrioformis!133. P.ubique!134. P.thermopropionicum!135. P.syringae!tomato!136. P.putida!KT2440!137. P.propionicus!138. P.profundum!139. P.phaeoclathratiforme!140. P.pentosaceus!141. P.multocida!142. P.marinus!MIT!9313!143. P.luteolum!144. P.luminescens!145. P.ingrahamii!146. P.haloplanktis!147. P.gingivalis!W83!148. P.fluorescens!PfJ5!149. P.entomophila!150. P.denitrificans!151. P.cryohalolentis!152. P.carbinolicus!153. P.atlantica!154. P.arcticus!155. P.amoebophila!156. P.aestuarii!157. P.aeruginosa!LMG!12228!158. O.oeni!159. O.iheyensis!160. Nostoc!sp.!
161. N.winogradskyi!162. N.oceani!163. N.multiformis!164. N.meningitidis!165. N.hamburgensis!166. N.gonorrhoeae!ATCC!700825!167. N.eutropha!168. N.europaea!169. N.aromaticivorans!170. Mesorhizobium!sp.!171. Magnetococcus!sp.!172. M.xanthus!173. M.thermoacetica!174. M.succiniciproducens!175. M.magneticum!176. M.capsulatus!177. L.welshimeri!178. L.sakei!179. L.reuteri!JCM!1112!180. L.reuteri!DSM!20016!181. L.pneumophila!Paris!182. L.plantarum!WCFS1!183. L.plantarum!JDM1!184. L.monocytogenes!EGDJe!185. L.mesenteroides!186. L.lactis!IL1403!187. L.lactis!188. L.johnsonii!NCC!533!189. L.intracellularis!190. L.interrogans!copenhageni!191. L.innocua!192. L.delbrueckii!ATCC!BAAJ365!193. L.casei!ATCC!334!194. L.brevis!195. L.borgpetersenii!L550!196. L.acidophilus!197. Jannaschia!sp.!198. I.loihiensis!199. H.somnus!129Pt!200. H.pylori!26695!201. H.orenii!202. H.neptunium!203. H.influenzae!ATCC!51907!
204. H.hepaticus!205. H.halophila!206. H.chejuensis!207. H.aurantiacus!208. Geobacter!sp.!FRCJ32!209. G.violaceus!210. G.uraniireducens!211. G.sulfurreducens!ATCC!51573!212. G.oxydans!213. G.metallireducens!214. G.kaustophilus!215. G.bethesdensis!216. F.tularensis!LVS!217. F.nucleatum!nucleatum!218. F.johnsoniae!219. E.sibiricum!220. E.ruminantium!CIRAD!221. E.litoralis!222. E.faecalis!V583!223. E.coli!MG1655!224. E.chaffeensis!225. E.carotovora!226. E.canis!227. Dehalococcoides!sp.!CBDB1!228. D.vulgaris!DP4!229. D.reducens!230. D.radiodurans!231. D.psychrophila!232. D.hafniense!Y51!233. D.geothermalis!234. D.ethenogenes!235. D.desulfuricans!G20!236. D.aromatica!237. Caulobacter!sp.!238. C.violaceum!239. C.trachomatis!D/UWJ3/Cx!240. C.thermocellum!ATCC!27405!241. C.tetani!242. C.tepidum!243. C.salexigens!244. C.saccharolyticus!245. C.psychrerythraea!246. C.pneumoniae!J138!
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247. C.pinatubonensis!248. C.phytofermentans!249. C.phaeobacteroides!DSM!266!250. C.perfringens!13!251. C.necator!252. C.muridarum!253. C.limicola!254. C.jejuni!O:2!255. C.hydrogenoformans!256. C.hutchinsonii!257. C.difficile!630!258. C.crescentus!CB15!259. C.chlorochromatii!260. C.burnetii!Nine!Mile!phase!!261. C.beijerinckii!262. C.aurantiacus!ATCC!29366!263. C.acetobutylicum!264. Burkholderia!sp.!ATCC!17760!265. Bradyrhizobium!sp.!BTAi1!266. B.xenovorans!267. B.weihenstephanensis!268. B.vietnamiensis!269. B.thuringiensis!konkukian!270. B.thetaiotaomicron!271. B.thailandensis!272. B.suis!1!273. B.subtilis!168!274. B.quintana!275. B.pseudomallei!K96243!276. B.pertussis!277. B.parapertussis!278. B.ovis!279. B.microti!280. B.melitensis!1!281. B.mallei!ATCC!23344!282. B.licheniformis!Novozymes!283. B.japonicum!284. B.henselae!285. B.halodurans!286. B.fragilis!ATCC!25285!287. B.floridanus!288. B.clausii!
289. B.cicadellinicola!290. B.cereus!ZK!291. B.cenocepacia!HI2424!292. B.canis!293. B.bronchiseptica!294. B.bacteriovorus!295. B.avium!296. B.anthracis!Sterne!297. B.ambifaria!AMMD!298. B.abortus!2308!299. Acinetobacter!sp.!ADP1!300. Acidovorax!sp.!301. A.vinelandii!302. A.variabilis!303. A.tumefaciens!304. A.succinogenes!305. A.phagocytophilum!306. A.oremlandii!307. A.metalliredigens!308. A.marginale!St.!Maries!309. A.ehrlichei!310. A.dehalogenans!2CPJC!311. A.cryptum!312. A.citrulli!313. A.borkumensis!314. A.bacterium!315. A.aromaticum!316. A.aeolicus!317. Y.lipolytica!318. U.methanogenic!319. U.maydis!320. T.volcanium!321. T.nigroviridis!322. T.cruzi!323. T.acidophilum!324. S.tokodaii!325. S.solfataricus!ATCC!35092!326. S.pombe!327. S.acidocaldarius!328. R.norvegicus!329. P.torridus!330. P.nodorum!331. P.furiosus!332. P.aerophilum!333. P.abyssi!
334. O.tauri!335. O.sativa!336. N.pharaonis!337. N.fumigata!ATCC!MYAJ4609!338. N.crassa!339. M.thermoautotrophicum!340. M.stadtmanae!341. M.oryzae!342. M.musculus!343. M.mazei!344. M.marisnigri!345. M.maripaludis!S2!346. M.kandleri!347. M.jannaschii!348. M.hungatei!349. M.burtonii!350. M.barkeri!351. M.acetivorans!352. H.walsbyi!353. H.sapiens!354. H.salinarium!355. H.marismortui!356. G.gallus!357. D.rerio!358. D.pseudoobscura!359. D.melanogaster!360. D.discoideum!361. C.neoformans!BJ3501A!362. C.globosum!NBRC!6347!363. C.elegans!364. C.briggsae!365. B.taurus!366. A.thaliana!367. A.terreus!368. A.pernix!369. A.oryzae!370. A.fulgidus!371. A.aegypti!
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Appendix C Pathway!Holes!Table!Pathway!L3! Reaction! EC!#! Pathway!Tools! Missing!in!KEGG!Global! In!other!orgs!Pyrimidine!Metabolism! Thymine!<J>!dihydrothymine!AND!uracil!<J>!dihydrouracil! 1.3.1.1/2! Yes! Yes! No!! 3Jureidoisobutyrate!J>!3JaminoJisobutanoate!AND!3Jureidopropionate!J>!betaJalanine! 3.5.1.6! No! Yes! No!! Cytidine!<J>!cytosine! 2.4.2.2!3.2.2.8! No! No! No!! Deoxycytidine!J>!dCMP! 2.7.1.74! No! No! No!! Deoxyuridine!<J>!uracil! 2.4.2.23! No! No! No!Purine!Metabolism! IDP!J>!IMP! 3.6.1.5/6! No! No! No!! AMP!J>!IMP! 3.5.4.6! No! No! No!! Adenine!J>!Hypoxanthine! 3.5.4.2! No! No! No!! 5Jhydroxyisourate!J>!5JhydroxyJ2JoxoJ4JureidoJ2,5JdihydroJ1HJimidazoleJ5Jcarboxylate! 3.5.2.17! No! Yes! Yes!! 5JhydroxyJ2JoxoJ4JureidoJ2,5JdihydroJ1HJimidazoleJ5Jcarboxylate!J>!(S)Jallantoin! 4.1.1.J! No! Yes! Yes!! (R)Jallantoin!<J>!(S)Jallantoin! 5.1.99.3! No! Yes! Yes!! Allantoate!<J>!urea! 3.5.3.4! No! Yes! Yes!! 3’,5’Jcyclic!AMP!J>!AMP! 3.1.4.17/53! No! No! No!! Inosine!<J>!IMP?!AND!GMP!<J>!guanosine?! 2.7.1.73?! No! No! No!Histidine!Metabolism! LJHistidine!J>!urocanate! 4.3.1.3! No! Yes! Yes!! Urocanate!J>!4JimidazoloneJ5Jpropanoate! 4.2.1.49! No! Yes! Yes!! NJformiminoJLJglutamate!J>!LJglutamate! 3.5.3.8! No! Yes! No!Tyrosine!Metabolism! Tyrosine!J>!LJDOPA! 1.10.3.1!1.14.18.1!1.14.16.2! No! No! No!! LJDOPA!J>!Dopamine! 4.1.1.25!4.1.1.28! No! Yes! No!! Dopamine!J>!LJnoradrenaline! 1.14.17.1! No! Yes! No!! LJnoradrenaline!J>!LJadrenaline! 2.1.1.28! No! Yes! No!! Tyrosine!J>!3JiodoJtyrosine!AND!3JiodoJtyrosine!J>!3,5JdiiodoJtyrosine!AND!3,5JdiiodoJtyrosine!J>!triiodothronine!
1.11.1.8! No! Yes! No!
! 4Jhydroxyphenylpyruvate!J>!4J 4.1.1.80! No! No! No!
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hydroxyJphenylacetaldehyde!! Homogentisate!J>!4JmaleylJacetoacetate! 1.13.11.5! No! Yes! Yes!! 4JmaleylJacetoacetate!J>!4JfumarylJacetoacetate! 5.2.1.2! No! Yes! No!! 3,4JdihydroxyJphenylacetaldehyde!<J>!3,4JdihydroxyJphenylacetate!AND!3JmethoxyJ4JhydroxyphenylJacetaldehyde!J>!homovanillate!AND!3,4JdihydroxyJmandeladehyde!<J>!3,4JdihydroxyJmandelate!AND!3JmethoxyJ4JhydroxyJphenylglycolJaldehyde!J>!3JmethoxyJ4JhydroxyJmandelate!
1.2.1.5! No! No! No!
! Homoprotocatechuate!J>!2JhydroxyJ5JcarboxyJmethylmuconate!semialdehyde! 1.13.11.15! No! No! No!! 5JcarboxymethylJ2Jhydroxymuconate!J>!5JcarboxyJ2JoxoheptJ3Jenedioate! 5.3.3.10! No! No! No!! 5JcarboxyJ2JoxoheptJ3Jenedioate!J>!2JhydroxyheptaJ2,4Jdienedioate! 4.1.1.68! No! No! No!! 2,4JdihydroxyheptJ2Jenedioate!J>!succinate!semialdehyde! HpaI! No! No! Yes!Tryptophan!Metabolism! Tryptophan!→!5Jhydroxytryptophan! 1.14.16.4! No! No! No!! 5Jhydroxytryptophan!→!serotonin!AND!tryptophan!→!tryptamine! 4.1.1.28! No! Yes! No!! Serotonin!→!NJacetylserotonin! 2.3.1.87! No! Yes! No!! NJacetylserotonin!→!melatonin! 2.1.1.4! No! Yes! No!! Tryptophan!→!indolepyruvate! 2.6.1.27! Yes! No! No!! Tryptophan!→!indoleJ3Jacetamide! 1.13.12.3! No! No! No!! indoleJ3Jacetonitrile!→!indoleJ3Jacetamide! 4.2.1.84! No! No! Yes!! Indoleacetate!→!2JformaminoJbenzoylacetate! 1.13.11.J! No! No! No!! Tryptophan!→!NJformylJkynurenine! 1.13.11.11/52! No! No! No!! Anthranilate!→!3Jhydroxyanthranilate! 1.14.16.3! No! Yes! No!! LJkynurenine!→!3JhydroxyJLJkynurenine! 1.14.13.9! No! Yes! No!
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! 3Jhydroxyanthranilate!→!2JaminoJ3Jcarbocymuconate!semialdehyde! 1.13.11.6! No! Yes! No!! 2JaminoJ3Jcarbocymuconate!semialdehyde!→!2Jaminomuconate!semialdehyde! 4.1.1.45! No! Yes! No!! 2Jaminomuconate!→!2Joxoadipate! 1.5.1.J! No! No! No!Phenylalanine!Metabolism! Phenylalanine!J>!transJcinnamate! 4.3.1.24!4.3.1.25! No! Yes! No!! TransJcinnamate!J>!transJ4Jhydroxycinnamate! 1.14.13.11! No! Yes! No!! 4JcoumaroylJcoA!J>!caffeoylJcoA! 1.14.13.J! No! Yes! No!! feruloylJcoA!J>!4JhydroxyJ3JmethoxyphenylJbetaJhydroxypropionylJcoA! 4.2.1.101! No! Yes! No!! 4JhydroxyJ3JmethoxyphenylJbetaJhydroxypropionylJcoA!J>!vanillin! 4.1.2.41! No! Yes! No!! Phenylalanine!J>!phenylJethylamine! 4.1.1.28!4.1.1.53! No! No! No!! TransJ2,3JdihydroxyJcinnamate!J>!2JhydroxyJ6Joxononatrienedioate!AND!2,3JdihydroxyJphenylpropanoate!J>!2JhydroxyJ6JoxononaJ2,4JdieneJ1,9Jdioate!
1.13.11.16! No! Yes! Yes!
Arginine!and!Proline!Metabolism! Arginine!J>!ornithine!+!urea! 3.5.3.1! Yes! Yes! No!! UreaJ1Jcarboxylate!J>!CO2! 3.5.1.54! No! Yes! Yes!! NH3!<J>!carbamoylJP! 2.7.2.2! Yes! Yes! No!! NH3!J>!carbamoylJP! 6.3.4.16! Yes! Yes! No!! LJproline!J>!DJproline! 5.1.1.4! No! No! No!! LJproline!J>!transJ4JhydroxyJLJproline! 1.14.11.2! No! No! No!! transJ4JhydroxyJLJproline!J>!LJ1JprolineJ3JhydroxyJ5Jcarboxylate! PRODH2! No! No! No!! DJ4JhydroxyJ2Joxoglutarate!J>!glyoxylate! 4.1.3.16!4.1.1.3! No! No! Yes!! TransJ4JhydroxyJLJproline!<J>!cisJ4JhydroxyJDJproline! 5.1.1.8! No! No! No!! Arginine!<J>!guanidinoacetate! 2.1.4.1! No! No! No!! Guanidinoacetate!J>!creatine! 2.1.1.2! No! No! No!! Creatine!<J>!creatinine! 3.5.2.10! No! No! Yes!! Creatinine!J>!NJmethylJhydantoin! 3.5.4.1! No! No! Yes!! NJmethylJhydantoin!J>!NJcarbamoylJsarcosine! 3.5.2.14! No! No! Yes!! NJcarbamoylJsarcosine!J>!sarcosine! 3.5.1.59! No! No! No!! Agmatine!J>!NJcarbamoylJputrescine! 3.5.3.12! Yes! No! Yes!! Agmatine!J>!putrescine! 3.5.3.11! Yes! No! Yes!! N4JaceylJaminobutanoate!J>!4Jaminobutanoate! 3.5.1.63! No! No! No!! SJadenosylJLJmethionine! 4.1.1.50! Yes! No! No!Cysteine!and!Methionine! LJhomoserine!J>!OJsuccinylJLJhomoserine! 2.3.1.46! Yes! Yes! No!
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Metabolism!! SJadenosylJLJmethionine!J>!SJadenosylJmethioninamine! 4.1.1.50! Yes! Yes! No!! SJmethylJ5JthioJDJribose!J>!SJmethylJ5JthioJDJribose!1Jphosphate! 2.7.1.100! No! Yes! No!! 2,3JdiketoJ5JmethylJthiopentylJ1Jphosphate!J>!1,2JdihydroxyJ3JketoJ5JmethylJthiopentene! 3.1.3.77! No! Yes! No!but!in!others!! 1,2JdihydroxyJ3JketoJ5JmethylJthiopentene!J>!4JmethylthioJ2Joxobutanoate! 1.13.11.54! No! Yes! No!! 4JmethylthioJ2Joxobutanoate!J>!LJmethionine! 2.6.1.5!2.6.1.57! No! Yes! No!! SJadenosylJLJmethionine!J>!SJadenosylJLJhomocysteine! 2.1.1.37! Yes! Yes! No!! SJDJribosylJLJhomocysteine!J>!LJhomocysteine! 4.4.1.21! No! No! No!Valine,!Leucine!and!Isoleucine!Degradation! 4JmethylJ2Joxopentanoate!J>!3JmethylbutanoylJcoA!AND!3JmethylJ2Joxobutanoate!J>!isobutyrylJcoA!AND!3JmethylJ2Joxopentanoate!J>!(S)J2JmethylJbutanoylJcoA!
1.2.7.7! Yes! No! No!
! SJ(3JmethylJbutanoyl)JdihydrolipoamideJE!J>!3JmethylbutanoylJcoA!+!dihydroJlipoamideJE!AND!SJ(2JmethylJpropanoyl)JdihydrolipoamideJE!J>!isobutyrylJcoA!+!dihydrolipoamideJE!AND!SJ(2JmethylJbutanoyl)JdihydrolipoamideJE!J>!(S)J2JmethylJbutanoylJcoA!+!dihydroJlipoamideJE!
2.3.1.168! No! Yes! No!
! 3JmethylJglutaconylJcoA!<J>!(S)J3JhydroxyJ3JmethylglutarylJcoA! 4.2.1.18! No! Yes! No!! (S)J3JhydroxyJisobutyrylJcoA!J>!(S)J3JhydroxyJisobutyrate! 3.1.2.4! Yes! No! No!Valine,!Leucine!and!Isoleucine!Biosynthesis! Pyruvate!+!acetylJcoA!J>!(R)J2Jmethylmalate! 2.3.1.182! No! Yes! No!Lysine!Biosynthesis! LJ2JaminoJadipate!J>!5JadenylJ2Jaminoadipate!J>!AlphaJaminoadipoylJSJacyle!enzyme!J>!LJ2Jaminoadipate!6Jsemialdehyde!
1.2.1.31! No! Yes! No!
! LJ2Jaminoadipate!J>!LysWJgammaJLJalphaJaminoadipate! LysX! No! Yes! No!! LysWJgammaJLJalphaJaminoadipate!J>!LysWJgammaJLJalphaJaminoadipyl!6Jphosphate! LysZ! No! Yes! No!! LysWJgammaJLJalphaJaminoadipyl!6Jphosphate!J>!LysWJgammaJLJalphaJaminoadipate!6Jsemialdehyde! LysY! No! Yes! No!
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! LysWJgammaJLJalphaJaminoadipate!6Jsemialdehyde!J>!LysWJgammaJLJlysine! LysJ! No! Yes! No!! LysWJgammaJLJlysine!J>!LJlysine! LysK! No! Yes! No!! 2Joxoglutarate!+!acetylJcoA!J>!homocitrate! 2.3.3.14! No! Yes! No!! Homocitrate!<J>!homoJcisJaconitate! 4.2.1.114! No! Yes! No!! HomoJcisJaconitate!<J>!homoisocitrate! 4.2.1.114!4.2.1.36! No! Yes! No!! Homoisocitrate!<J>!2Joxoadipate! 1.1.1.87!1.1.1.286! No! Yes! No!! 2Joxoadipate!<J>!LJ2JaminoJadipate! 2.6.1.39!2.6.1.57! No! Yes! No!Lysine!Degradation! Saccharopine!<J>!LJ2Jaminoadipate!6Jsemialdehyde! 1.5.1.9!1.5.1.10! No! Yes! No!! LJ2Jaminoadipate!6Jsemialdehyde!J>!LJ2Jaminoadipate! 1.2.1.31! No! Yes! No!! LJ2Jaminoadipate!<J>!2Joxoadipate! 2.6.1.39! No! Yes! No!Alanine,!Aspartate!and!Glutamate!Metabolism!
NH3!J>!carbamoylJphosphate! 6.3.4.16! Yes! No! No!
Glycine,!Serine!and!Threonine!Metabolism! Glycine!J>!guanidinoacetate! 2.1.4.1! Yes! No! No!! Guanidinoacetate!J>!creatine! 2.1.1.2! Yes! No! No!! Betaine!J>!dimethylglycine! 2.1.1.5! Yes! No! No!! Dimethylglycine!J>!sarcosine! 1.5.8.4! No! No! No!! Glycine!<J>!glyoxylate! 2.6.1.44! Yes! Yes! No!! Glycine!<J>!threonine! 4.1.2.5! Yes! Yes! Yes!! NJgammaJacetylJLJ2,4Jdiaminobutyrate!J>!LJectoine! 4.2.1.108! No! No! Yes!! LJectoine!J>!5Jhydroxyectoine! 1.14.11.J!EctD! No! No! Yes!AlphaJLinolenic!Acid!Metabolism! AlphaJlinolenic!acid!J>!13(S)JHpOTrE! 1.13.11.12! No! Yes! No!! 13(S)JHpOTrE!J>!12,13JEOTrE! 4.2.1.92! No! Yes! No!! 12,13JEOTrE!J>!12JOPDA! 5.3.99.6! No! Yes! No!! 12JOPDA!J>!OPC8! 1.3.1.42! No! Yes! No!! OPC8!J>!OPC8JCoA! OPCL1! No! Yes! No!! TransJ2JenoylJOPC8JcoA!J>!3JoxoJOPC8JcoA!AND!TransJ2JenoylJOPC6JcoA!J>!3JoxoJOPC6JcoA!AND!TransJ2JenoylJOPC4JcoA!J>!3JoxoJOPC4JcoA!
MFP2! No! Yes! No!
! JAJcoA!J>!(+)J7Jisojasmonate! 3.1.2.J! No! Yes! No!Biosynthesis!of!Unsaturated!Fatty!Acids! Δ12,!Δ15,!Δ6,!Δ5,!Δ4! ! No! No! No!! Arrows!1,!3!and!4!going!down! ! No! No! No!! Arrows!3!and!4!going!up! ! No!! No! No!! Δ9,12,15!J>!alphaJlinolenic!acid! 3.1.2.2! No! Yes! No!
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Synthesis!and!Degradation!of!Ketone!Bodies! AcetoacetylJcoA!+!acetylJcoA!J>!(S)J3JhydroxyJ3JmethylglutarylJcoA! 2.3.3.10! No! Yes! No!! Acetoacetate!J>!acetone! 4.1.1.4! No! Yes! No!Glycerophospholipid!Metabolism! CDPJdiacylJglycerol!J>!phosphatidylJ1DJmyoJinositol! 2.7.8.11! No! Yes! No!! PhosphatidylJglycerophosphate!J>!phosphatidylJglycerol! 3.1.3.27! Yes! No! No!! PhosphatidylJglycerol!J>!cardiolipin! 2.7.8.J!Cls! Yes! No! No!! 1,2JdiacylJsnJglycerol!3Jphosphate!J>!1,2JdiacylJsnJglycerol! 3.1.3.4! Yes! No! No!! Choline!J>!phosphocholine! 2.7.1.32! No! Yes! No!! Phosphocholine!J>!CDPJcholine! 2.7.7.15! No! Yes! No!! CDPJcholine!J>!phosphatidylcholine!(lecithin)! 2.7.8.2! No! Yes! No!! Acetaldehyde!<J>!ethanolamine! 4.3.1.7! No! No! Yes!! Ethanolamine!J>!phosphoethanolamine! 2.7.1.82! No! Yes! No!! Phosphoethanolamine!J>!CDPJethanolamine! 2.7.7.14! No! Yes! No!! CDPJethanolamine!J>!phosphatidylethanolamine! 2.7.8.1! No! Yes! No!Glycerolipid!Metabolism! 1,2JdiacylJsnJglycerol!3Jphosphate!J>!1,2JdiacylJsnJglycerol! 3.1.3.4! Yes! Yes! No!Glyoxylate!and!Dicarboxylate!Metabolism! AcetoacetylJcoA!J>!(R)J3JhydroxyJbutanoylJcoA! 1.1.1.36! No! No! No!! CrotonoylJcoA!J>!(2S)JethylJmalonylJcoA! 1.3.1.85! No! No! No!! Oxalate!J>!formate! 4.1.1.2! No! No! Yes!! Hydroxypyruvate!J>!tartronateJsemialdehyde! 5.3.1.22! No! No! Yes!! H2O2!J>!O2! 1.11.1.6! No! No! Yes!! Glyoxylate!J>!glycine! 2.6.1.45! Yes! No! No!! LJglutamate!J>!2Joxoglutarate!+!glycine! GGAT! Yes! No! No!Glycolysis/!Gluconeogenesis! AlphaJDJglucoseJ1P!J>!alphaJDJglucose! 3.1.3.10! Yes! No! No!! Pyruvate!<J>!LJlactate! 1.1.1.27! Yes! No! No!! GlyceraldehydeJ3P!J>!glycerateJ3P!(may!be!covered!tho)! 1.2.1.9! Yes! No! No!Pyruvate!Metabolism! Phosphoenolpyruvate!J>!oxaloacetate! 4.1.1.31! Yes! Yes! Yes!! Pyruvate!<J>!LJlactate! 1.1.1.27! Yes! No! No!! Pyruvate!<J>!formate!+!acetylJcoA! 2.3.1.54! Yes! Yes! No!Propanoate!Metabolism! 2JpropynJ1Jol!J>!2JpropynJ1Jal! 1.1.2.8! No! No! Yes!! MalonateJsemialdehyde!J>!propynoate! 4.2.1.27! Yes! No! No!! MalonateJsemialdehyde!<J>!3JhydroxyJpropanoate! 1.1.1.59! Yes! Yes! No!! Lactate!<J>!lactoylJcoA! 2.8.3.1! Yes! No! No!! LactoylJcoA!<J>!acryloylJcoA! 4.2.1.54! Yes! No! No!
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! 2JoxoJbutanoate!<J>!propanoylJcoA! 2.3.1.54! Yes! No! No!! PropanoylJcoA!<J>!(S)J2JmethylJmalonylJcoA! 4.1.1.41! Yes! Yes! No!! 2JmethylJcisJaconitate!<J>!(2S,3R)J3JhydroxybutaneJ1,2,3Jtricarboxylate! 4.2.1.99! Yes! No! No!! 2JmethylJcitrate!<J>!propanoylJcoA! 2.3.3.5! No! No! No!Pentose!Phosphate!Pathway! DJglucose!J>!DJgluconoJ1,5Jlactone! 1.1.5.2! Yes! No! No!! DJgluconoJ1,5Jlactone!J>!DJgluconate! 3.1.1.17! Yes! No! Yes!! DJgluconate!J>!6JphosphoJDJgluconate! 2.7.1.12! Yes! Yes! No!! 2JdehydroJ3JdeoxyJDJgluconate!J>!2JdehydroJ3JdeoxyJDJgluconateJ6P! 2.7.1.45! No! Yes! Yes!! 2JdehydroJ3JdeoxyJDJgluconateJ6P!<J>!pyruvate!+!DJglyceraldehydeJ3P! 4.1.2.14! No! Yes! Yes!! DJriboseJ1,5P!J>!PRPP! 2.7.4.23! Yes! No! No!Fructose!and!Mannose!Metabolism! AlphaJDJglucose!<J>!DJsorbitol! 1.1.1.21! No! Yes! No!! DJfructoseJ1P!<J>!DJfructose! 2.7.1.69! No! No! Yes!! DJfructose!J>!betaJDJfructoseJ6P! 2.7.1.4! No! Yes! Yes!! DJmannose!J>!DJmannoseJ6P! 2.7.1.7! Yes! No! No!! GDPJDJrhamnose!<J>!GDPJ4JoxoJ6JdeoxyJDJmannose! 1.1.1.187! Yes! No! No!Pentose!and!Glucuronate!Interconversions!
Ribitol!<J>!DJribulose! 1.1.1.56! No! No! No!
! LJarabinose!<J>!LJribulose! 5.3.1.4! No! No! Yes!! DJxylulose!<J>!DJxylose! 5.3.1.5! No! No! Yes!! DJxylose!<J>!xylitol! 1.1.1.21! No! No! No!! LJxylulose!<J>!LJxyluloseJ1P! 2.7.1.5! No! Yes! Yes!Ascorbate!and!Aldarate!Metabolism! UDPJDJglucuronate!J>!DJglucuronateJ1P! 2.7.7.44/!2.7.7.64! No! Yes! No!! DJglucuronateJ1P!<J>!DJglucuronate! 2.7.1.43! No! Yes! No!! DJglucuronate!<J>!LJgulonate! 1.1.1.19! No! Yes! No!! LJgulonate!<J>!LJgulonoJ1,4Jlactone! 3.1.1.17! No! Yes! Yes!! DJglucuronate!<J>!DJglucuronoJlactone! 3.1.1.19! No! Yes! No!! DJglucarate!<J>!5JdehydroJ4JdeoxyJDJglucarate! 4.2.1.40! No! No! Yes!Starch!and!Sucrose!Metabolism! UDPJglucose!J>!sucrose! 2.4.1.13! Yes! No! No!! BetaJDJfructose!<J>!betaJDJfructoseJ6P! 2.7.1.4! No! No! Yes!! UDPJDJglucuronate!J>!UDPJDJxylose! 4.1.1.35! Yes! No! No!! DJglucose!<J!Maltose! 2.4.1.8! Yes! No! No!Amino!Sugar!and!Nucleotide!Sugar!Metabolism!
GlcNAcJ6P!<J>!GlcNAc! 2.7.1.59! Yes! No! No!
! ManJ6P!<J>!Man! 2.7.1.7! Yes! No! No!! UDPJGlcA!<J>!GlcAJ1P! 2.7.7.44/! No! Yes! No!
! 129!
2.7.7.64!! GlcAJ1P!<J>!GlcA! 2.7.1.43! No! Yes! No!C5JBranched!Dibasic!Acid!Metabolism! PropanoylJcoA!+!glyoxylate!J>!LJerythroJ3JmethylmalylJcoA! 4.1.3.24! Yes! No! Yes!Butanoate!Metabolism! Fumarate!<J>!maleate! 5.2.1.1! No! Yes! Yes!! Maleate!<J>!(R)Jmalate! 4.2.1.31! No! No! No!! (R)J2Jacetoin!<J>!2Jacetolactate! 4.1.1.5! No! No! No!! Pyruvate!J>!acetylJcoA! 2.3.1.54! Yes! Yes! No!! ButanoylJcoA!<J>!crotonoylJcoA! 1.3.8.1/!1.3.1.44! No! No! No!Inositol!Phosphate!Metabolism! 1DJmyoJinositol!<J>!scylloJinosose! 1.1.1.18! No! No! Yes!! ScylloJinosose!<J>!3,5/4JtrihydroxycyclohexaJ1,2Jdione! 4.2.1.44! No! No! Yes!! 5JdeoxyJglucuronate!J>!2JdeoxyJ5JketoJDJgluconate! 5.3.1.J! No! No! Yes!! 2JdeoxyJ5JketoJDJgluconateJ6P!J>!malonic!semialdehyde!+!dihydroxyacetone!phosphate! 4.1.2.29! No! No! No!Nitrogen!Metabolism! Ammonia!J>!carbamoylJP! 6.3.4.16! Yes! No! No!! CarbamoylJP!J>!carbamate! 2.7.2.2! Yes! No! No!! Formamide!J>!formate!+!ammonia! 3.5.1.49! No! No! Yes!Methane!Metabolism! 5JaminoJ6Jribitylaminouracil!+!4Jhydroxyphenylpyruvate!J>!7,8JdidemethylJ8JhydroxyJ5Jdeazariboflavin!
2.5.1.77! Yes! No! No!
! Coenzyme!F420!J>!coenzyme!F420H2! 1.12.98.1! Yes! Yes! No!! 5JmethylJTHMPT!+!coenzyme!M!<J>!methylJcoM!+!THMPT! 2.1.1.86! No! Yes! No!! MethylJcoM!J>!methane! 2.8.4.1! No! Yes! No!! AcetylJcoA!J>!pyruvate! 1.2.7.1! Yes! No! No!! Phosphoenolpyruvate!J>!oxaloacetate! 4.1.1.31! Yes! No! Yes!! LJmalate!J>!malylJcoA! 6.2.1.9! Yes! No! No!! MalylJcoA!J>!acetylJcoA!+!glyoxylate! 4.1.3.24! Yes! No! No!! Glyoxylate!+!LJserine!J>!hydroxypyruvate!+!glycine! 2.6.1.45! Yes! No! No!! Dihydroxyacetone!J>!dihydroxyacetoneJphosphate! 2.7.1.29! No! No! Yes!! CO2!J>!formate! 1.2.1.43! Yes! Yes! No!! CO2!+!methanofuran!<J>!formylJMFR! 1.2.99.5! No! Yes! No!! FormylJMFR!+!THMPT!<J>!methanofuran!+!N5JformylJTHMPT! 2.3.1.101! No! Yes! No!! N5JformylJTHMPT!<J>!5,10JmethenylJTHMPT! 3.5.4.27! No! Yes! No!! 5,10JmethenylJTHMPT!+!coenzyme!F420!<J>!5,10JmethyleneJTHMPT!+!coenzyme!F420H2! 1.5.99.9! Yes! Yes! No!! 5,10JmethyleneJTHMPT!J>!5,10JmethenylJTHMPT! 1.5.1.15! Yes! Yes! No!Sulfur!Metabolism! LJhomoserine!J>!OJsuccinylJLJhomoserine!(DUPLICATE)! 2.3.1.46! Yes! Yes! No!Geraniol! Geraniol!J>!geranial! 1.1.1.183! No! No! No!
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Degradation!! TransJgeranylJcoA!J>!cisJgeranylJcoA! 5.2.1.J! No! No! No!! Citronellate!J>!citronellylJcoA! AtuH! No! No! No!! CitronellylJcoA!J>!cisJgeranylJcoA! AtuD! No! No! No!! CisJgeranylJcoA!J>!isohexenylglutaconylJcoA! 6.4.1.5! No! No! No!! IsohexenylglutaconylJcoA!J>!3JhydroxyJ3JisohexenylglutarylJcoA! 4.2.1.57!AtuE! No! No! No!Limonene!and!Pinene!Degradation! AlphaJpinene!oxide!J>!cisJ2JmethylJ5JisopropylhexaJ2,5Jdienal! 5.5.1.10! No! No! No!! SJlimonene!J>!perillyl!alcohol! 1.14.13.49! No! No! No!! 3JhydroxyJ2,6JdimethylJ5JmethyleneJheptanoylJcoA!J>!2,6JdimethylJ5JmethyleneJ3JoxoJheptanoylJcoA! 1.1.J.J! No! No! No!! 3JisopropylbutJ3JenoylJcoA!J>!3JisopropylbutJ3Jenoic!acid! 3.1.2.J! No! No! No!! RJlimonene!J>!transJcarveol! 1.14.13.80! No! No! No!! 4SJcarvone!J>!1R,4SJisodihydroJcarvone! 1.3.99.25! No! No! No!! 1R,4SJisodihydroJcarvone!J>!4S,7RJ4JisopropenylJ7JmethylJ2JoxoJoxepanone! 1.14.13.105! No! No! No!! 4S,7RJ4JisopropenylJ7JmethylJ2JoxoJoxepanone!J>!3SJ6JhydroxyJ3JisopropenylJheptanoate! 3.1.1.83! No! No! No!! 2JhydroxyJ4JisopropenylJcyclohexaneJ1JcarboxylJcoA!J>!4JisopropenylJ2JketocyclohexaneJ1JcarboxylJcoA!
1.1.J.J! No! No! No!
! 4JisopropenylJ2JketocyclohexaneJ1JcarboxylJcoA!J>!3JisopropenylJpimelylJcoA! 3.7.1.J! No! No! No!Porphyrin!and!Chlorophyll!Metabolism! CoJprecorrin!5B!J>!coJprecorrin!6A! 2.1.1.195! Yes! No! No!! CoJprecorrin!7!J>!coJprecorrin!8X! 2.1.1.196! Yes! No! No!! Cob(II)yrinate!a,c!diamide!J>!cob(I)yrinate!a,c!diamide! 1.16.8.1! Yes! No! No!Ubiquinone!and!Other!TerpenoidJQuinone!Biosynthesis!
2JsuccinylJ5JenolpyruvylJ6JhydroxyJ3JcyclohexeneJ1Jcarboxylate!J>!(1R,6R)J2JsuccinylJ6JhydroxyJ2,4JcyclohexadieneJ1Jcarboxylate!
4.2.99.20! Yes! No! No!
! 1,4JdihydroxyJ2JnaphthoylJcoA!J>!1,4JdihydroxyJ2Jnaphthoate! 3.1.2.28! Yes! No! No!! Menaquinone!J>!menaquinol!AND!Phylloquinone!J>!phylloquinol! 1.6.5.2! Yes! No! Yes!Thiamine!Metabolism! [ThiI]JSSH!J>![ThiS]JCOSH! ThiI! No! No! No!! [ThiS]JCOSH!J>![ThiS]JCOSSJ[ThiF]! 2.7.7.73! No! No! No!Riboflavin!Metabolism! 5JaminoJ6J(5JphosphoJDJribitylamino)!uracil!J>!5JaminoJ6JribitylJaminouracil! 3.1.3.J! No! No! No!
! 131!
Vitamin!B6!Metabolism! 3JaminoJ2Joxopropyl!phosphate!J>!Pyridoxine!phosphate! 2.6.99.2! Yes! No! No!! OJphosphoJ4JhydroxyJLJthreonine!J>!(2S)J2JaminoJ3JoxoJ4Jphosphono!butyanoate! 1.1.1.262! Yes! No! No!! DJerythrose!4Jphosphate!<J>!4JphosphoJDJerythronate! 1.2.1.72! Yes! No! No!! 4JphosphoJDJerythronate!<J>!2JoxoJ3JhydroxyJ4Jphosphobutanoate! 1.1.1.290! Yes! No! No!Nicotinate!and!Nicotinamide!Metabolism! NJribosylJnicotinamide!J>!nicotinamide!DJribonucleotide! 2.7.1.22! No! No! No!! Nicotinate!DJribonucleoside!J>!nicotinate!DJribonucleotide! 2.7.1.173! No! No! No!Pantothenate!and!CoA!Biosynthesis! NJpantothenoylJcysteine!J>!Pantetheine! 4.1.1.30! Yes! No! No!! Pantetheine!J>!(R)Jpantothenate! 3.5.1.92! Yes! No! No!! AcylJcarrier!protein!J>!4’Jphosphopantetheine! 3.1.4.14! Yes! No! No!! Uracil!<J>!5,6Jdihydrouracil! 1.3.1.1!1.3.1.2! No! No! No!! NJcarbamoylJbetaJalanine!J>!betaJalanine! 3.5.1.6! No! No! No!Biotin!Metabolism! 3JhydroxyJpimeloylJ[acp]!methyl!ester!J>!enoylJpimeloylJ[acp]!methyl!ester! FabZ! No! Yes! No!! PimeloylJ[acp]!methyl!ester!J>!pimeloylJ[acp]! BioH!BioG! No! Yes! No!! LongJchainJacylJ[acp]!J>!pimeloylJ[acp]! BioI! Yes! Yes! No!! Pimelate!J>!pimeloylJcoA! 6.2.1.14!BioW! Yes! Yes! No!! N6JDJbiotinylJLJlysine!(biocytin)!J>!LJlysine!+!biotin! 3.5.1.12! Yes! Yes! No!One!Carbon!Pool!by!Folate! 5,6,7,8Jtetrahydrofolate!(THF)!J>!10JformylJTHF! 6.3.4.3! Yes! Yes! No!! 5,10JmethenylJTHF!<J>!5,10JmethyleneJTHF! 1.5.1.15! Yes! Yes! No!! 5,10JmethyleneJTHF!J>!5JmethylJTHF! 1.5.1.20! Yes! Yes! Yes!Folate!Biosynthesis!! 7,8Jdihydroneopterin!3’Jtriphosphate!J>!dihydroneopterin! 3.1.3.1! Yes! Yes! Yes!Peptidoglycan!Biosynthesis! UDPJMurNAcJLJAlaJDJGlu!J>!UDPJMurNAcJLJAlaJgammaJDJGluJLJLys! 6.3.2.7! No! No! No!! UndJPPJMurNAcJ(GlcNAc)JLJAlaJgammaJDJGluJLJLysJDJAlaJDJAla!J>!UndJPPJMurNAcJ(GlcNAc)JLJAlaJgammaJDJGluJLJLysJ(LJAla)JDJAlaJDJAla!
murM! No! No! No!
! UndJPPJMurNAcJ(GlcNAc)JLJAlaJgammaJDJGluJLJLysJ(LJAla)JDJAlaJDJAla!J>!UndJPPJMurNAcJ(GlcNAc)JLJAlaJgammaJDJGluJLJLysJ(LJAla)2JDJAlaJDJAla!
murN! No! No! No!
Lipopolysaccharide!Biosynthesis! DJglyceroJalphaJDJmannoJheptoseJ1JP!J>!GDPJDJglyceroJalphaJDJmannoJheptose! 2.7.7.71! No! No! No!
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! LauroylJKDO2Jlipid!IV(A)!+!myristoylJACP!J>!KDO2Jlipid(A)! MsbB! No! No! No!Taurine!and!Hypotaurine!Metabolism! Taurine!+!pyruvate!<J>!sulfoacetaldehyde!+!LJalanine! 2.6.1.77! Yes! No! No!! Sulfoacetaldehyde!J>!acetyl!phosphate!+!sulfite! 2.3.3.15! No! No! No!! Sulfoacetaldehyde!J>!isethionate! 1.1.1.313! No! No! No!BetaJAlanine!Metabolism! Spermidine!J>!1,3JdiaminoJpropane!+!4Jaminobutanal! 1.5.99.6! No! No! No!! BetaJalanine!<J>!NJcarbamoylJbetaJalanine! 3.5.1.6! No! No! No!! 5,6Jdihydrouracil!<J>!uracil! 1.3.1.1!1.3.1.2! No! No! No!! 3JhydroxyJpropanoylJcoA!<J>!3JhydroxyJpropanoate! 3.1.2.4! Yes! No! No!! 3JhydroxyJpropanoate!<J>!malonate!semialdehyde! 1.1.1.59! No! No! No!! MalonylJcoA!J>!AcetylJcoA! 4.1.1.9! No! No! No!Selenocompound!Metabolism! Selenocysteine!J>!SeJmethylJselenoJcysteine! 2.1.1.J! No! No! No!DJGlutamine!and!DJGlutamate!Metabolism!
LJglutamate!<J>!2Joxoglutarate! 1.4.1.3! Yes! No! No!
DJArginine!and!DJOrnithine!Metabolism! DJarginine!J>!DJornithine! 3.5.3.10! Yes! No! No!! DJarginine!<J>!LJarginine!AND!DJornithine!<J>!LJornithine! 5.1.1.9! No! No! No!Cyanoamino!Acid!Metabolism! Cyanide!J>!LJ3Jcyanoalanine! 4.4.1.9! No! No! No!Glutathione!Metabolism! Glutathione(GSH)!+!RX!J>!RJSJglutathione! 2.5.1.18! No! No! No!! LJgammaJglutamylcysteine!+!glycine!J>!glutathione!(GSH)! 6.3.2.3! Yes! No! No!! Glutathione!(GSH)!J>!glutathione!disulfide!(GSSG)! 1.11.1.9! No! Yes! Yes!Streptomycin!Biosynthesis! dDTPJLJdihydroJstreptose!J>!OJ1,4JalphaJLJdihydroJstreptosylJstreptidineJ6P! 2.4.2.27! No! No! No!! StreptomycinJ6P!J>!streptomycin! 3.1.3.39! No! No! No!! Streptomycin!J>!streptomycinJ6P! 2.7.1.72! No! No! No!Benzoate!Degradation! 4JhydroxyJbenzoylJcoA!J>!4JhyroxyJbenzoate! 3.1.2.23! No! No! In!Rjost!! 3,4JdihydroxyJbenzoate!J>!betaJcarboxyJmuconate! 1.13.11.3! No! No! Yes!! 3Joxoadipate!J>!3JoxoadipylJcoA! 2.8.3.6! Yes! Yes! No!! 2JhydroxyJmuconate!J>!gammaJoxalocrotonate! 5.3.2.J! No! No! In!Rjost!! GlutarylJcoA!J>!glutaconylJcoA! 1.3.99.32! Yes! Yes! No!! GlutaconylJcoA!J>!crotonoylJcoA! 4.1.1.70! Yes! Yes! No!Chlorocyclohexane!and!Chlorobenzene! 3,4,6JtrichloroJcisJ1,2JdihydroxyJcyclohexaJ3,5Jdiene!J>!3,4,6JtrichloroJcatechol! 1.3.1.19! No! No! No!
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Degradation! AND!CisJdihydrobenzenediol!J>!catechol!AND!3JchloroJcisJ1,2JdihydroxyJcyclohexaJ3,5Jdiene!J>!3Jchlorocatechol!! 2JchloroJcis,cisJmuconate!J>!transJ4JcarboxymethyleneJbutJ2JenJ4Jolide!AND!3JchloroJcis,cisJmuconate!J>!2JchloroJ5JoxoJ2,5JdihydrofuranJ2Jacetate!AND!2,3,5JtrichloroJcis,cisJmuconate!J>!2,5JdichloroJcarboxymethyleneJbutJ2JenJ4Jolide!AND!TetrachloroJcis,cisJmuconate!J>!2,3,5JtrichloroJdienelactone!
5.5.1.7! No! No! No!
Xylene!Degradation! 2JhydroxyJ5JmethylJcis,cisJmuconate!J>!2JoxoJ5JmethylJcisJmuconate! 5.3.2.J! No! No! Yes!! pJxylene!J>!4JmethylbenzylJalcohol!AND!oJxylene!J>!2JmethylbenzylJalcohol!AND!mJxylene!J>!3JmethylbenzylJalcohol!
XylM!XylA! No! No! No!
Nitrotoluene!Degradation! 4JhydroxylaminoJ2,6Jdinitrotoluene!J>!2,4JdiaminoJ6Jnitrotoluene!AND!2,hydroxylaminoJ4,6Jdinitrotoluene!J>!2,4JdiaminoJ6Jnitrotoluene!
1.7.1.J! No! No! No!
! 2,4JdiaminoJ6Jhydroxylaminotoluene!J>!2,4,6JtriaminoJtoluene! 1.8.99.3! No! No! No!Styrene!Degradation! Phenylacetonitrile!J>!phenylacetamide!AND!Acrylonitrile!J>!acrylamide!
4.2.1.84! No! Yes! Yes!
! Acrylonitrile!J>!acrylate! 3.5.5.7! No! Yes! Yes!! AcrylylJcoA!J>!lactoylJcoA! 4.2.1.54! Yes! Yes! No!! LactoylJcoA!LJlactate! 2.8.3.1! Yes! Yes! No!Atrazine!Degradation! Cyanuric!acid!J>!biuret! 3.5.2.15! No! No! Yes!! Biuret!J>!allophanate! 3.5.1.84! No! No! No!! Hydroxyatrazine!J>!NJisopropylammelide! 3.5.99.3! No! No! Yes!! NJisopropylammelide!J>!cyanuric!acid! 3.5.99.4! No! No! No!Naphthalene!Degradation! 1Jmethylnaphthalene!J>!cisJ1,2JdihydroxyJ1,2JdihydroJ8Jmethylnaphthalene!AND!2JhydroxymethylJnaphthalene!J>!cisJ1,2JdihydroxyJ1,2JdihydroJ7JhydroxyJmethylnaphthalene!
1.14.12.12! No! No! No!
! cisJ1,2JdihydroxyJ1,2JdihydroJ8Jmethylnaphthalene!J>!1,2JdihydroxyJ8Jmethylnaphthalene!AND!cisJ1,2JdihydroxyJ1,2JdihydroJ7JhydroxyJmethylnaphthalene!J>!1,2J
1.3.1.29! No! No! No!
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dihydroxyJ7Jhydroxymethylnaphthalene!! 1,2JdihydroxyJ8Jmethylnaphthalene!J>!2JhydroxyJ8JmethylJchromeneJ2Jcarboxylate!AND!1,2JdihydroxyJ7Jhydroxymethylnaphthalene!J>!2JhydroxyJ7JhydroxymethylJchromeneJ2Jcarboxylate!
1.13.J.J! No! No! No!
! 2JhydroxyJ8JmethylJchromeneJ2Jcarboxylate!J>!2JhydroxyJ3JmethylJbenzalpyruvate!AND!2JhydroxyJ7JhydroxymethylJchromeneJ2Jcarboxylate!J>!2JhydroxyJ4JhydroxymethylJbenzalpyruvate!
5.3.99.J! No! No! No!
Aminobenzoate!Degradation! Benzonitrile!J>!benzamide! 4.2.1.84! Yes! Yes! Yes!! 4Jnitrophenol!J>!4Jnitrocatechol! 1.14.13.29! No! No! No!! CyclopropaneJcarboxylJcoA!J>!crotonoylJcoA! 5.5.1.J! No! No! No!Chloroalkane!and!Chloroalkene!Degradation!
2Jchloroethanol!J>!chloroacetaldehyde! 1.1.2.8! Yes! Yes! Yes!
! TransJ3Jchloroacrylic!acid!J>!malonate!semialdehyde! CaaD! No! No! No!! CisJ3Jchloroacrylic!acid!J>!malonate!semialdehyde! CisJCaaD! No! No! No!! Malonate!semialdehyde!J>!acetaldehyde! 4.1.1.J! No! No! No!Toluene!Degradation! 3JmethylJmuconolactone!J>!4JmethylJ3JoxoadipateJenolJlactone! 5.5.1.J! No! No! No!! 4JmethylJ3JoxoadipateJenolJlactone!J>!4JmethylJ3Joxoadipate! 3.1.1.J! No! No! No!! Toluene!J>!3Jhydroxytoluene!AND!Toluene!J>!benzyl!alcohol!AND!Toluene!J>!4Jhydroxytoluene!
1.14.13.J! No! No! No!
! Benzaldehyde!J>!benzoate!AND!4JhydroxyJbenzaldehyde!J>!4JhydroxyJbenzoate!
1.2.1.28! No! No! Yes!
! 4,6JdichloroJ3JmethylJcisJ1,2JdihydroxycyclohexaJ3,5Jdiene!J>!4,6JdichloroJ3Jmethylcatechol! 1.3.1.J! No! No! No!! 4,6JdichloroJ3Jmethylcatechol!J>!3,5JdichloroJ2JmethylJmuconate! 1.13.11.J! No! No! No!! 3,5JdichloroJ2JmethylJmuconate!J>!2JchloroJ5JmethylJcisJdienelactone! 5.5.1.7! No! No! No!Ethylbenzene!Degradation! CisJ1,2JdihydroxyJ2,3Jdihydroethylbenzene!J>!2,3JdihydroxyJethylbenzene! 1.3.1.66! No! No! No!
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Caprolactam!Degradation! Cyclohexane!J>!cyclohexanol!! 1.14.15.J! No! Yes! No!! 6Jhexanolide!J>!6Jhydroxyhexanoate! 3.1.1.17! Yes! Yes! Yes!Bisphenol!Degradation! 4Jhydroxyphenyl!acetate!J>!hydroquinone! 3.1.1.2! No! No! No!! Bis(4Jhydroxyphenyl)Jmethanol!J>!4,4’JdihydroxyJbenzophenone! 1.1.J.J! Yes! No! No!Polycyclic!Aromatic!Hydrocarbon!Degradation!
CisJ3,4JdihydroxyJ3,4Jdihydrophenanthrene!J>!3,4JdihydroxyJphenanthrene! 1.3.1.49! No! No! No!! 2JhydroxyJ2HJbenzo[h]chromeneJ2Jcarboxylate!J>!isJ4J(1’JhydroxyJnaphthJ2’Jyl)J2JoxobutJ3Jenoate! 5.1.2.J! No! No! No!! 1JhydroxyJ2Jnaphthoate!J>!cisJ2’JcarboxyJbenzalpyruvate! 1.13.11.38! No! No! Yes!! 2JcarboxyJbenzaldehyde!J>!phthalate! 1.2.1.78! No! No! No!! PhthalateJ4,5JcisJdihydrodiol!J>!4,5JdihydroxyJphthalate! 1.3.1.64! No! No! No!! 4,5JdihydroxyJphthalate!J>!3,4JdihydroxyJbenzoate! 4.1.1.55! No! No! Yes!! 1JmethoxyJpyrene!J>!1JmethoxypyreneJ6,7Joxide! 1.14.J.J! No! No! Yes!!
